



Contents

Group Overview

About Us	1
Highlights of the Year	2
Group Certifications and Accreditations	4

Executive Reviews

Chairman's Review	6
Group CEO's Review	8
Group Operations Review	11

Leadership & Governance

Board of Directors	16
Group Senior Management Team	20
Group Consultant Medical Team	22
Corporate Governance	28
Risk Management Report	32
Ethics Committee Report	35
Audit Committee Report	36
Remuneration Committee Report	38
Report of the Related Party Transactions Review Committee	39
Statement of Directors' Responsibilities	40
Annual Report of the Board of Directors	41

Financial Reports

Independent Auditors' Report	45
Statement of Profit or Loss	48
Statement of Comprehensive Income	49
Statement of Financial Position	50
Statement of Changes in Equity	51
Statement of Cash Flows	53
Notes to the Financial Statements	54

Supplementary Information

Shareholder Information	116
Five Year Summary	119
Economic Value Added Statement	121
Notice of Meeting	122
Form of Proxy	123
Corporate Information	IBC



Scan the QR Code with your smart device to view this report online.
<https://asirihealth.com/>

About Us

Asiri Health (Asiri Hospital Holdings PLC) continues to be Sri Lanka's largest private healthcare provider. Established in 1986, the Asiri Health Group now boasts of seven hospitals in three provinces, and the country's largest private laboratory service – Asiri Laboratories, which offers the widest range of tests, and encompasses one main lab, 6 hospital labs, 17 satellite labs, and 62 collection centres across the island.

Asiri Health continually invests in infrastructure, expansion, and capacity building. The Group has evolved rapidly over the last decade, doubling its reach while continuing to offer the most advanced clinical programmes in the country. We conduct over 3,000 consultations and 12,000 tests every day, and have a capacity of over 800 beds across our hospitals.

Commitment to quality and safety remains at the core of our ethos. Our hospitals meet global accreditation standards of Joint Commission International (JCI) and Australian Council of Health Standards International (ACHSI) for quality and patient safety, and our laboratories have obtained relevant industry-specific and quality management ISO certifications.

The Group employs, consults, and partners with some of the most dedicated, skilled, and experienced healthcare professionals in Sri Lanka. With ongoing capacity building, training, and development, our employees are abreast of the latest medical practices, and are adept at using cutting-edge medical equipment. Our team is the heart of Asiri Health, and an extension of our commitment and care for patients.

Our Vision

To be a leading healthcare provider in South Asia with highest quality of clinical standards

Mission

To care for and improve the quality of human life, through the provision of ethical healthcare solutions together with cutting-edge technology

Values

Care

Caring with a human touch
Caring for society
Caring for our employees

Innovation

Innovation and forward-focus

Respect

Respect for all stakeholders

1600+

Consultants

3,000+

Consultations per day



12,000+

Tests per day

4100

Tests offered



800+

Beds

Highlights of the Year

1,250+ Medical Professionals

Benefited by continuous medical education programme

3.5+ million

Patients served

12,000+ Diagnostic Tests

Conducted per day

125

Free health clinics conducted

1,272

Benefited from free health clinics

104 Workshops

Conducted for continuous medical education

402

Training programmes conducted

11,662

Man-hours of training provided

90% of Discharges

Reduced to one hour

All clinical waste disposed as recommended by CEA

Most Respected Healthcare Company

LMD Most Respected Entities Edition 2020


Most Valuable Healthcare Brand

Brand Finance Report 2020


Group

	2020/21	2019/20
Financial Performance (LKR MN.)		
Revenue	15,785	15,510
Operating Profit	2,667	2,854
Pre-Tax Profit	1,611	1,411
Income Tax Reversal/(Expense)	134	(492)
Net Profit	1,745	918
Financial Position (LKR MN.)		
Total Assets	32,071	32,198
Borrowings	16,928	16,531
Shareholder's Funds	10,294	9,960
Information per Ordinary Share (LKR)		
Earnings Per Share (EPS)	1.35	0.71
Dividend Per Share (DPS)	1.60	-
Market Price Per Share	25.50	17.00
Net Assets Value Per share	9.05	8.76


EPS /DPS (LKR)




Revenue (LKR MN.)



Earnings Before Interest and Tax









Revenue Breakdown by Group



Group Certifications and Accreditations

HOSPITALS

Accreditation	Asiri Central Hospital	Asiri Surgical Hospital	Asiri Medical Hospital	Asiri Hospital Kandy	Asiri Hospital Galle	Asiri Hospital Matara
 <p>Joint Commission International (JCI) Accreditation the gold standard in global healthcare, JCI is widely accepted to be the author and evaluator of the most rigorous international standards in patient safety and quality.</p>	X					
 <p>Australian Council on Healthcare Standards International (ACHSI)</p>		X	X		X	X
 <p>ISO 22000:2005 – Food Safety Management demonstrates the Organisation's ability to control food safety hazards in order to ensure that food is safe.</p>	X	X	X	Y	Y	Y
 <p>ISO 14001:2015 – Environmental Management Systems Design and implementation of a set of standards of effective Environment Management.</p>	X	Y	X	Y	Y	Y
 <p>OHSAS 18001:2007 – Occupational Health and Safety Management Systems Certification.</p>	X	Y	X	Y	Y	Y
 <p>ISO 9001:2015 – Quality Management Systems Certifications.</p>	X					

ASIRI LABORATORIES

Accredited



X - Accredited

Y - In progress

Executive Reviews

Chairman's Review	6
Group CEO's Review	8
Group Operations Review	11

Chairman's Review



“ Moreover, having always shown leadership in innovative healthcare solutions, we are fundamentally committed to continually innovate to keep up with the ever- changing context of the healthcare industry. ”

Saying that this past year was tough would be an understatement. For many people, businesses and countries, it was without a doubt one of the most challenging in living memory.

Like most other healthcare providers around the world, Asiri Group too was faced with the unprecedented and constantly evolving realities of the COVID-19 pandemic. Not willing to “wait and see how things pan out”, we moved swiftly at the onset of the pandemic itself, to implement the best of clinical and operational systems to ensure all Asiri Group hospitals can continue to function at an optimum capacity serving both COVID and Non-COVID patients simultaneously. In fact, we went above and beyond recommended public health guidelines, taking extraordinary precautions and adjusting protocols to make sure we are equipped to provide the best possible quality of care for all our patients, while safeguarding their health as well as the safety of clinical and non-clinical staff. I am proud to say that throughout this entire experience, our staff and physicians kept working to do what they do best - provide safe and quality care to our patients. The way the entire team has shown its versatility and ability to adapt to change to meet our patients' needs is proof that the Asiri Group's COVID response is a true team effort.

Meanwhile expecting the pandemic to test our resilience as a business, we responded by refining our Group Strategy to focus on strengthening our capacity in order to safeguard our competitive advantage. Needless to say, our desire to ensure that all Sri Lankans have easy access to quality healthcare and best clinical outcomes have remained the driving force behind the capacity building efforts undertaken across all Group hospitals in the current financial year. As per our strategic map, we continued to prioritise our specialty services including Cardiac Services, Oncology, Neurosciences and Orthopedics.

Giving back to the community has always been one of our core beliefs. Regretfully however, pandemic related restriction in the current financial year prevented the Group from implementing its flagship community initiatives conducted by Asiri Surgical, Asiri Medical and Asiri Central. Nonetheless, we did offer support in other ways. We responded immediately to the request made by the Governor of the Northern Province requesting support to uplift healthcare standards in the Northern Province, which saw a three-day programme conducted for clinical and non-clinical staff at Government hospitals and healthcare institutions, in the North. Beyond this, we supported several state owned hospitals by donating necessary equipment to enable them to handle the rapidly rising COVID cases in those areas.

LOOKING FORWARD

The coming year will be crucial in determining if Sri Lanka as a nation has truly turned a corner in its fight against COVID-19. Regardless, the Asiri Group mission is clear and unwavering. We will remain dedicated towards meeting the health care needs of all Sri Lankans, now and going forward. Anchored to the Asiri Group's core values - Care, Innovation and Respect, we are determined to find new ways to deliver world class care and have earmarked several areas to enhance our facilities. Moreover, having always shown leadership in innovative healthcare solutions, we are fundamentally committed to continually innovate to keep up with the ever-changing context of the healthcare industry.

APPRECIATIONS

Let me end my statement by reiterating my deep appreciation to the entire Asiri family - all medical, para-medical and non-medical staff who have truly demonstrated what it means to be Better Together. Thank you for selflessness and the sacrifices you have made this past year.

I also wish to take this opportunity to extend my gratitude to my colleagues on the Board, for their valuable support and guidance throughout the year.

To conclude, I would like to thank our shareholders for their long standing support. I urge you to stay invested in the Asiri Group as we move ahead to tackle new frontiers in the coming years.

Sgd.

Ashok Pathirage

Chairman / Managing Director

30 June 2021

Group CEO's Review



“ More importantly, the events of this last year have only served to strengthen our resolve to raise the bar for the local healthcare industry. ”

This past year was a year like no other with the COVID-19 pandemic redefining human existence. The pandemic, although global in scale, is personal in its impact and I am sure you will agree that we have all faced loss in many different ways. While for some it has been the loss of income or the loss of stability, for others the loss has been much deeper and more personal and often even life changing.

For us at Asiri, this past year was a watershed moment as it provided the opportunity for us to truly live up to the Asiri Group vision “to care for and improve the quality of human life, through the provision of ethical healthcare solutions together with cutting-edge technology”

RESPONDING TO THE COVID-19 CRISIS

As a hospital, responding to emergencies is ingrained in our DNA, which is why we wasted no time shaping ourselves up to tackle the unknown. No sooner had the first COVID-19 patient been detected way back in March 2020, we moved into high gear and began meticulously planning out how to prevent COVID patients from coming into contact with other patients in our hospitals. After a rigorous analysis of our systems, a comprehensive set of infectious control guidelines was implemented across all Group hospitals with effect from March 2020. We then proceeded to revamp all major patient handling processes, including triage systems. The red alert system to prioritise patient admissions which was implemented during the initial 2-month lockdown remains in place and continues to contribute significantly to improve the daily patient handling process. These steps which were taken to improve essential ground readiness of our hospitals in response to the pandemic, were highly commended by the Country's health authorities, and acknowledged as a new benchmark for the industry as a whole.

Meanwhile, well aware that it was an exceptionally challenging time for our patients who were faced with lockdown and other pandemic related restrictions, we rolled out a number of value added mobile services across all Group hospitals to enable patients to continue to receive care without attending hospital during COVID-19 restrictions. Most notable among them was the mobile pharmacy service whereby we undertook to deliver

medicines to the patients doorstep and the tele consultant facility to allow patients to channel their respective specialist consultants via video technology.

In the months following the second wave of COVID-19 in Sri Lanka, we responded to the rapidly evolving situation, by shifting our focus to ensure we continued to care for the needs of the community every day. Seeing the nature of the COVID-19 virus was such that isolation is required to keep people safe and prevent further transmission, the Asiri Group was one of the first to establish dedicated COVID-19 isolation units at all its hospitals.

Finding that state-run quarantine centers were overburdened by the rising number of infections, the Asiri Group did not hesitate to lend its support with four hospitals taking on the responsibility to set up Intermediary Care Centers under their supervision. A total of four Intermediary Care Centers were set up under the Asiri banner in partnership with leading hotels. The centers located in Mount Lavinia, Wattala, Hikkaduwa and Kandy, with a collective capacity to care for 500+ COVID-19 patients at a given time, are outfitted to offer the same high standards of patient care synonymous with the Asiri brand.

In addition purpose built COVID ICUs were set up across the group with the largest unit commissioned at Asiri Surgical whilst smaller but equally well equipped units were set up at Asiri Central, Asiri Kandy, Asiri Matara and Asiri Galle. These became necessary to care for patients who deteriorated either from the ICC Centers or from isolation units as state facilities started to get overrun.

The ASH Center for Genomic Studies, which in the past had been limited to small scale genetic studies, was significantly expanded in the year under review in order to boost the Group's PCR testing capability. This was coupled with the launch of a new mobile screening unit tasked with handling large scale PCR testing during outbreaks, at identified clusters and for corporates. Additional resources including a number of virologists were added to the team to facilitate 24-hour laboratory operations. Steps were also taken to connect the PCR laboratory with the Superiksha health database

of the Ministry of Health to enable the national epidemiology unit to have access to the Group's PCR statistics. Other Group-wide initiatives include the Amazing Care ambulance service.

We were also adamant that Asiri Group continues offering critical services such as chemotherapy and radiotherapy programmes even when these services were disrupted in the state hospitals during the lockdown. Similarly cardiac care facilities too were offered throughout, while Asiri Surgical remained the only hospital in the Country where PET scan facilities were available throughout the lockdown period. Might I add that the Asiri Group was also one of the first healthcare providers in the Country to resume offering elective surgeries, post-lockdown in May 2020. However, taking nothing for granted, we took additional precautions in insisting all our post-surgical patients were kept for an additional day and released subject to a negative PCR test result.

At this point I must mention that while forcing us to adapt to new realities, the pandemic brought out the spirit and dedication of our clinical teams who have not only provided healthcare services, but gone above and beyond to bring comfort and relief to patients and their families in these times of uncertainty. I am deeply proud of the way in which these “frontliners” have responded to the crisis, proving that nothing – not even a global pandemic - can distract them from the fundamental reason they entered the medical profession in the first place – the passion to care for our patients.

STAYING ON COURSE

Admittedly while COVID response was a major priority this past year, we did not lose sight of the fact that investing in other aspects of our business are equally important in driving our efforts to achieve excellence in patient care. We made good headway in building capacity across all our hospitals. A new emergency treatment facility is being commissioned at Asiri Surgical, after the ground floor which housed the former ETU was taken over to set up the COVID isolation unit.

At Asiri Medical we broke ground for a new IVF center, thus fulfilling a long felt need for the Asiri Group. The new IVF center which will

Group CEO's Review

benefit from the technical expertise of Nova - India's leading fertility specialist, would upon completion be Sri Lanka's most advanced facility for treating sub-fertility and infertility.

At Asiri Central, we focused on upgrading our Stem Cell laboratory, becoming the only stem cell processing and storage facility available in the private healthcare sector in Sri Lanka. With this new development, we are now able to bring fresh hope and lifesaving treatment to patients, especially children, needing bone marrow transplants by ensuring they receive the best possible outcomes.

Capacity building at Asiri Galle and Asiri Matara were aimed at improving surgical capacity in selected disciplines to allow us to increase the spectrum of services offered at each of these hospitals. Accordingly, at Asiri Matara we added a dedicated theatre for orthopaedics focused on building capacity in the specialty, while at Asiri Galle we invested in developing surgical capability in the fields of Urology, Neurosurgery and Laparoscopy.

Meanwhile, keen to position Asiri Kandy - the Group's newest hospital, as the leading private healthcare facility in the Central province, we pushed through with a wide range of capacity building initiatives, key among them being the unveiling of a second cardiac theatre and adding bed capacity to the state of the art cardiac care center that continues to be the center of excellence in the Central province. The Acute Stroke (CVA) Thrombolysis Management Unit was another notable addition to the hospital during the year under review.

I am also very pleased with the performance of the Asiri Laboratory network in this past year. Our network of labs - 17 satellite labs and 62 collection centers and the main laboratories at all 7 Asiri Group hospitals collectively recorded an average of 12,000 tests per day, which I feel is a commendable achievement given the pandemic related challenges, including staff mobility restrictions that disrupted laboratory operations from time to time. Another key highlight for the year was the Merit (Silver Award) for quality, awarded by the Sri Lanka National Quality Awards (SLNQA) 2020, which

makes Asiri Laboratories the only Medical Diagnostic Company in Sri Lanka to achieve such an accolade to date.

MOVING AHEAD

Reflecting on the future, it is clear that COVID-19 is far from over in Sri Lanka and that the challenges will likely continue for some time yet. However, I do firmly believe that the lessons learned in this past year will hold us in good stead as we move ahead to tackle what lies ahead. More importantly the events of this last year have only served to strengthen our resolve to raise the bar for the local healthcare industry.

That said, we will move forward by continuing to build capacity at our hospitals in response to the evolving healthcare needs of the Country and do so by transforming healthcare standards to ensure all Sri Lankans have access to the highest standards of care and the best possible patient outcomes every time.

APPRECIATIONS

This year, the words 'thank you' alone cannot convey my deep appreciation for the Asiri Group team - the doctors, nurses, paramedics, and staff who kept on working to care for our patients, despite all odds. Nevertheless, let me take this opportunity to thank each and every one of you for your selflessness and for making it your daily mission to care for our patients above all else. I am indeed honoured to be a part of such a heroic team.

I also wish to express my appreciation to the Chairman and Board of Directors for their sound advice and unfailing support at all times.

Finally, to the Group's strategic partners and shareholders - thank you for continuing this journey with the Asiri Group.

Sgd.

Dr. Manjula Karunaratne
Chief Executive Officer

30 June 2021

Group Operations Review

Being the leading private healthcare chain in the Country, the Asiri Group continued to focus on further augmenting its value proposition to offer world class healthcare services to all Sri Lankans. Adopting a two-pronged strategy, the Group's focus for the year was centered on improving COVID-19 response mechanisms at a Group level, while at the same time investing in capacity building at each individual hospital.

GROUP LEVEL COVID-19 RESPONSE MECHANISMS

Taking immediate action at the onset of the pandemic itself, a broad based initiative was launched to standardize COVID care systems across the Group. To ensure COVID readiness across all Group hospitals, a set of new infection control guidelines were issued detailing processes, procedures and precautionary measures to promote systematic management and handling of all patients and prevent contact between COVID and non-COVID patients within the hospital. Steps were also taken to revamp existing protocols such as the triage systems. A new online patient registration system featuring a colour coded notification mechanism to alert the respective hospital regarding patient arrivals was also rolled out across all Asiri Group hospitals with effect from April 2020. These systems proved highly effective in streamlining bottlenecks at the admissions counters and thereby eliminating unnecessary waiting times.

The Group took steps to establish several Intermediary Care Centers in partnership with leading hotels. Asiri Medical Hospital in February 2021 partnered with the Siddhalepa Group to set up a 100-room Intermediary Care Centre at the Anarva Hotel in Mount Lavinia. Several other Intermediary Care Centres were set up by the Group in the latter part of the year, in partnership with Pegasus, Citadel and Hikka Tranz hotels to meet the requirements of the community.

Meanwhile new value added services continued to be launched throughout the year to support patients' needs during frequent lockdowns and travel restrictions. The online pharmacy with a doorstep delivery service was one. Patients were only required to place their orders online through the Asiri Health website or via direct WhatsApp message with their prescriptions and avail themselves of this much needed facility at the time. The service was made available at all Group hospitals, with free delivery within a 10 km radius of the respective hospital. The tele consultation facility was also implemented to give patients the opportunity to channel their respective specialist consultants via video technology. A large number of specialist services were offered through this mechanism, ranging from physicians, pediatricians and cardiologists

along with psychological counseling sessions and wellness activities as well. All Group hospitals offered the service free of charge for a period of 3 months from April to June 2020.

The mobile laboratory service was activated along with the Amazing Care ambulance and home care services, at all Asiri Group hospitals.

At an operational level, activities at the Group's nursing school were affected, as the school remained shut down for several months in adherence with COVID-19 health protocols. Meanwhile, prioritising the health and safety of its own personnel, the Group undertook random PCR testing for staff with dedicated isolation facilities established for the purpose of quarantining staff members, when required.

ASIRI SURGICAL HOSPITAL (ASH)

Aside from the Group-level COVID response measures, several other initiatives were taken to strengthen the COVID care services at ASH. The ASH Center for Genomic Studies, which in the past had been limited to small scale genetic studies, was significantly expanded in the year under review in order to boost the Group's PCR testing capability. Additional resources including a number of virologists were added to the team to facilitate 24-hour laboratory operations. Steps were also taken to connect the ASH laboratory with the Superiksha health database of the Ministry of Health to enable the national epidemiology unit to have access to the Group's PCR statistics.

As part of the expansion programme, a new mobile screening unit was launched to handle large scale PCR testing during outbreaks, at identified clusters and for corporates.

Group Operations Review

As part of the expansion programme, a new mobile screening unit was launched to handle large scale PCR testing during outbreaks, at identified clusters and for corporates. The expanded PCR testing capability enabled ASH to capitalise on other opportunities in the market as well, including the demand for PCR testing for outbound travelers. ASH also received approval to conduct mandatory PCR testing and undertake patient care for seafarers who were part of the crew exchange programme at the Colombo and Galle ports.

ASH was one of the few hospitals where all elective surgeries were being carried out. Offering surgical facilities at a time when many state and private sector hospitals had temporarily discontinued such services, enabled ASH to benefit from a sizable increase in patient numbers in the period under review. Moreover due to COVID related travel restrictions, ASH was also able to capture a share of the patients who would otherwise have sought treatment overseas. ASH continued to offer its chemotherapy and radiotherapy programmes for cancer patients without disruption during this period. Cardiac care services continued, while ASH was also the only hospital in the Country offering PET scan facilities during this period.

In affirmation of its efforts to benchmark global healthcare standards, ASH secured the ACHSI (Australian Council on Healthcare Standards International) accreditation in March 2020.

A new dedicated psychiatric wing was established, making AMH one of the few private hospitals offering this service.

The mindfulness programmes run by ASH's Wellness center were revamped to create customised solutions to address the specific needs of groups and individuals in the context of the pandemic. Further expanding the service offered by the Wellness center, a new cardiac rehabilitation programme was launched. This programme includes sessions on nutrition, physical wellbeing and mindfulness, is designed to support post-surgical recovery of cardiac patients and enable them to optimise their physical performance allowing them to resume normal activity as soon as possible.

Free clinics conducted by ASH for the benefit of the wider community, continued throughout the year, interrupted only during the lockdown months. The breast clinic conducted by a multidisciplinary team led by a lady surgeon proved to be immensely popular, and well attended by patients with various issues related breast ailments. The hernia and urology clinics too attracted patients who found the detailed consultation with doctors quite useful and less hurried. The free cancer clinic conducted by the resident Oncologist at Asiri AOI Cancer Centre continued to attract patients seeking information, second opinions and treatment options.

ASIRI MEDICAL HOSPITAL (AMH)

AMH took some important steps to reaffirm its position in the mother-and-baby care space, with the commencement of construction work on a dedicated IVF fertility centre in October 2020. The facility, which would be located on the 3rd floor of AMH, will be built as a full-fledged center for the treatment of subfertility and infertility. For this purpose AMH signed up with Nova, the 2nd largest sub fertility specialist in India to tap into Nova's globally recognised technology and 20+ years of expertise in the field of subfertility or infertility. With the expectation that the fertility centre will be completed by mid-2021, AMH went ahead with recruitment and training activities

To enhance the services offered by AMH under its mother-and-baby programme, a series of value added services were launched during the year, among them an interactive online platform

to support mothers through their pregnancy. AMH also tied up with Softlogic Invest to enable each baby born at an Asiri hospital to receive an Investment Account in the Softlogic Money Market Fund, with an initial deposit of Rs. 5,000/-.

A new dedicated psychiatric wing was established, making AMH one of the few private hospitals offering this service. Designed in line with world class standards, the 5-room unit is equipped to provide acute psychiatric care.

AMH's pharmacy network was expanded with another new pharmacy established during the year, at newly opened Glomark supermarket in Malabe. With this new addition, AMH now operates a total 3 remote pharmacies under its purview.

ASIRI CENTRAL HOSPITAL (ACH)

ACH - the Group's flagship hospital continued to strengthen its position as one of the leading healthcare facilities in the broader south asian region. The hospital's existing Stem Cell Laboratory was expanded, paving the way for the haplo-identical transplants more safely and effectively, which greatly enhances the level of care for Bone Marrow Transplant patients. The upgraded facility is staffed by an expert team including a Consultant Haematologist and a personnel specially trained in this field, with in-depth expertise in the processing and storage of haematopoietic stem cells.

It should be noted that several of the capacity building initiatives implemented at ASH were replicated at ACH as well, among them the cardiac rehabilitation programme and the mobile laboratory service offering PCR testing to corporates. Going a step further however, drive-thru PCR facilities were also introduced onsite at the ACH premises.

Other new initiatives by ACH during the year include the specialized free clinics for screening of Heart, Brain and Spine and Diabetes.

Moreover, by demonstrating continuous compliance with its internationally-recognized standards ACH obtained the Joint Commission

Other new initiatives by ACH during the year include the specialized free clinics for screening of Heart, Brain and Spine and Diabetes.

International's Gold Seal of Approval for Hospital Accreditation. This is the 5th consecutive year in which ACH has secured this accreditation.

ASIRI HOSPITAL MATARA (AHM)

Ongoing efforts to build capacity at AHM continued, with several key investments being made in the current financial year to increase surgical and intensive care capability. The main focus was to enhance both ICU and Critical care facilities. In this regard, special emphasis was placed on building AHM's capacity in the area of Orthopedics, which saw new investments being made in a state of the art orthopedic operating theater. The hospital's Urology facilities were also significantly upgraded.

A new drive-thru pharmacy was set up as a value added service to patients during the pandemic.

Marking a significant milestone in its journey to achieve excellence in healthcare, AHM was awarded the ACHSI accreditation in the year under review.

ASIRI HOSPITAL GALLE (AHG)

Construction work at Asiri Galle, which is undergoing a major renovation programme, was disrupted badly during the year in the face of the pandemic and the new look hospital is now scheduled for completion in Mid-2021.

With capacity building being the main priority at AHG as well, steps were taken to expand existing ETU facilities at AHG. Construction work on a new ETU wing commenced in

late-2020 and is expected to be completed by mid-2021. Additional investments were made to strengthen the hospitals' surgical capability in the disciplines of Urology, Neurosurgery and Laparoscopy. Meanwhile a section of the first floor of the hospital was carved out to set up a primary care treatment facility for COVID patients.

In another important development, the imaging services at AHG which included both MRI and CAT scanning was transferred to a new building following its completion in mid-2020.

AGH too achieved ACHSI accreditation in the year under review, becoming the latest Asiri Group hospital to do so.

ASIRI HOSPITAL KANDY (AHK)

With the onset of the pandemic AHK firmly established itself as the preferred healthcare provider in the province. This was largely due to the strict COVID protocols and infection control measures implemented, thereby providing a safer environment for both its consumers and clinicians.

AHK, as the newest addition to the Asiri portfolio also continued with capacity building efforts, solidly positioning itself as the leading private hospital in the Central province. Several existing facilities were strengthened, most notably the Cardiac services were expanded with capacity expansion of the cardiac operating suites. AHK also began offering CT Coronary angiograms and Cardiac MRIs, a first in the Central province. The Acute Stroke (CVA) Thrombolysis Management unit was another new addition to AHK's facilities in the current financial year.

Meanwhile, as a value addition to AHK's Brain and Spine unit, an in-house Neurophysiology unit was established to offer EEG, NCV-EMG and Sleep-study tests.

In other notable developments, AHK commenced Fetal Anomaly Screening, Corneal grafting, and Chemotherapy services during the year. The Dental Unit was further strengthened by the acquisition of an Orthopantomogram.

A number of drive thru services were implemented for the benefit of patients, such as booking of Consultations, Laboratory testing and the Pharmacy. Several initiatives were rolled out as part of AHK's ongoing process improvement programme aimed at further enhancing the patient experience, key among them being the special unit set up for the purpose of facilitating Patient Admission and Discharges.

ASIRI LABORATORIES


Asiri Laboratories is recognized as Sri Lanka #1 Private hospital Laboratory network with the most comprehensive coverage in the Island. In the year under review, the Asiri Laboratory network collectively catered to over 3 million individual patients conducting over 12,000 tests per day across the Country through its islandwide network of 17 satellite labs and 62 collection centers as well as the main labs at all 7 Asiri Group hospitals.

An important accolade was being recognized for the 6th consecutive year, as the number 1 private diagnostic company in Sri Lanka, by the Medical Research Institute in the National External Quality Assessment Scheme (NEQAS) in Microbiology.

While the past financial year has been a challenging one in terms of continuous operations and HR related concerns, Asiri Laboratories has been able to steadily move forward, by dynamically adapting to the changes to maintain an uninterrupted service to its customers.

Group Operations Review

ASIRI LABORATORIES AND COLLECTION CENTRES



Leadership & Governance

Board of Directors	16
Group Senior Management Team	20
Group Consultant Medical Team	22
Corporate Governance	28
Risk Management Report	32
Ethics Committee Report	35
Audit Committee Report	36
Remuneration Committee Report	38
Report of the Related Party Transactions Review Committee	39
Statement of Directors' Responsibilities	40
Annual Report of the Board of Directors	41

Board of Directors



MR. VISHAL BALI

Non-Executive Independent
Director

MR. SAMANTHA RAJAPAKSA

Non-Executive Independent
Director

DR. MANJULA KARUNARATNE

Group Chief Executive Officer

MR. ASHOK PATHIRAGE

Chairman/Managing Director



DR. SIVAKUMAR SELLIAH
Deputy Chairman

MR. HARRIS PREMARATNE
Non-Executive Independent
Director

MR. SUDARSHAN AHANGAMA
Non-Executive Independent
Director

MR. ANKUR THADANI
Non-Executive Independent
Director

Board of Directors

MR. ASHOK PATHIRAGE

Chairman/Managing Director

Mr. Ashok Pathirage, recognised as a visionary leader of Sri Lanka's corporate world, is the founding member of Softlogic Group, one of Sri Lanka's leading conglomerates. He manages over 50 companies with a pragmatic vision providing employment to more than 11,000 employees. Mr. Pathirage gives strategic direction to the Group which has a leading market presence in three core verticals – Retail, Healthcare and Financial Services and three non-core verticals - IT, Leisure and Automotive. The Asiri Hospital chain is the country's leading private healthcare provider which has achieved technological milestones in medical innovation in Sri Lanka's private healthcare. He is the Chairman/Managing Director of Softlogic Holdings PLC, Asiri Surgical Hospital PLC, and Odel PLC. He also serves as the Chairman of Softlogic Capital PLC and Softlogic Life Insurance PLC in addition to the other companies of the Group. He is also the Chairman of NDB Capital Holdings Limited, Sri Lankan Airlines Limited and Sri Lankan Catering Limited.

DR. SIVAKUMAR SELLIAH

Deputy Chairman

MBBS, M Phil

Dr. Selliah holds an MBBS Degree and a Master's Degree (M Phil), and has over two decades of experience in diverse fields including Manufacturing, Healthcare, Insurance, Logistics and Packaging, Renewable Power, Plantation, Retail etc.

Dr. Selliah is currently the Deputy Chairman of Asiri Hospital Holdings PLC, Asiri Surgical Hospital PLC and Central Hospital Ltd.

Dr. Selliah is the Chairman of JAT Holdings Ltd., Vydexa (Lanka) Power Corporation (Pvt) Ltd. and Cleanco Lanka (Pvt) Ltd. Dr. Selliah is also the Deputy Chairman of Evoke International Ltd.

He is a Director of Lanka Tiles PLC, HNB Assurance PLC, Softlogic Holdings PLC, Odel PLC, Lanka Walltiles PLC, Lanka Ceramic PLC, ACL Cables PLC, Swisstek (Ceylon) PLC and Swisstek Aluminium (Pvt) Ltd.

He has also served as a Senior Lecturer in the Medical Faculty for many years in the past. Currently he serves as a Council Member of the University of Colombo.

Dr. Selliah also serves on the following Board sub committees of some of the companies listed above as a member or Chairman: Human Resource and Remuneration committee, Related Party Transactions Review committee, Audit committee, Investment committee and Strategic Planning committee.

DR. MANJULA KARUNARATNE

Group Chief Executive Officer

MBBS, MSc (Trinity, Dublin), Dip. MS Med (Eng) MSOrth Med. (UK)

Dr. Karunaratne was appointed to the Board of Asiri Hospital Holdings PLC and Asiri Surgical Hospital PLC in 2006, and currently serves as the Chief Executive Officer of the Asiri Group. He also serves on the Boards of Central Hospital Ltd., Asiri Central Hospitals Ltd., Asiri Hospital Matara (Pvt) Ltd., Asiri Hospital Galle (Pvt) Ltd., Asiri Diagnostic Services (Pvt) Ltd, Asiri A O I Cancer Centre (Pvt) Ltd, Jendo Innovations (Pvt) Ltd, Softlogic Pharmaceuticals (Pvt) Ltd, Softlogic Healthcare Holdings (Pvt) Ltd. He previously held the positions of Medical Director, Asiri Hospital Holdings PLC (1996-2000) and was Chief Operating Officer, Asiri Hospitals Group during the period 2006-2014. He possesses over 30 years of experience in the field of healthcare, and is responsible for the overall medical policy of the Group. Under his guidance the Group has introduced over twenty new medical procedures and technologies to Sri Lanka amongst which are the country's first Bone Marrow Transplant Unit, first Stem Cell Laboratory, first Minimally Invasive Cardiac Surgery service, first fully fledged Stroke Unit with facilities for "clot retrieval" and a high end Interventional Radiology service. In addition, a 'live donor' Liver Transplant service is currently being set up.

MR. HARRIS PREMARATNE

Non-Executive Independent Director

Mr. Premaratne was appointed to the Board in March 2008 after 40 years of banking experience with Commercial Bank of Ceylon PLC. He is specialised in Corporate Banking, and is an Associate of the Chartered Institute of Bankers of London. He served as the Managing Director of Sampath Bank PLC from 2009 to December 2011. He was the Managing Director of Cargills Bank Limited from 2012 to 2014. He held the position of Chairman of Sri Lanka Banks' Association. He was the Deputy Chairman of Pan Asia Banking Corporation PLC in the year 2017, and Deputy Chairman of Softlogic Finance PLC during 2015-2017. He was a Director of Softlogic Holdings PLC during 2008 - 2020 and Softlogic Capital PLC during 2014- 2020. He serves on the Board of Asiri Surgical Hospital PLC and Central Hospital Limited, Asiri Central Hospitals Limited. He functions as the Chairman of the Remuneration Committee and also a member of the Audit Committee and Related Party Transactions Review committee of the above hospitals.

MR. SAMANTHA RAJAPAKSA

Non-Executive Independent Director

Mr. Rajapaksa is a Fellow Member of the Institute of Chartered Accountants of Sri Lanka, Chartered Institute of Management Accountants of UK, Institute of Certified Management Accountants of Sri Lanka and Chartered Institute of Marketing of UK. He also holds an MBA from the Postgraduate Institute of Management of University of Sri Jayewardenepura.

He began his career at Messrs. Ernst & Young and went on to serve as Director/General Manager at Informatics International. Thereafter, he took on the appointment of Director/Chief Executive Officer of CF Venture Fund Ltd. He was also appointed as a Group Director of Central Finance Co. PLC during the same period. He thereon took a posting overseas as Senior Project Manager at AT&T Inc. USA. He returned to Sri Lanka in 2008 to take up the appointment as Group Director of Kshatriya Holdings PLC and thereafter joined as a Group Director of the Softlogic Group

responsible for Group Business Development and as Director/Chief Executive Officer of Softlogic Communications (Pvt) Ltd. Mr. Rajapaksa thereafter held the position of Group Managing Director of Associated Motorways (Pvt) Ltd. and also served as a Director of Bank of Ceylon.

Mr. Rajapaksa currently serves as the Chairman of Kitra Holdings (Pvt) Ltd. and the Rakuen Group of Hotels. He also currently serves as a Director of Asiri Hospital Holdings PLC & Asiri Surgical Hospital PLC. Mr. Rajapaksa is the recipient of the Platinum Honours Award in recognition of Professional Excellence in the Field of Management from the Postgraduate Institute of Management of University of Sri Jaywardenepura.

He functions as the Chairman of the Related Party Transactions Review Committee.

MR. SUDARSHAN AHANGAMA

Non-Executive Independent Director

Mr. Sudarshan Ahangama is a fellow member of the Institute of Chartered Accountants of Sri Lanka. He served on the board of MAS Holdings, as its Group Finance Director for 15 years where he had responsibilities for the finance function in 17 countries across multiple regions. He continues with MAS as Director Strategic Investments handling the Groups mergers & acquisitions, cross border transactions, venture capital investments and organizational restructuring.

Previously he was with John Keells Holdings PLC, where he was Managing Director of John Keells Stock Brokers (Pvt) Ltd for 10 years. He was part of the exchange automation task force of the CSE and led several roadshows overseas promoting the equity markets. In a subsequent role as Managing Director of the software out-sourcing activities of the Group he was also responsible for setting up several development centres in collaboration with leading global airlines and telecommunication companies. He served on many boards in both the Financial Services and IT Sectors at John Keells.

MR. VISHAL BALI

Non-Executive Independent Director

Mr. Bali brings with more than two decades of experience in building and leading global healthcare delivery organisations through organic and M&A driven strategic growth initiatives across Asia Pacific. His experience of managing a billion-dollar integrated healthcare delivery organisation comprising Hospitals, Diagnostics, Primary Care and Day Care Speciality in diversified geographies of India, Australia, New Zealand, Hong Kong, Singapore, Vietnam, Sri Lanka and Dubai has given him the exceptional opportunity to transform healthcare businesses in both developing and developed countries. Mr. Bali is currently Asia Head – Healthcare, TPG Growth which is amongst the leading private equity firms globally. He is also Executive Chairman, Asia Healthcare Holdings. Prior to his current assignment he was the Group CEO for Fortis Healthcare Limited which is the leading provider of healthcare services in India with a network of 68 hospitals and had earlier built Asia's leading integrated healthcare delivery system with presence across 12 countries and a human capital base of more than 20,000 people and \$1.2 Bn. annualised revenue. His earlier roles also include CEO for Fortis Healthcare International in Singapore and CEO for Fortis Hospitals in India. His past assignment also includes spearheading the growth and transformation of Wockhardt Hospitals from a single hospital to one of India's largest speciality hospital chains as its CEO and Managing Director. He has successfully led post-merger integration and divestments of multiple healthcare delivery assets in different countries. His expertise in integrating healthcare strategy with operations and management has set industry benchmarks. Mr. Bali completed his Bachelors in Science and Post-graduation in Business from Bombay University and completed an advance programme in hospital management from Harvard Medical, Boston. He sits on the Board of leading healthcare organisations and has been an invited member of the Strategic Initiatives Group of Joint Commission International, US and a past member of the

Global Agenda Healthcare Council of the World Economic Forum. His keen interest in education and globalisation of healthcare takes him to leading Healthcare Education Institutes and Business Schools globally which include case studies at the Harvard Business School. He is an active member of various Industry bodies and globally recognised industry public speaker.

MR ANKUR THADANI

Non-Executive Independent Director

Mr. Ankur Thadani is Partner and co-head of India at TPG Growth and RISE Fund. He joined TPG in 2013 and has worked on multiple investments in Healthcare, Energy and Consumer sectors across India and the broader South-Asia region. Mr. Ankur also serves on the Board of API Holdings, Solara Active Pharma, Stelis Biopharma, Rhea Healthcare, Nova IVF and Fourth Partner Energy. Prior to joining TPG, he worked with an Indian private equity fund, India Equity Partners, focusing on investments in consumer and healthcare sectors. Mr. Ankur received his MBA from IIFT, where he was awarded a Gold Medal for all-round achievement.

Group Senior Management Team



DR. SAMANTHI DE SILVA

Director Operations Asiri Medical and Surgical Hospitals Asiri Hospitals Matara and Galle



MR. NIHAL RATHNAYAKE

Director Operations Asiri Central Hospital



DR. PRASAD MEDAWATTE

Director Operations Asiri Hospital Kandy



DR. MAHESH KANDAMBI

General Manager Asiri Hospitals Matara and Galle



DR. RUWAN SENATILLEKE

Medical Director Asiri Central Hospital



DR. CHAMPIKA BOGAHAWATTE

Medical Director Asiri Surgical Hospital



DR. UTHPALA MALAWARA ARACHCHI

Medical Director Asiri Hospital Kandy



MRS. THELANI WEERASINGHE

Director Nursing



DR. HASANTHIE IDDAMALGODA

Medical Director Asiri Medical Hospital



MR. AJITH KARUNARATHNE
Chief Financial Officer



**MRS. HASANTHI DE SARAM
KARANDAGASPITIYA**
Director Human Resources



MR. N P JOHN
Director Laboratory Services



**MS. INDRESH PUVIMANASINGHE
FERNANDO**
Chief Process Officer



MS. MIHIRI CABANDUGAMA
Director Strategic Planning and
Laboratory Development



MRS. ROCHELLE RODÉ DE SILVA
Director Marketing



MR. SUDATH HEWAGE
Director Pharmacy Operations

Group Consultant Medical Team



PROF. L R AMARASEKARA
Consultant Histopathologist



DR. MENIK GOONEWARDHENE
Consultant Neonatologist



DR. CHRISANTHA MENDIS
Consultant / Head Dept. of
Anaesthesiology - Asiri Central Hospital



DR. DARSHANI AMARASINGHE
Consultant Anaesthesiologist



DR. GAYANI SENANAYAKE
Consultant Anaesthesiologist



DR. ANIL PERERA
Consultant / Head Dept. of Anaesthesiology
- Asiri Medical & Asiri Surgical Hospital



DR. STELLA FERNANDO
Consultant Anaesthesiologist



DR. DINESH DE SILVA
Consultant Eye Surgeon



DR. RANGIKA GOONARATNE
Consultant Eye Surgeon

**DR. LAKMALI PARANAHEWA**

Consultant / Head Dept. of Radiology -
Asiri Central Hospital

**DR. GULPA SUBASINGHE**

Consultant Radiologist

**DR. SAMAN PERERA**

Consultant Radiologist

**DR. GAMINI JAYAWEERA**

Consultant /Head Dept. of Transfusion
Medicine - Asiri Group

**DR. NATASHA PEIRIS**

Consultant Resident Physician

**DR. VIVEK GUPTHA**

Senior Consultant Cardiothoracic Surgeon

**DR. THURUL ATTYGALLE**

Resident Physician Stroke Unit

**DR. THUSHARA FERNANDO**

Consultant Anaesthesiologist

**PROF. VAJIRA DISSANAYAKE**

Consultant Medical Geneticist

Group Consultant Medical Team



DR. AJITH KARUNARATNE
Consultant Cardiothoracic Surgeon



DR. RAJEEVA PIERIS
Consultant Cardiothoracic Surgeon



DR. PHILOMENA CHANDRASIRI
Consultant Microbiologist/Head of
infection Control



**PROF. LALLINDRA VIRAJJAN
GOONERATNE**
Director- Bone Marrow Transplant &
Clinical Haematology Unit Asiri Central
Hospital



DR. ROHINI RANWALA
Clinical Director - Dept. of Neuro Science,
Asiri Central Hospital



DR. SUNIL PERERA
Consultant/Head - Dept. of Neuro Science,
Asiri Central Hospital



DR. DISHNA DE SILVA
Consultant Pediatrician



DR. SUMEDHA AMARASEKARA
Consultant Orthopaedic Surgeon



MRS. GITANJALI JAYATHILAKA
Consultant Anaesthesiologist



DR. HIRANTHI ABEYSINGHE
Consultant Anaesthesiologist



DR. Y K M LAHIE
Consultant Cardiothoracic Surgeon



DR. KALYANI MIRANDA
Consultant Radiologist



DR. VERNON MANIL FERNANDO
Consultant Orthopedic Surgeon



DR. ROMANIE NISHANTHI FERNANDO
Consultant Obstetrician & Gynaecologist



DR. SHAMA GOONATHILAKE
Consultant Clinical Oncologist - Asiri AOI
Cancer Centre (PVT) Ltd.



DR. HIMARU WIRITHAMULLA
Consultants General Surgeon



DR. UDENI DISSANAYAKE
Consultant Eye Surgeon



DR. SUJATHA PATHIRAGE
Consultant Microbiologist

Group Consultant Medical Team



DR. CHAMPIKA ABEYSINGHE
Consultant Anaesthesiologist



DR. NIMALI PUWAKWATHTHA
Consultant Anaesthesiologist



DR. NIRODHIKA DAYARATNE
Consultant Paediatrician



DR. DUMINDA KALUTHANTHRI
Consultant Physician



DR. GOWRIE GALAPPATHTHY
Consultant Community Physician



DR. CHAMARA RATNAYAKE
Consultant Cardiologist



DR. IRANGA PERERA
Resident Consultant Radiologist



DR. ASITHA DASSANAYAKE
Consultant Anaesthetist



DR. NIROSHINI GANEGODA
Head of Transplant - Asiri Central Hospital



DR. NILWALA JAYASINGHE
Resident Consultant Physician



DR. MANOJ CHRISTOPHER MEDAGAMA
Consultant Resident Anaesthetist



DR. SUVINI WIJESINGHE
Consultant Radiologist



DR. SAMAN HEWAMANA
Consultant Haematologist & Haemato -
Oncologist

Corporate Governance

BOARD OF DIRECTORS

The Board of Directors are responsible to shareholders of creating and delivering sustainable shareholder value through to the Management of the Group's operations. The committees assist the Board in its responsibilities, rendered in the form of reports and recommendations submitted to the Board.

BOARD COMPOSITION

The Board consists of eight Directors, with a split between 2 Executive and 6 Non-Executive Directors, out of whom 3 are Independent. The composition of the Board is in compliance with the Corporate Governance Rules of the Colombo Stock Exchange. The Directors provide the objectivity and are equipped with the skills and experience required to discharge their responsibilities in an effective manner. (Refer to pages 18 and 19 for the full profiles of the Directors).

RESPONSIBILITIES OF THE BOARD

The key roles and responsibilities of the Board are as follows:

- Exercise leadership, enterprise, integrity and judgement in directing the Company so as to achieve continuing prosperity in a manner based on transparency, accountability and responsibility.
- Ensure a managed and effective process of Board appointments.
- Determine the Company's purpose, values and strategy and ensure that procedures and practices are in place.
- Monitor and evaluate the implementation of strategies and policies for better management performance. Ensure compliance with the relevant laws, regulations and codes of best practice on corporate governance. Communicate with shareholders effectively and serve the legitimate interest of the shareholders.
- Periodic and timely reporting to shareholders of the progress and performance of the Company.
- Review processes and procedures regularly and ensure that internal control is effective.
- Identify key risk areas and ensure that these risks are addressed and managed effectively.
- Appoint and evaluate the performance of the Managing Director.
- Approve the Annual Budget.
- Authorisation of Directors' conflicts or possible conflicts of interest.
- Determination of independence of Non-Executive Directors.
- Ensure the continuation of the Company as a going concern.

APPOINTMENT AND RE-ELECTION TO THE BOARD

- Directors are appointed by the Board in a structured and transparent manner.
- Appointments are made with due consideration given to the diversity of skills and experience within the Board.
- As per the Company's Articles of Association, one-third of the Directors shall retire from office at each Annual General Meeting and offer themselves for re-election.
- All Directors appointed during the year seek election at the subsequent AGM.
- The Managing Director is not subject to retirement by rotation.

BOARD MEETINGS AND ATTENDANCE

The Board meets on a regular basis and additional meetings are convened when necessary. Scheduled Board meetings are arranged well in advance to ensure, as far as possible, that Directors can manage their time commitments. All Directors are provided with supporting documents and relevant information for each meeting and are expected to prepare themselves for and to attend all Board meetings, shareholders' meetings and all meetings of the committees on which they serve, unless there are exceptional circumstances that prevent them from doing so. Directors have full access to Group information and are entitled to obtain independent professional advice at the Group's expense in appropriate situations.

Name of Director	Board meetings	Audit Committee meetings	Related Party Transactions Review Committee	Remuneration Committee
Mr. A K Pathirage	3/3	-	-	-
Dr. S Selliah	3/3	-	-	1/1
Dr. K M P Karunaratne	3/3	-	-	-
Mr. G H L Premaratne	3/3	4/5	4/4	1/1
Mr. S A B Rajapakse	3/3	5/5	4/4	-
Mr. S Ahangama	2/2	3/3	2/2	-
Mr. V Bali	3/3	-	-	-
Mr. A N Thadani	3/3	-	-	-
Mr. R A Ebell	1/1	1/1	1/1	-

CHAIRMAN

The Chairman leads the Board in order to ensure that it operates effectively and fully discharges its fiduciary and regulatory responsibilities. The Chairman is also responsible for ensuring that no single individual has autonomous decision-making powers, thus protecting stakeholder interests. Within the Group, the Chairman also serves as the Managing Director and is responsible for recommending the strategic direction to be followed by the Group and for implementing the decisions of the Board. The performance of the Managing Director is reviewed by the Board on an annual basis.

REMUNERATION OF THE BOARD

The remuneration of the Directors is determined by the Board and is disclosed on page 68 of this Annual Report.

COMPANY SECRETARIES

Messrs. Softlogic Corporate Services (Pvt) Ltd. function as Company Secretaries to the Group. The Company Secretaries provide guidance to the Board as a whole and to individual Directors with regard to discharging of their responsibilities. The Company Secretaries are responsible to ensure that the Board complies with the applicable rules, regulations and procedures and all activities relating to the Board.

BOARD COMMITTEES

The Board has delegated certain authorities to the Board Committees in order to manage the affairs of the Board. The committees operate under terms of reference approved by the Board.

AUDIT COMMITTEE	Composition
<p>Duties and responsibilities</p> <ul style="list-style-type: none"> Review the Group's annual and interim Financial Statements and compliance reports. Review the performance of the internal audit function. Review the effectiveness of the Group's internal controls. Periodically approve and review the appointment and retirement of External Auditors and their relationship with the Group. 	<p>Chairman: Mr. S Ahangama Independent Non-Executive Director (Appointed as a Chairman w.e.f 22nd September 2020)</p> <p>Committee members: Mr. G L H Premaratne Independent Non-Executive Director Mr. S A B Rajapaksa Independent Non-Executive Director</p> <p>Frequency of meetings: Committee meets quarterly</p>
REMUNERATION COMMITTEE	Composition
<p>Duties and responsibilities</p> <p>Provide recommendations to the Board on the following:</p> <ul style="list-style-type: none"> Remuneration policy for Executive Directors Remuneration policy and specific incentives for certain Senior Executives. Employee benefits and long-term incentive schemes Principles governing the Group's remuneration policy. To deliver improved shareholder value by ensuring that individual performance and reward reflect and reinforce the business objectives of the Group. To support the recruitment, motivation and retention of high quality Senior Executives. To ensure that performance is the key factor in determining individual reward. To communicate the reward structure clearly and effectively to Executives and shareholders. 	<p>Chairman: Mr. G L H Premaratne Independent Non-Executive Director</p> <p>Committee member: Dr. S Selliah Independent Non-Executive Director</p> <p>Frequency of meetings: Committee meets annually</p>

Corporate Governance

RELATED PARTY TRANSACTIONS REVIEW COMMITTEE	Composition
<p>Duties and responsibilities</p> <ul style="list-style-type: none"> Review in advance all the related party transactions carried out by the Company and its listed companies in the Group except related party transactions set out in Rule 9.5 of the Listing Rules of the Colombo Stock Exchange. Formulating policies and procedure to review related party transactions of the Company and of the Group and overseeing existing policies and procedures. Determining whether the relevant related party transactions are fair to, and in the best interest of the Company and/or Companies in the Group and its stakeholders. Determining whether the related party transactions that are to be entered into by the Company or Companies of the Group require the approval of the shareholders. Where necessary, the Committee may request the Board to approve related party transactions, which are under review by the Committee. Ensure that immediate market disclosures and disclosures in the Annual Report as required by the applicable rules and regulations are made appropriately. 	<p>Chairman: Mr. S A B Rajapaksa Independent Non-Executive Director</p> <p>Committee members: Mr. G L H Premaratne Independent Non-Executive Director Mr. S Ahangama Independent Non-Executive Director (Appointed as a member w.e.f 22nd September 2020)</p> <p>Frequency of meetings Committee meets quarterly</p>

INDEPENDENCE OF THE DIRECTORS

Dr. S Selliah, Mr. G L H Premaratnem, Mr. S A B Rajapaksa and Mr. S Ahangama function as Independent Directors of the Company.

As per the rules issued by the Colombo Stock Exchange Mr. S A B Rajapaksa and Mr. G L H Premaratne meet all the criteria of Independence except one.

Dr. S Selliah meets all the criteria of independence except two.

Mr. S A B Rajapaksa, Dr. S. Selliah and Mr. G L H Premaratne had served on the Board of the Company continuously for a period exceeding nine (9) years from the date of their first appointment.

Dr. S Selliah is also a Director of Softlogic Holdings PLC which has a significant shareholding in the immediate parent Company.

The Board having evaluated all the factors concluded that their independence have not been impaired due to them serving on the Board of another Company which has a significant shareholding in the Company and having served on the Board of the Company continuously for a period exceeding nine (9) years from the date of the first appointment.

COMPLIANCE WITH CORPORATE GOVERNANCE RULES OF THE CSE

The following disclosures are made in conformity with Section 7 of the Listing Rules of the Colombo Stock Exchange:

Section	Criteria	Has the company met the criteria
7.10.1	Non-Executive Directors	Complied with. Out of 8 Directors 6 are Non-Executive Directors.
7.10.2	Independent Directors	Complied with. There are 3 Independent Directors on the Board. All Non-Executive Directors have submitted the declaration with regard to their independence/non-independence.
7.10.3	Disclosures relating to Directors	Mr. G L H Premaratne and Mr. S A B Rajapaksa meet all the criteria except one and Dr. S. Selliah meets all the criteria except two.
7.10.5	Remuneration Committee	Complied with. Comprises 2 Independent Non-Executive Directors. The names of the members of the Committee are given in the page 29 of the Annual Report.
7.10.6	Audit Committee	Complied with. Comprises 3 Independent Non-Executive Directors The names of the members of the Committee are given in the page 29 of the Annual Report. The report of the Committee is given on pages 36 and 37 The Chief Financial Officer attends all the meetings.

Risk Management Report

INTEGRATED RISK MANAGEMENT

Risk management is a fundamental responsibility of the Board of Directors. The Asiri Group Board of Directors has established a robust Risk management framework which empowers all employees of the group to effectively manage risk in their day to day business activities. Being the key player in the private Healthcare industry in Sri Lanka, our main focus is on Health & safety of patients and the wellbeing of our employees, where we strive to improve the quality of human life, through the provision of ethical healthcare solutions together with cutting-edge technology. Driving towards a culture of safety, the Board regularly reviews the adequacy of risk management controls in line with the defined risk appetite and to determine the Group's ability to fulfill operational and clinical compliance requirements. These risk assessments provide

greater insights on the areas of improvements while the Risk scoring matrix helps top priorities the Group's key risks.

The Asiri Group keeps a keen eye on emerging Risks and has adopted number of Risk mitigation strategies to strengthen the Group's resilience. This includes ensuring the highest level of industry standards and best practices are followed to eliminate expensive lawsuits and undue damages to the Group's reputation.

The Asiri Group has adopted an integrated Risk Management framework to identify, assess, prioritize the significant risks and manage those with appropriate risk mitigation actions. In this regard, the Risk Management Committee is assisted by special sub-committees that focus

on Quality & Patient safety, Facility management, Incidents review, patient feedback & complaints review and Mortality & Morbidity review. Heads of the business unit act as the first line of defense, while financial controls, Information Security practices and Compliance functions serve as the second line of defense. The third line of defense comprises of Assurance services and internal controls as well as the Internal & External Auditors. Adequacy and effectiveness of the Risk management framework is periodically reviewed by the Board Audit Committee and required changes are recommended to Board of Directors.

PERCEIVED RISKS

Below table presents the key risks identified by Asiri Group of Hospitals together with potential impact and measures taken to mitigate those risks.

Risk	Potential Impact	Mitigation Strategy
<p>Adverse Clinical outcomes rated as ISR 1 or 2</p> <p>Any event or incident that leads to an adverse outcome for a patient rated as Incident severity rating 1 or 2 would be detrimental to the reputation of the organization. Examples- death of a patient due to negligence of the clinical team, surgical complications, hospital acquired infections of an immunocompromised patient, patient fall leading to head injury or fracture.</p>	<p>As a hospital, Risks associated with patient care are extremely imperative. Clinical risks can lead to other risks including reputation and legal risk in addition to causing financial losses.</p> <p>The likelihood and consequences of Clinical Risks may vary time to time. However it is the most significant and vulnerable area to Asiri Group of Hospitals in terms of Risk.</p>	<p>Regular supervision of all clinical work at unit level to ensure competent staff are deployed and instructions followed at all times.</p> <p>Abide by the clinical guidelines, SOP's and unit protocols to ensure consistency of services, Regular training and evaluation of clinical staff to ensure competency and update of knowledge</p> <p>Strict credentialing and evaluation process of all clinical staff at point of recruitment to ensure appropriate skill and competency, while practicing privileges granted accordingly to all clinicians, nurses and para medical staff.</p> <p>Timely preventive repair, replacement of medical equipment, instruments through comprehensive service contracts for critical equipment.</p> <p>Strict infection control program</p> <p>Monthly patient feedback, complaint review and Incident review as a continuous improvement process</p> <p>Subcommittee on Clinical Risk Management fully operates within its sphere to ensure that all clinical Risks that are reported, are addressed adequately and appropriate controls are in place to prevent additional Clinical Risk events. Frequent monitoring and review of Clinical Risks to ensure the Group's Clinical Risk Management plan is adequate and effective.</p>

Risk	Potential Impact	Mitigation Strategy
Strategic Risk		
<p>Strategic Risk is the risk that arises due to the timeliness and accuracy of the Group's strategy, and objectives, as well as the effectiveness of the strategy execution process. It is a possible source of loss that might arise from pursuing of an unsuccessful business plan.</p> <p>Strategic Risk might also arise from inadequate resource allocation or from a failure to respond well to changes in the business environment.</p>	<p>Strategic risk is often a major factor in determining a Group's worth and may lead to a complete failure if not addressed accordingly.</p> <p>Incompetent strategic decisions will adversely affect shareholder objectives while failure to execute innovative decisions will hinder the expansion and opportunities in the emerging markets.</p>	<p>Annual business planning sessions which involve brain storming with cross functional teams from senior management and heads of departments to staff members.</p> <p>Monthly reviews with sales and marketing teams to understand and take appropriate action based on market behaviour and competitor activity.</p> <p>Regular follow up/ review on all new projects with the Group CEO and MD.</p> <p>All strategic decisions are scrutinized by the Board of Directors who have expertise knowledge and vast experience in the industry.</p>
Operational Risk		
<p>These are the Risk of losses resulting from inadequate or failed internal processes, people and systems or from external events.</p>	<p>Operational risk exists in the natural course of business activity. Failure to manage operational risks can expose the Group to significant losses.</p>	<p>The Group is committed to enhance the effectiveness of Operational Risk Management process through identification, assessment, treatment, monitoring and control of all operational aspects of the business.</p> <p>Regular review of processes and redesign to ensure smooth operation from customer's point of view.</p> <p>Our Risk management framework has been designed to promptly detect deficiencies in the policies, procedures and processes. However, some Risks may be latent and we have crisis management processes designed to improve our resilience to unforeseen events.</p> <p>Business continuity arrangements are in place to address supply chain disruption, employee repatriation, natural disasters, cyber-attacks, technical mishaps and can minimize their impact on our stakeholders as well as the Group's reputation and performance.</p> <p>Robust policies for IT Security have been implemented and frequent IT audits and reviews are conducted to ensure the adequacy of controls and areas of improvements.</p>

Risk Management Report

Risk	Potential Impact	Mitigation Strategy
Human Resources (People)		
Service industry, in which the Group operates, is heavily dependent on human resources.	Human resource issues could affect the continuity of business operations. The consequences could be serious, when loss of key executives without suitable replacement.	The Group has introduced a comprehensive recruitment and retention process. Clinical staff are recruited following a thorough evaluation of their credentials and regulatory requirements. While ensuring the safety and welfare of the employees, our risk management approach is directed towards minimizing the Human related concerns. A succession planning program is in place which includes; regular trainings, developments, promotions, KPI and supervision.
Risks may arise from employee negligence, conflict of interest, fraud or misappropriation and due to poorly trained employees.	Thus the ability to recruit and retain qualified and skilled healthcare professionals are crucial for the Group's success.	Recognition and reward schemes to encourage and promote desirable behaviour is in place.
Human capital may affect by failure to attract, develop and retain skilled workforce.		Retaining key talent with appropriate incentive schemes and periodic review of performance if in place.
Technological & information security		
The healthcare industry is exposed to frequent technological change and failure to adopt these latest technologies will drive the Group towards technological obsolescence.	If systems are disrupted over the internet, by an adversary or an accident, that can have a profound impact on patient care.	Research and innovations in the healthcare industry are regularly perused as the Group is intent on adopting most innovative & advance technologies for diagnostics and treatments.
Increasing use of technology has hosted new levels of complexity and threats such as: security breaches, system failures, malicious attacks, IT fraud and many other issues.	Inability to adopt the latest pioneering technology could result in loss of customers, leading to fall in revenue and loss of market leadership.	Preventive maintenance of IT infrastructure, scheduled data backups, offsite storage and round-the-clock IT support by the parent Group are some of the strategies adopted to ensure zero losses of data during a system failure.
		The Asiri Group makes regular investments in pioneering technology and training of staff for optional application of existing technology.
Legal and Compliance Risk		
In a highly regulated, high Risk industry such as healthcare, compliance is especially important.	The Group will be exposed to legal penalties, financial forfeiture and material losses and the consequences of litigation are difficult to predict or quantify.	Regulatory compliance is ensured with check lists, timely renewal of licenses, regular inspection and review of practices and training of staff in HR, Finance, waste management, pharmacy and laboratory services etc.
Compliance risk arises when the Group fails to act in accordance with industry laws and regulations, internal policies or prescribed best practices.	In addition to complying with the Colombo Stock Exchange, Securities and Exchange Commission and Companies Act disclosure requirements, the Group also complies with Sri Lanka Accounting Standards. Non-compliance would cause severe reputation damages as well.	The Group's corporate governance framework ensures the transparency, compliance with laws & regulation and ethical business in all affairs with stakeholders. The Related Party Transaction Review committee has been established to assure the highest level of integrity and transparency.

Ethics Committee Report

The Ethics Committee of the Asiri Group of Hospitals was constituted to serve as an advisory body on matters relating to conduct of research and clinical trials within the Asiri Group of Hospitals. Also, the matters concerning ethics issues around patient care referred to it by the Management and visiting & resident staff. The committee is responsible to report its decisions to Management.

The committee is entrusted with the task of peruse, on behalf of the Management, all proposals for research that is proposed to be carried out on Asiri Hospital patients submitted to the hospital for permission:

- To verify that the proposed investigators have obtained ethics approval from a SIDCER recognition by FERCAP Ethics Committee/s;
- To verify that the proposed investigators have obtained all other approvals and permissions necessary depending on the nature of the research and the proposed research subjects; and
- Also to verify that it meets other requirements that may be decided from time to time and set out as Committee Decisions.

The committee has so far reviewed experimental therapy and clinical trial protocols submitted to it by clinicians at Asiri. These include protocols on experimental stem cell therapy for Parkinson Disease and spinal cord transaction and a phase II trial for rheumatoid arthritis using an anti TNF alpha antibody. Also, the committee has reviewed the proposal for "Dialog m Health Trial with Asiri – (Evaluation of ambulant remote monitoring technology for investigating cardiac arrhythmias)".

The committee will consider and advise the Management regarding ethics issues that arise around patient care as described in Standard Operating Procedures.

The committee is constituted and operates in accordance with an SLMA Ethics Committee proposal for the establishment of Hospital Ethics Committees in Sri Lanka.

Members:

Prof. Rohan W Jayasekara, (Chairperson)
(Emeritus Professor of Anatomy / Medical Geneticist, Faculty of Medicine, University of Colombo.)

Dr. Malik Fernando
(Retired Physician /Member of Ethics Review Committee of Sri Lanka Medical Association- sometime Chair Ethics Committee SLMA)

Dr. Arittha Wickramanayake
(Attorney at Law /Precedent Partner, Nithya Partners)

Dr. Siva Selliah
(Deputy Chairman of Asiri Hospital Holdings PLC / Senior Lecturer, Dept. of Physiology, Faculty of Medicine University of Kelaniya)

Prof. Kemal I Deen
(Consultant General Surgeon –Intestinal)

Dr. Indrani Amarasinghe
(Consultant Oncologist)

Prof. Chandani Wanigatunga
(Professor in Pharmacology and Consultant Physician)

Dr. Kamal Weerapperuma
(Company Director)

Prof. Shalini Sri Ranganathan
(Professor in Pharmacology and Specialist Paediatrician)

Sgd.

Prof. Rohan Jayasekara
Chairman – Ethics Committee

30 June 2021
Colombo

Audit Committee Report

SCOPE OF THE COMMITTEE

The Audit Committee supports the Board of Directors in fulfilling its oversight responsibility for the Group's financial reporting system, system of internal controls, risk management process, internal audit function, compliance with legal and regulatory requirements and review of the external auditors' performance and independence.

COMPOSITION OF THE COMMITTEE AND MEETINGS

The Audit Committee is appointed by the Board of Directors and comprises three independent Non-Executive Directors. Their names are stated in the Corporate Governance Report on Page 29.

Mr. R A Ebell ceased to be a director of Asiri Hospital Holdings PLC on 30th June 2020 and Mr. S Ahangama was appointed as a Director on 27th August 2020. Mr. Ahangama was appointed as the Chairman of the committee on 22nd September 2020, the position previously held by Mr. R A Ebell.

The Audit Committee met on five occasions during the year under review. The activities of the Audit Committee are reported periodically to the Group Chairman and the Board of Directors.

The attendance at Audit Committee meetings was as follows:

Name of Director	Attendance
Mr. S Ahangama (Member/Chairman from 22/9/2020)	3/3
Mr. R A Ebell (Member/Chairman to 30/6/2020)	1/1
Mr. S A B Rajapaksa	5/5
Mr. G L H Premaratne	4/5

The Chief Financial Officer and the Group Manager - Audit of Asiri Group were permanent attendees at these meetings, as were the Group Head of Risk & Audit and the Group Finance Director of Softlogic Group. The External Auditors attended meetings by invitation when required and the Company Secretaries, Softlogic Corporate Services (Pvt) Ltd served as secretaries to the committee.

DUTIES AND RESPONSIBILITIES

The duties of the Audit Committee include:

- Oversight of preparation, presentation and adequacy of disclosure in the financial statements, in accordance with applicable laws, regulations and accounting standards.
- Oversight of processes directed towards ensuring internal controls and risk management procedures are adequate and effective.
- Monitoring and reviewing the effectiveness of the internal audit function.
- Assessing the Company's ability to continue as a going concern in the foreseeable future
- Assessing the independence and performance of the Company's external auditor

The committee discharges the following responsibilities:

Financial Statements, Financial Reporting Process and Accounting Policies	<p>The Audit Committee reviews:</p> <ul style="list-style-type: none"> • The quarterly and annual Financial Statements prior to publication. • The appropriateness of Accounting Policies applied. • Significant estimates and judgements by management. • Compliance with Accounting Standards and regulatory requirements. • Issues arising from the Internal Audit and Independent External Audit. • The Company's ability to continue as a going concern.
Internal Controls and Risk Management	<p>The Audit Committee reviews and assesses:</p> <ul style="list-style-type: none"> • The internal control environment and areas of significant risk. • The effectiveness of internal control systems. • Policies and practices directed towards ensuring a sound system of internal control is in place. • Internal and external auditors' reviews of internal control over financial reporting and their reports on significant findings and recommendations, alongside management's responses.
Internal Auditing	<p>The Audit Committee reviews and approves:</p> <ul style="list-style-type: none"> • The internal audit charter. • The internal audit budget and resource plan including staffing and organizational structure of the function. • The annual audit plan, major changes to the plan and the internal audit activity's performance against the plan, ensuring there are no unjustified restrictions or limitations on their activity.

External Audit	<p>The Audit Committee:</p> <ul style="list-style-type: none"> • Reviews the external auditors' audit scope and approach, including coordination of audit effort with internal audit. • Reviews the performance, independence & objectivity of the external auditors. • Makes recommendations to the Board pertaining to the appointment, re- appointment and removal of external auditors and their remuneration and terms of engagement. Recommendations for re- appointment of external auditors consider their independence and performance & objectivity, which are assessed by reference to declarations made by them, to management views and to the Audit Committee's observations in their interactions with the external auditors. • Seeks to resolves disagreement between management and the external auditor regarding financial reporting.
Compliance	<p>The Audit Committee reviews:</p> <ul style="list-style-type: none"> • The effectiveness of the system for monitoring compliance with laws and regulations and the results of management's investigations. • The findings of examinations by regulatory agencies, and auditors' observations. • Updates from management and company legal counsel regarding compliance.

The Audit Committee recommends to the Board of Directors that M/s Ernst & Young be re-appointed as auditors of the Company for the financial year ending 31st March 2022, subject to the approval of the shareholders at the Annual General Meeting.

In making this recommendation, the Audit Committee believes M/s Ernst & Young have no other relationship with, or interest in, the Company or any company within the Asiri Hospital Holdings Group, and thus are independent in their role as auditors.

Sgd.

S. Ahangama

Chairman – Board Audit Committee

30 June 2021

Colombo

Remuneration Committee Report

The Remuneration Committee is a subcommittee of the Board constituted under the Company's Corporate Governance policies for the purpose of recommending and endorsing the remuneration of Senior Management. The members of the Committee comprise two Independent Non-Executive Directors. The names of the Committee members are stated in the Corporate Governance Report on page 29.

The remuneration policy is designed to reward, motivate and retain the Company's executive team, with market competitive remuneration and benefits, to support the continued success of the business and creation of shareholder value. Accordingly, salaries and other benefits are reviewed periodically taking into account the performance of the individual and industry standards.

All Non-Executive Directors receive a fee for serving on the Board and serving on subcommittees. They do not receive any performance related incentive payments.

The Directors' emoluments are disclosed on page 68.

The Committee meets annually. The Committee has acted within the parameters set by its terms of reference.

Sgd.

G L H Premaratne

Chairman – Remuneration Committee

30 June 2021

Colombo

Report of the Related Party Transactions Review Committee

PURPOSE

The Related Party Transactions Review Committee was established by the Board in order to comply with the Listing Rules of the Colombo Stock Exchange governing related party transactions in respect of listed companies as per the Code of Best Practice on Related Party Transactions (the Code) issued by the Securities and Exchange Commission of Sri Lanka (SEC) and the Listing Rules (the "Rules"). of the Colombo Stock Exchange (CSE).

The Board Related Party Transactions Review Committee (the "Committee") assists the Board in reviewing all related party transactions carried out by the Company and its listed companies in the Group by early adopting of the Code of Best Practice on Related Party Transactions as issued by the Securities and Exchange Commission of Sri Lanka.

COMPOSITION

The Related Party Transactions Review Committee is appointed by the Board of Directors of the Company and the following Directors served on the Committee as at 31st March, 2021:

Mr. S A B Rajapaksa – Chairman

Mr. G L H Premaratne – Independent Non-Executive Director

Mr. S Ahangama – Independent Non-Executive Director (Appointed as a member w.e.f. 22nd September 2020)

Mr. R A Ebell (Member) - Independent Non-Executive Director (Resigned w.e.f.30th June 2020)

Mr. Ajith Karunaratne - Chief Financial Officer attends all meetings by invitation.

Softlogic Corporate Services (Pvt) Ltd., Secretaries of the Company function as the Secretary to the Related Party Transactions Review Committee.

ATTENDANCE AT MEETINGS

Name of Director	Attendance
Mr S A B Rajapaksa	4/4
Mr G L H Premaratne	4/4
Mr S Ahangama (Appointed w.e.f. 22nd September 2020)	2/2
Mr. R A Ebell (Resigned w.e.f 30th June 2020)	1/1

ROLES AND RESPONSIBILITIES

- Reviewing in advance all proposed related party transactions of the Company and its listed companies in the Group in compliance with the Code.
- Adopting policies and procedures to review related party transactions of the Company and its subsidiaries and reviewing and overseeing existing policies and procedures.
- Determining whether related party transactions that are to be entered into by the Company and/or its subsidiaries require the approval of the Board or Shareholders of the respective companies.
- If related party transactions are ongoing (recurrent related party transactions) the Committee establishes guidelines for Senior Management to follow in its ongoing dealings with the relevant related party.
- Ensuring that no Director of the Company shall participate in any discussion of a proposed related party transactions for which he or she is a related party, unless such Director is requested to do so by the Committee for the express purpose of providing information concerning the related party transactions to the Committee.
- If there is any potential conflict in any related party transactions, the Committee may recommend the creation of a special committee to review and approve the proposed related party transactions.

- Ensuring that immediate market disclosures and disclosures in the Annual Report as required by the applicable rules/regulations are made in a timely and detailed manner.

REVIEW OF THE RELATED PARTY TRANSACTIONS DURING THE YEAR

The Committee reviewed the Related Party Transactions of Asiri Hospital Holdings PLC and compliances according to SEC Code and CSE Listing Rules. The activities and observations of the Committee have been communicated to the Board quarterly through tabling minutes of the meeting of the Committee at Board Meetings. Details of Related Party Transactions entered by the Group during the above period are disclosed in Note 32 to the Financial Statements.

The Committee in its review process, recognised the adequacy of the content and quality of the information forwarded to its members by the management during the year and is satisfied on the compliance of Related Party Transactions in accordance to SEC Code and CSE listing rules.

Sgd.

S A B Rajapaksa

Chairman – Related Party Transactions Review Committee

30 June 2021
Colombo

Statement of Directors' Responsibilities

The responsibilities of the Directors, in relation to the Financial Statements of the Company differ from the responsibilities of the Auditors, which are set out in the Report of the Auditors on pages 45 to 47. The Companies Act No. 07 of 2007 stipulates that the Directors are responsible for preparing the Annual Report and the Financial Statements. Company law requires the Directors to prepare Financial Statements for each financial year, giving a true and fair view of the state of affairs of the Company at the end of the financial year, and of the Statement of Comprehensive Income of the Company and the Group for the financial year, which comply with the requirements of the Companies Act. The Directors consider that, in preparing Financial Statements set out on pages 48 to 114 of the Annual Report, appropriate accounting policies have been selected and applied in a consistent manner and supported by reasonable and prudent judgements and estimates, and that all applicable accounting standards have been followed. The Directors confirm that they have justified in adopting the going concern basis in preparing the Financial Statements since adequate resources are available to continue operations in the foreseeable future. The Directors are responsible for keeping proper accounting records, which disclose reasonable accuracy, at any time, the financial position of the Company and to enable them to ensure the Financial Statements comply with the Companies Act No. 07 of 2007 and are prepared in accordance with Sri Lanka Accounting Standard (SLFRS/LKAS). They are also responsible for safeguarding the assets of the Company and for taking reasonable steps for the prevention and detection of fraud and other irregularities. In this regard the Directors have instituted an effective and comprehensive system of internal control. The Directors are required to prepare Financial Statements and to provide the External Auditor with every opportunity to take whatever steps and undertake whatever inspections they may consider to be appropriate to enable them to give their independent audit opinion. The Directors are of the view that they have discharged their responsibilities as set out in this statement.

COMPLIANCE REPORT

The Directors confirm that to the best of their knowledge, all taxes, duties and levies payable by the Company, all contributions, levies and taxes payable on behalf of and in respect of the employees of the Company and other known statutory dues as were due and payable by the Company as at the date of the Statement of Financial Position have been paid or, where relevant provided for, in arriving at the financial results for the year under review except as specified in Note 30 to the Financial Statements covering contingent liabilities.

COMPLIANCE WITH RELATED PARTY TRANSACTIONS RULES

Transactions of related parties (as defined in LKAS 24 – "Related Parties Disclosure") with the Company are set out in Note 32 to the Financial Statements.

For and on behalf of the Board of Asiri Hospital Holdings PLC

Sgd.
Secretaries
Softlogic Corporate Services (Pvt) Ltd.

30 June 2021
Colombo

Annual Report of the Board of Directors

The Directors of Asiri Hospital Holdings PLC have pleasure in presenting to the members their report together with the Audited Financial Statements of the Company and the Audited Consolidated Financial Statements of the Group for the year ended 31st March 2021.

PRINCIPAL ACTIVITIES AND NATURE

The principal activity of the Company continues to be carrying out Healthcare and Hospital Services. There has been no significant change in the nature of the Group's/Company's principal activities during the year.

REVIEW OF OPERATIONS

A review of the operations of the Group and its performance during the year is contained in the Group Operations Review on pages 11 to 14 of the Annual Report. This review together with the Financial Statements reflects the state of affairs of the Company and the Group. These reports form an integral part of the Directors' report.

FINANCIAL STATEMENTS

Section 168 (b) of the Companies Act No. 07 of 2007 requires that the Annual Report of the Directors to include Financial Statements of the Company, in accordance with Section 151 of the Act and Group Financial Statements for the accounting period, in accordance with Section 152 of the Act. The requisite Financial Statements of the Company are given on pages 48 to 114 of the Annual Report.

DIRECTORS' RESPONSIBILITY FOR FINANCIAL REPORTING

The Directors are responsible for the preparation of the Financial Statements of the Company to reflect a true and fair view of the state of affairs. The Directors are of the view that these Financial Statements have been prepared in conformity with the requirements of the Companies Act No. 07 of 2007 and the Sri Lanka Financial Reporting Standards. A statement in this regard is given on page 40.

AUDITOR'S REPORT

The Auditor's Report on the Financial Statements is given on pages 45 to 47.

ACCOUNTING POLICIES

The accounting policies adopted in the preparation of the Financial Statements are given on pages 54 to 65. There was no change in the accounting policies adopted, other than those disclosed in Note 2.5 to the Financial Statements.

INTERNAL CONTROL

The Board has overall responsibility for the Company's system of internal control and review of its effectiveness. The internal control system has been designed to meet the particular needs of the Organisation concerned, and the risk to which it is exposed, and by their nature can provide reasonable but not absolute assurance against material misstatement or loss. The Board is satisfied with the effectiveness of the internal control system for the period up to the date of signature of the accounts.

DIRECTORATE

The following Directors held office during the year under review:

Mr. A K Pathirage – Chairman/Managing Director
Dr. S Selliah – Deputy Chairman
Dr. K M P Karunaratne – Group Chief Executive Officer

DIRECTORS' SHAREHOLDING

The relevant interests of Directors in the shares of the Company are as follows:

Name of Director	Number of shares as at 31 March 2021	Number of share as at 31 March 2020
Mr. A K Pathirage	371,664	371,664
Dr. S Selliah	-	-
Dr. K M P Karunaratne	9,424	9,424
Mr. G L H Premaratne	-	-
Mr. S A B Rajapaksa	-	-
Mr. V Bali	-	-
Mr. A N Thadani	-	-
Mr. S Ahangama	-	-

INTERESTS REGISTER

The Interests Register is maintained by the Company as per the Companies Act No. 07 of 2007. All Directors have disclosed their interests pursuant to Section 192 (2) of the said Act.

Mr. G L H Premaratne
Mr. S A B Rajapaksa
Mr. S Ahangama (Appointed w.e.f. 27th August 2020)
Mr. V Bali
Mr. A N Thadani
Mr. A N Thadani (Alternate Director to Mr V Bali)
Mr. R A Ebell (Resigned w.e.f. 30th June, 2020)

In terms of Article 24 (6) of the Articles of Association of the Company, Mr. S A B Rajapaksa and Mr. A N Thadani retire by rotation and being eligible offer themselves for re-election.

In terms of Article 24 (2) of the Article of Association of the Company Mr. S Ahangama retires and being eligible offer himself for election.

The Directors have recommended the reappointment of Mr. G L H Premaratne who is 73 years of age, as a Director of the Company; and accordingly a resolution will be placed before the shareholders in terms of Section 211 of the Companies Act in regard to the reappointment of Mr. G L H Premaratne.

Annual Report of the Board of Directors

DIRECTORS' INTERESTS IN CONTRACTS AND PROPOSED CONTRACTS WITH THE COMPANY

Directors' interests in contracts, both direct and indirect are referred to in Note 32 to the Financial Statements. The Directors have no direct or indirect interest in any other contract or proposed contract with the Company.

DIRECTORS' REMUNERATION

Directors' remuneration in respect of the Company and the Group for the financial year 2020/21 are given in Note 5 to the Financial Statements on page 68.

DONATIONS

The donations made by the Company during the year amounted to LKR 120,590/- (2019/20 – LKR 504,019/-).

AUDITORS

Messrs Ernst & Young, Chartered Accountants, are willing to continue as Auditors of the Company and a resolution proposing their reappointment will be tabled at the Annual General Meeting. As far as the Directors are aware the Auditors Messrs Ernst & Young does not have any relationship (other than that of an auditor) with the Company. The Auditors also does not have any interest in the Company or in the subsidiary Companies.

DIVIDENDS

The Directors recommended that to the shareholders that the first interim dividend of LKR 0.80 per share paid on 12th October, 2020.

The Directors recommended that to the shareholders that the second interim dividend of LKR 0.80 per share paid on 16th April, 2021.

CAPITAL EXPENDITURE

The capital expenditure of the Group and the Company during the year amounted to LKR 1,526 Mn. and LKR 891 Mn. respectively (2019/20 – Group LKR 4,232 Mn. and Company – LKR 1,425 Mn.) details of which are given in Note 9 to the Financial Statements.

STATED CAPITAL

The stated capital of the Company as at 31st March 2021 was LKR 4,748,108,334/- (2019/20- LKR 4,748,108,334) represented by 1,137,533,596 ordinary shares.

RESERVES

The total reserves of the Group and the Company as at 31st March 2021 amounted to LKR 5,546 Mn and LKR 3,663 Mn respectively (2019/20 – Group LKR 5,212 Mn and Company – LKR 3,187 Mn). The composition of reserves is shown in the Statement of Changes in Equity in the Financial Statements.

SHAREHOLDERS' INFORMATION

The distribution of shareholders is indicated on pages 116 and 117 in the Annual Report. There were 5,613 registered shareholders as at 31st March 2021.

SHARE INFORMATION

Information on share trading is given on page 118 of the Annual Report.

EVENTS AFTER THE DATE OF THE STATEMENT OF FINANCIAL POSITION

No circumstances have arisen and no material events have occurred since after the date of Statement of Financial Position, which would require adjustments to, or disclosure in the accounts other than those disclosed in Note 31 to the Financial Statements.

STATUTORY PAYMENTS

The Directors, to the best of their knowledge and belief are satisfied that all taxes, duties and levies payable by the Company and the Group, all contributions, levies and taxes payable on behalf of, and in respect of, the employees of the Company and the Group, and all other known statutory dues as were due and payable by the Company and the Group as at the date of the Statement of Financial Position have been paid or, where relevant provided for, except as specified in Note 30 to the Financial Statements, covering contingent liabilities.

GOING CONCERN

The Board is satisfied that the Company has adequate resources to continue its operations in the foreseeable future and the Directors have adopted the going concern basis in preparing the accounts.

ANNUAL GENERAL MEETING

The Forty First (41) Annual General Meeting of the Company will be held by electron means on Monday, the 23rd August 2021 at 10.30 am. The Notice of the 41st Annual General Meeting is on page 122 of the Annual Report.

For and on behalf of the Board,

Sgd.
Ashok Pathirage
Chairman/Managing Director

Sgd.
Dr Manjula Karunaratne
Group Chief Executive Officer

Sgd.
Secretaries
Softlogic Corporate Services (Pvt) Ltd.

30 June 2021
Colombo

Financial Reports

Independent Auditors' Report	45
Statement of Profit or Loss	48
Statement of Comprehensive Income	49
Statement of Financial Position	50
Statement of Changes in Equity	51
Statement of Cash Flows	53
Notes to the Financial Statements	54

Independent Auditors' Report



Ernst & Young
Chartered Accountants
201 De Saram Place
P.O. Box 101
Colombo 10
Sri Lanka

Tel : +94 11 2463500
Fax Gen : +94 11 2697369
Tax : +94 11 5578180
eysl@lk.ey.com
ey.com

TO THE SHAREHOLDERS OF ASIRI HOSPITAL HOLDINGS PLC

Report on the audit of the Consolidated Financial Statements

Opinion

We have audited the financial statements of Asiri Hospital Holdings PLC ("the Company") and the consolidated financial statements of the Company and its subsidiary ("the Group"), which comprise the statement of financial position as at 31 March 2021, and the statement of profit or loss, statement of comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying financial statements of the Company and the Group give a true and fair view of the financial position of the Company and the Group as at 31 March 2021, and of their financial performance and

cash flows for the year then ended in accordance with Sri Lanka Accounting Standards.

Basis for opinion

We conducted our audit in accordance with Sri Lanka Auditing Standards (SLAuSs). Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the Group in accordance with the Code of Ethics issued by CA Sri Lanka (Code of Ethics) and we have fulfilled our other ethical responsibilities in accordance with the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key audit matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial statements of the current period. These matters

were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. For each matter below, our description of how our audit addressed the matter is provided in that context.

We have fulfilled the responsibilities described in the Auditor's responsibilities for the audit of the financial statements section of our report, including in relation to these matters. Accordingly, our audit included the performance of procedures designed to respond to our assessment of the risks of material misstatement of the financial statements. The results of our audit procedures, including the procedures performed to address the matters below, provide the basis for our audit opinion on the accompanying financial statements.

Partners: W R H Fernando FCA FCMA R N de Saram ACA FCMA Ms. N A De Silva FCA Ms. Y A De Silva FCA W R H De Silva ACA ACMA W K B S P Fernando FCA FCMA
Ms. K R M Fernando FCA ACMA Ms. L K H L Fonseka FCA A P A Gunasekera FCA FCMA A Herath FCA D K Hulangamuwa FCA FCMA LLB (Lond) H M A Jayasinghe FCA FCMA
Ms. A A Ludowyke FCA FCMA Ms. G G S Manatunga FCA A A J R Perera ACA ACMA Ms. P V K N Sajeewani FCA N M Sulaiman ACA ACMA B E Wijesuriya FCA FCMA
Principals: G B Goudian ACMA T P M Ruberu FCMA FCCA

A member firm of Ernst & Young Global Limited

Independent Auditors' Report

Key Audit Matter	How our audit addressed the key audit matter
<p>Revaluation of freehold land and buildings</p> <p>Property, Plant and Equipment include land and buildings carried at fair value. The fair values of land and buildings were determined by external valuers engaged by the Group. Valuation of land and buildings was a key audit matter due to;</p> <ul style="list-style-type: none"> Materiality of the reported values for land and buildings which amounted to Rs. 6.0 Bn and Rs.13.0 Bn respectively and collectively accounted for 60% of Total Assets as at 31 March 2021. The degree of assumptions, judgements and estimation uncertainties associated with valuation of land and buildings. The valuation contained higher estimation uncertainties as comparable market transactions, which are generally considered to be a strong source of evidence regarding fair value, were fewer, due to the COVID-19 pandemic. <p>Key areas of significant judgments, estimates and assumptions included the following:</p> <ul style="list-style-type: none"> Estimate of the per perch value of land. Estimate of the per square foot value of building. 	<p>Our audit procedures included the following;</p> <ul style="list-style-type: none"> We evaluated the competence, capability and objectivity of the external valuers engaged by the Group. We read the reports of the external valuers and understood the key estimates made and the approach taken by the valuers in determining the valuation of land and buildings. We engaged our internal resources to assist us in assessing the appropriateness of the valuation techniques used and the reasonableness of the significant judgements and assumptions such as per perch price and value per square foot used by the valuers. We assessed the adequacy of the disclosures made in Note 2.4.6 and 9 in the financial statements.
<p>Revenue</p> <p>The Group's revenue generated from its healthcare services is disclosed in Note 3.1. We considered revenue as a focus area due to the significance of the balance to the financial statements, its high volume of transactions, Management's use of judgements in the determination of appropriateness of gross or net basis of revenue recognition in certain service arrangements and reliance on Information Technology (IT).</p>	<p>Our audit procedures included among others the following;</p> <ul style="list-style-type: none"> We obtained an understanding and selected key controls over revenue recognition in respect of initiation of transactions, the basis of calculation and timing of the recognition. We also tested the integrity of the general IT control environment relating to the most significant IT systems relevant to revenue recognition and tested relevant IT application controls. We discussed with Management regarding the service arrangements particularly relating to involvement of consultant medical personnel and reviewed appropriateness of Management's determination of recognition of underlying revenue on a gross or net basis. We assessed the adequacy of the disclosures made in Note 2.4.15 and 3.1 in the financial statements.

Other information included in the Group's 2021 Annual Report

Other information consists of the information included in the Annual Report, other than the financial statements and our auditor's report thereon. Management is responsible for the other information.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of management and those charged with governance

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with Sri Lanka Accounting Standards, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's and the Group's financial reporting process.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SLAuSs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SLAuSs, we exercise professional judgement and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of

expressing an opinion on the effectiveness of the internal controls of the Company and the Group.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with ethical requirements in accordance with the

Code of Ethics regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

As required by section 163 (2) of the Companies Act No. 07 of 2007, we have obtained all the information and explanations that were required for the audit and, as far as appears from our examination, proper accounting records have been kept by the Company.

CA Sri Lanka membership number of the engagement partner responsible for signing this independent auditor's report is 2471.



30 June 2021
Colombo

Statement of Profit or Loss

Year ended 31 March	Note	Group		Company	
		2021 Rs.	2020 Rs.	2021 Rs.	2020 Rs.
Revenue	3.1	15,784,522,792	15,510,422,042	6,138,339,296	5,706,706,324
Cost of Services		(8,994,512,839)	(8,499,000,884)	(3,022,664,028)	(2,720,156,402)
Gross Profit		6,790,009,953	7,011,421,158	3,115,675,268	2,986,549,922
Other Income	3.2	195,045,397	210,192,284	99,662,750	105,803,524
Administrative Expenses		(3,617,515,545)	(3,699,887,346)	(1,504,199,023)	(1,410,817,380)
Selling and Distribution Expenses		(565,510,696)	(532,670,577)	(205,115,532)	(233,266,355)
Finance Cost	4.1	(1,433,382,356)	(1,789,973,739)	(1,373,921,685)	(1,731,635,094)
Finance Income	4.2	242,331,432	191,699,550	74,328,094	92,361,885
Dividend Income	4.3	-	-	1,617,051,213	-
Changes in Fair Value of Investment Property	11	-	19,211,705	-	-
Share of Results of Equity Accounted Investees (Net of Tax)		-	704,357	-	-
Profit/(Loss) Before Tax	5	1,610,978,185	1,410,697,392	1,823,481,085	(191,003,498)
Tax Reversal/(Expense)	6	133,639,658	(492,490,274)	55,213,970	(110,456,901)
Profit/(Loss) for the Year		1,744,617,843	918,207,118	1,878,695,055	(301,460,399)
Attributable to:					
Equity Holders of the Parent Company		1,531,236,445	807,995,772		
Non-Controlling Interests		213,381,398	110,211,346		
		1,744,617,843	918,207,118		
Earnings / (Loss) Per Share - Basic	7	1.35	0.71	1.65	(0.27)
Dividend Per Share	8	1.60	-	1.60	-

Figures in brackets indicate deductions.

The Accounting Policies and Notes on pages 54 through 114 form an integral part of these Financial Statements.

Statement of Comprehensive Income

Year ended 31 March	Note	Group		Company	
		2021 Rs.	2020 Rs.	2021 Rs.	2020 Rs.
Profit/(Loss) for the Year		1,744,617,843	918,207,118	1,878,695,055	(301,460,399)
Other Comprehensive Income not to be reclassified to Statement of Profit or Loss in subsequent periods (net of tax):					
Net (Loss)/Gain on Equity Instruments at Fair Value Through Other Comprehensive Income	15.2	(67,437,190)	19,554,134	-	-
Revaluation of Land and Buildings		282,614,063	739,827,975	129,422,452	485,435,914
Actuarial Loss on Post Employment Benefit Liability	26.1	(79,859,407)	(38,232,002)	(56,432,374)	(18,607,573)
Share of Other Comprehensive Expense of Equity Accounted Investees (Net of Tax)		-	(84,001)	-	-
Net Other Comprehensive Income not to be reclassified to Statement of Profit or Loss in subsequent periods		135,317,466	721,066,106	72,990,078	466,828,341
Other Comprehensive Income to be reclassified to Statement of Profit or Loss in subsequent periods:					
Currency Translation of Foreign Operation		(670,556)	-	-	-
Net Other Comprehensive Income to be reclassified to Statement of Profit or Loss in subsequent periods		(670,556)	-	-	-
Tax on Other Comprehensive Income	25.1	579,084,544	(180,284,122)	344,566,308	(129,327,897)
Other Comprehensive Income for the Year, Net of Tax		713,731,454	540,781,984	417,556,387	337,500,444
Total Comprehensive Income for the Year, Net of Tax		2,458,349,297	1,458,989,102	2,296,251,442	36,040,045
Total Comprehensive Income Attributable to:					
Equity Holders of the Parent Company		2,210,477,746	1,330,695,919		
Non-Controlling Interest		247,871,551	128,293,183		
		2,458,349,297	1,458,989,102		

Figures in brackets indicate deductions.

The Accounting Policies and Notes on pages 54 through 114 form an integral part of these Financial Statements.

Statement of Financial Position

Year ended 31 March	Note	Group		Company	
		2021 Rs.	2020 Rs.	2021 Rs.	2020 Rs.
ASSETS					
Non-current Assets					
Property, Plant and Equipment	9	25,253,490,931	24,270,835,214	12,203,949,133	11,805,042,090
Right of Use Assets	10	1,309,859,796	1,367,469,429	946,612,185	942,802,774
Investment Property	11	-	215,000,000	-	-
Goodwill	12	609,654,071	609,654,071	-	-
Investment in Subsidiaries	13	-	-	12,341,176,740	12,219,356,753
Investment in Equity Accounted Investees	13.5	-	32,245,027	-	30,000,000
Other Non Current Assets	14	54,472,751	54,292,771	28,490,753	28,310,771
Non Current Financial Assets	15	323,258,010	360,695,200	30,000,000	-
		27,550,735,559	26,910,191,712	25,550,228,811	25,025,512,388
Current Assets					
Inventories	18	664,297,012	665,626,374	203,027,074	208,916,437
Trade and Other Receivables	19	789,098,929	902,177,693	551,037,804	368,877,292
Loans Granted to Related Parties	21	1,679,771,446	1,733,487,185	133,717	50,990,120
Other Current Assets	20	401,695,539	538,200,572	180,516,504	161,509,910
Cash and Cash Equivalents	29.1	985,680,944	1,448,291,268	530,712,583	817,434,641
		4,520,543,870	5,287,783,092	1,465,427,682	1,607,728,400
Total Assets		32,071,279,429	32,197,974,804	27,015,656,493	26,633,240,788
EQUITY AND LIABILITIES					
Capital and Reserves					
Stated Capital	22	4,748,108,334	4,748,108,334	4,748,108,334	4,748,108,334
Other Components of Equity	23	3,218,096,325	2,528,372,972	2,293,120,542	1,827,032,313
Retained Earnings		2,327,573,999	2,683,467,360	1,369,840,065	1,359,730,605
Equity Attributable to Equity Holders of the Parent		10,293,778,658	9,959,948,666	8,411,068,941	7,934,871,252
Non-Controlling Interests		1,003,479,433	901,355,166	-	-
Total Equity		11,297,258,091	10,861,303,832	8,411,068,941	7,934,871,252
Non-current Liabilities					
Interest Bearing Loans and Borrowings	24	8,199,548,738	7,116,012,064	10,603,858,481	11,240,572,603
Deferred Tax Liabilities	25	1,107,083,521	1,833,614,913	489,519,484	900,909,924
Employee Benefit Liability	26	666,289,845	555,610,806	259,084,763	205,950,583
		9,972,922,104	9,505,237,783	11,352,462,728	12,347,433,110
Current Liabilities					
Trade and Other Payables	27	1,909,338,080	1,996,830,599	1,132,361,719	1,120,198,833
Dividend Payable		91,176,933	38,711,372	73,144,253	30,429,896
Interest Bearing Loans and Borrowings	24	6,011,703,946	5,796,004,076	3,460,143,255	2,474,495,601
Income Tax Payable	28	71,930,530	380,597,337	22,977,995	50,916,945
Bank Overdraft	29.2	2,716,949,746	3,619,289,805	2,563,497,602	2,674,895,151
		10,801,099,235	11,831,433,189	7,252,124,824	6,350,936,426
Total Equity and Liabilities		32,071,279,429	32,197,974,804	27,015,656,493	26,633,240,788

I certify that these Financial Statements are in compliance with the requirements of the Companies Act No. 7 of 2007.

Sgd.
Ajith Karunaratne
 Chief Financial Officer

The Board of Directors is responsible for these Financial Statements. Signed for and on behalf of the Board by:

Sgd. **Ashok Pathirage** Director
 Sgd. **Dr. Manjula Karunaratne** Director

The Accounting Policies and Notes on pages 54 through 114 form an integral part of these Financial Statements.

30 June 2021
 Colombo

Statement of Changes in Equity

Year ended 31 March	Attributable to Equity Holders of the Parent									
	GROUP	Stated Capital	Fair Value Reserve of Financial Assets at FVOCI	Revaluation Reserve	Other Reserve	Retained Earnings	Foreign Currency Translation Reserve	Total	Non-Controlling Interest	Total Equity
	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.
As at 1 April 2019	4,748,108,334	(7,675,757)	2,846,611,421	(862,298,725)	1,951,118,946	-	8,675,864,219	792,320,223	9,468,184,442	
Adjustment due to initial application of SLFRS-16	-	-	-	-	(44,933,365)	-	(44,933,365)	(12,277,439)	(57,210,804)	
Adjusted balance as at 01 April 2019	4,748,108,334	(7,675,757)	2,846,611,421	(862,298,725)	1,906,185,581	-	8,630,930,854	780,042,784	9,410,973,639	
Profit for the Year	-	-	-	-	807,995,773	-	807,995,773	110,211,346	918,207,118	
Other Comprehensive Income	-	15,475,550	537,938,591	-	(30,713,994)	-	522,700,147	18,081,837	540,781,984	
Total Comprehensive Income	-	15,475,550	537,938,591	-	777,281,779	-	1,330,695,920	128,293,183	1,458,989,102	
Acquisition of Non-Controlling Interests	-	-	-	(1,678,108)	-	-	(1,678,108)	(6,980,801)	(8,658,909)	
As at 31 March 2020	4,748,108,334	7,799,793	3,384,550,012	(863,976,833)	2,683,467,360	-	9,959,948,666	901,355,166	10,861,303,832	
Profit for the Year	-	-	-	-	1,531,236,445	-	1,531,236,445	213,381,398	1,744,617,843	
Other Comprehensive Income	-	(54,039,864)	801,027,773	-	(67,076,053)	(670,556)	679,241,300	34,490,154	713,731,454	
Total Comprehensive Income	-	(54,039,864)	801,027,773	-	1,464,160,392	(670,556)	2,210,477,745	247,871,552	2,458,349,297	
Acquisition of Subsidiary	-	-	-	-	-	-	-	33,800,105	33,800,105	
Acquisition of Non-Controlling Interests	-	-	-	(56,593,999)	-	-	(56,593,999)	(65,225,988)	(121,819,988)	
Interim Dividends 2020/21	-	-	-	-	(1,820,053,753)	-	(1,820,053,753)	-	(1,820,053,753)	
Subsidiaries Dividends to Minority Shareholders	-	-	-	-	-	-	-	(114,321,402)	(114,321,402)	
As at 31 March 2021	4,748,108,334	(46,240,071)	4,185,577,785	(920,570,832)	2,327,573,999	(670,556)	10,293,778,658	1,003,479,433	11,297,258,091	

Figures in brackets indicate deductions.

The Accounting Policies and Notes on pages 54 through 114 form an integral part of these Financial Statements.

Statement of Changes in Equity

Year ended 31 March COMPANY	Note	Stated Capital Rs.	Revaluation Reserve Rs.	Retained Earnings Rs.	Total Rs.
As at 1 April 2019		4,748,108,334	1,476,134,417	2,077,058,984	8,301,301,735
Loss for the Year		-	-	(301,460,399)	(301,460,399)
Other Comprehensive Income		-	350,897,896	(13,397,453)	337,500,443
Total Comprehensive Income		-	350,897,896	(314,857,852)	36,040,044
Amalgamation Reserve	23.1	-	-	(402,470,527)	(402,470,527)
As at 31 March 2020		4,748,108,334	1,827,032,313	1,359,730,605	7,934,871,252
Profit for the Year		-	-	1,878,695,055	1,878,695,055
Other Comprehensive Income		-	466,088,229	(48,531,842)	417,556,387
Total Comprehensive Income		-	466,088,229	1,830,163,213	2,296,251,442
Interim Dividends 2020/21		-	-	(1,820,053,753)	(1,820,053,753)
As at 31 March 2021		4,748,108,334	2,293,120,542	1,369,840,065	8,411,068,941

Figures in brackets indicate deductions.

The Accounting Policies and Notes on pages 54 through 114 form an integral part of these Financial Statements.

Statement of Cash Flows

Year ended 31 March	Note	Group		Company	
		2021 Rs.	2020 Rs.	2021 Rs.	2020 Rs.
Cash Flows From Operating Activities					
Profit/(Loss) Before Income Tax Expense		1,610,978,185	1,410,697,392	1,823,481,085	(191,003,498)
Adjustments for					
Depreciation	9	1,342,099,529	1,232,869,169	596,621,281	415,605,163
Amortisation of Right of Use Assets	10.2	178,900,256	146,078,908	91,293,496	89,895,443
Share of (Profit)/Loss of Associates/Joint Ventures		-	(704,357)	-	-
Profit Realisation on Investment in Associates	3.2	(30,000,000)	-	-	-
Net Loss on Disposal of Property, Plant and Equipment	3.2	3,881,409	12,809,295	2,255,694	2,298,902
Provision for Bad and Doubtful Debts	5	29,850,197	16,697,426	208,898	(8,041)
Provision and Inventory Write-off		4,727,708	3,766,675	-	-
Provision for Retirement Gratuity	26.1	126,361,485	110,560,881	49,096,281	39,306,463
Finance Cost	4.1	1,433,382,356	1,789,973,739	1,373,921,685	1,731,635,094
Finance Income	4.2	(242,331,432)	(191,699,550)	(74,328,094)	(92,361,885)
Dividend Income		-	-	(1,617,051,213)	-
Changes in Fair Value of the Investment Property	11	-	(19,211,705)	-	-
Operating Profit Before Working Capital Changes		4,457,849,693	4,511,837,873	2,245,499,113	1,995,367,641
Changes in Working Capital					
(Increase)/Decrease in Inventories		(1,388,661)	(216,874,040)	5,889,363	(37,514,741)
(Increase)/ Decrease in Trade and Other Receivables		85,299,992	(181,211,251)	(175,062,260)	2,330,908,884
(Increase)/ Decrease in Other Current Assets		80,593,990	599,640,408	(19,006,594)	(16,083,059)
Increase/ (Decrease) in Trade and Other Payables		(131,848,724)	405,886,014	12,162,885	490,382,415
Cash Generated From Operations		4,490,506,291	5,119,279,004	2,069,482,507	4,763,061,140
Income Tax Paid	28	(253,728,683)	(487,277,535)	(39,549,111)	(139,971,301)
Defined Benefit Plan Costs Paid	26	(96,397,140)	(77,632,908)	(52,624,267)	(30,808,433)
Finance Cost Paid		(1,433,382,356)	(1,789,973,739)	(1,399,444,711)	(942,086,216)
Net Cash From Operating Activities		2,706,998,111	2,764,394,822	577,864,418	3,650,195,190
Cash Flows From/(Used in) Investing Activities					
Acquisition of Property, Plant and Equipment and Investment Properties		(1,525,906,693)	(4,235,060,657)	(890,700,187)	(1,425,470,434)
Acquisition of Right of use Assets		(9,790,891)	(53,527,323)	(2,889,954)	(28,621,432)
Increase in Interest in Subsidiaries		-	-	(121,819,987)	(8,658,909)
Proceeds from Disposal of Property, Plant and Equipment		37,620,773	58,269,338	22,338,623	13,176,664
Interest and Guarantee Income Received		229,043,707	166,628,050	74,328,094	27,949,386
Dividends Received		5,410,428	7,876,891	1,617,051,213	-
Net Cash Flow due to Amalgamation of Subsidiary		-	-	-	(395,594,813)
Net Cash Flow due to Acquisition of Subsidiary	13.5.2	27,555,476	-	-	-
(Increase)/ Decrease in Loans Granted to Related Parties		53,715,739	(274,859,737)	50,856,403	(2,195,544,840)
Net Cash Flows From/(Used in) Investing Activities		(1,182,351,461)	(4,330,673,438)	749,164,205	(4,012,764,378)
Cash Flows From/(Used in) Financing Activities					
Dividends Paid		(1,777,339,397)	(901,699,584)	(1,777,339,397)	(909,981,060)
Dividends Paid to Minority Shareholders		(104,570,198)	-	-	-
Proceeds from Interest Bearing Borrowings		3,019,746,664	6,596,963,983	1,679,248,255	4,264,813,121
Repayment of Interest Bearing Borrowings		(1,917,137,486)	(2,472,869,705)	(1,337,045,756)	(2,382,111,329)
Repayment of Lease Obligations		(183,796,513)	(151,997,164)	(67,216,235)	(62,888,091)
Acquisition of Non Controlling Interests		(121,819,987)	(8,658,908)	-	-
Net Cash Flows From/ (Used in) Financing Activities		(1,084,916,918)	3,061,738,622	(1,502,353,133)	909,832,641
Net Increase/(Decrease) in Cash and Cash Equivalents		439,729,734	1,495,460,003	(175,324,509)	547,263,452
Cash and Cash Equivalents at the Beginning of the Year		(2,170,998,536)	(3,666,458,539)	(1,857,460,510)	(2,404,723,962)
Cash and Cash Equivalents at the End of the Year	29	(1,731,268,802)	(2,170,998,536)	(2,032,785,019)	(1,857,460,510)

Figures in brackets indicate deductions.

The Accounting Policies and Notes on pages 54 through 114 form an integral part of these Financial Statements.

Notes to the Financial Statements

1. CORPORATE INFORMATION

1.1 General

Asiri Hospital Holdings PLC (“Company”) is a public limited liability Company, incorporated and domiciled in Sri Lanka and listed on the Colombo Stock Exchange. The registered office and principal place of business is located at No. 181, Kirula Road, Colombo 5.

1.2 Principal Activities and Nature of Operations

During the period, principal activities of the Company were to operate a hospital, provide healthcare services and managing and holding of investments in the healthcare industry .

The principal activities of the Subsidiaries are disclosed in Note 2.2 to the Financial Statements.

1.3 Parent Enterprise and Ultimate Parent Enterprise

The Company’s parent undertaking is Softlogic Holdings PLC which is incorporated and domiciled in Sri Lanka and listed on the Colombo Stock Exchange (CSE).

1.4 Date of Authorization for Issue

The Financial Statements of Asiri Hospital Holdings PLC and its Subsidiaries for the year ended 31st March 2021 was authorised for issue in accordance with a resolution of the Board of Directors on 30th June 2021.

1.5 Statement of Compliance

The Financial Statements which comprise the Statement of Financial Position, Statement of Profit or Loss, Statement of Comprehensive Income, Statement of Changes in Equity and the Statement of Cash Flows, together with the accounting policies and notes (the “Financial Statements”) have been prepared in accordance with Sri Lanka Accounting Standards (SLFRSs/LKASs) as issued by the Institute of Chartered Accountants of Sri Lanka (CA Sri Lanka) and the requirement of the Companies Act, No. 07 of 2007.

2. BASIS OF PREPARATION AND SIGNIFICANT ACCOUNTING POLICIES

2.1 Basis of Preparation

The Consolidated Financial Statements have been prepared on an accrual basis and under the historical cost convention except for lands and buildings, investment properties, fair valued through other comprehensive income financial assets, which have been measured at fair value.

Going Concern

Management has assessed the existing and potential impact of COVID- 19 in determining the basis of preparing financial statements for the year ended 31st March 2021. The Company evaluated it’s resilience considering factors such as expected revenue streams, cost management, profitability, ability to defer non-essential capital expenditure etc. and due to the nature of healthcare operations, the Board of Directors is satisfied and confident that the Company will be able to continue in operation for the foreseeable future. In addition, the directors are not aware of any material uncertainties that may cast significant doubt upon the Company’s ability to continue as a going concern. Accordingly, these Financial Statements have been prepared on a going concern basis.

Presentation and Functional Currency

The Financial Statements are presented in Sri Lankan Rupees (Rs.) the Company’s functional and presentation currency, which is the currency of the primary economic environment in which the Company operates.

Offsetting

Assets and liabilities or income and expenses, are not offset unless required or permitted by Sri Lanka Accounting Standards.

Materiality and Aggregation

Each material class of similar items is presented separately in the Financial Statements. Items of a dissimilar nature

or function are presented separately unless they are immaterial.

Comparative Information

The presentation and classification of the Financial Statements of the previous years have been amended, where relevant for better presentation and to be comparable with those of the current year. Certain comparatives figures have been reclassified in order to conform to the presentation for the current period. Such reclassifications were made to improve the quality of presentation and do not affect previously reported profit or equity.

2.2 Basis of Consolidation

The Consolidated Financial Statements encompass Company, its Subsidiaries (together referred to as the “Group”) and the Group’s interest in equity accounted investees (Associates and Joint Ventures)

2.2.1 Subsidiaries

Subsidiaries are those entities controlled by the Group. Control is achieved when the Group is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee. Specifically, the Group controls an investee if, and only if, the Group has:

1. Power over the investee (i.e., existing rights that give it the current ability to direct the relevant activities of the investee)
2. Exposure, or rights, to variable returns from its involvement with the investee
3. The ability to use its power over the investee to affect its returns

Generally, there is a presumption that a majority of voting rights result in control. To support this presumption and when the Group has less than a majority of the voting or similar rights of an investee, the Group considers all relevant facts and circumstances in assessing whether it has power over an investee, including:

1. The contractual arrangement with the other vote holders of the investee
2. Rights arising from other contractual arrangements
3. The Group's voting rights and potential voting rights

The Group re-assesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control. Consolidation of a subsidiary begins when the Group obtains control over the subsidiary and ceases when the Group loses control of the subsidiary. Assets, liabilities, income and expenses of a subsidiary acquired or disposed of during the year are included

in the Consolidated Financial Statements from the date the Group gains control until the date the Group ceases to control the subsidiary.

Profit or Loss and each component of Other Comprehensive Income (OCI) are attributed to the equity holders of the parent of the Group and to the non-controlling interests, even if this results in the non-controlling interests having a deficit balance. When necessary, adjustments are made to the Financial Statements of subsidiaries to bring their accounting policies into line with the Group's accounting policies. All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation.

A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as an equity transaction in a separate component of equity i.e. Other Reserve.

If the Group loses control over a subsidiary, it derecognises the related assets (including goodwill), liabilities, non-controlling interest and other components of equity while any resultant gain or loss is recognised in Statement of Profit or Loss. Any investment retained is recognised at fair value.

The Financial Statements for the year ended 31st March 2021 of the following subsidiary companies are included in the Consolidated Financial Statements.

Company	Effective Holding 2021	Effective Holding 2020	Principal Activities
1. Asiri Central Hospitals Ltd	94.48%	94.42%	The principal activities of the Company were providing medical services. With the cessation of the medical services business operations, the Company operated as an investment company.
2. Asiri Hospital Matara (Pvt) Ltd	100%	100%	The principal activities of the Company are to operate a hospital and provide healthcare services.
3. Asiri Diagnostics Services (Pvt) Ltd	66.54%	66.54%	The principal activities of the Company are to carry out diagnostic laboratory services.
4. Asiri Surgical Hospital PLC	79.96%	78.54%	The principal activities of the Company are to operate a two tier hospital and provide healthcare services.
5. Central Hospital Ltd	99.73%	99.73%	The principal activities of the Company are to operate a hospital and provide healthcare services.
6. Asiri Laboratories (Pvt) Ltd	100%	100%	The principal activities of the Company are to carry out diagnostic laboratory services. Company was incorporated on 20 January 2016 under the Companies Act No. 07 of 2007 and has not commenced its operations.
7. Asiri Hospital Galle (Pvt) Ltd	100%	100%	The principal activities of the Company are to operate a hospital and provide healthcare services.
8. Asiri AOI Cancer Centre (Pvt) Ltd	39.98%	-	The principal activities of the Company are to carry out cancer treatment services
9. Asiri Myanmar Limited	100%	100%	The principal activities of the Company are to investment in medical diagnostic opportunities in South and South East Asia and has not commenced its operations.
10. Asiri Diagnostic Services (Asia) Pte. Ltd	100%	100%	The principal activities of the Company are to investment in medical diagnostic opportunities in South and South East Asia and has not commenced its operations.

Notes to the Financial Statements

The total profits or losses for the year of the Company and Its Subsidiaries included in consolidation and all assets and liabilities of the Company and Its Subsidiaries included in consolidation are shown in the Consolidated Statement of Profit or Loss, Statement of Comprehensive Income and Statement of Financial Position respectively.

Non-controlling interest which represents the portion of profit or loss and net assets not held by the group, are shown as a component of profit for the year in the Statement of Profit or Loss, Statement of Other Comprehensive Income and as a component of equity in the Consolidated Statement of Financial Position, separately from parent's shareholders' equity.

The Consolidated Statement of Cash Flows includes the cash flows of the Company and Its Subsidiaries.

2.2.2 Equity Accounted Investees (Investment in Associates and Joint Ventures)

An associate is an entity over which the Group has significant influence. Significant influence is the power to participate in the financial and operating policy decisions of the investee, but is not control or joint control over those policies.

Asiri Hospital Holdings PLC ownership interest over the Digital Health (Pvt) Ltd has reduced from 22.8% to 15.96% during the financial period. Hence the Company discontinued the use of equity method and reclassified the investment as an equity investment designated as Fair Value through Other Comprehensive Income (FVOCI).

A joint venture is a type of joint arrangement whereby the parties that have joint control of the arrangement have rights to the net assets of the joint venture. Joint control is the contractually agreed sharing of control of an arrangement, which exists only when decisions about the relevant activities require unanimous consent of the parties sharing control.

The Group re-assessed circumstances of the joint venture arrangement and the determined as the Asiri Surgical Hospital PLC is the parent company of the Asiri AOI Cancer Centre (Pvt) Ltd with effect from 1st April 2020 and recognised as a subsidiary of the Asiri Hospital Holdings PLC.

2.3 Significant Accounting Judgments, Estimates and Assumptions

The preparation of the Financial Statements of the Group require the management to make judgments, estimates and assumptions, which may affect the amounts of income, expenditure, assets, liabilities and the disclosure of contingent liabilities, at the end of the reporting period. In the process of applying the Group's accounting policies, the key assumptions made relating to the future and the sources of estimation at the reporting date together with the related judgments that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.

Fair Value of Property, Plant and Equipment

The Group measures land and buildings at revalued amounts with changes in fair value being recognised in Other Comprehensive Income. Land and buildings were valued by reference to market-based evidence, using comparable prices adjusted for specific market factors such as nature, location and condition of the property.

Fair value related disclosures for assets measured at fair value are summarised in the Note 17.1 to the Financial Statements.

Deferred Tax Assets

Deferred tax assets are recognised for all unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilised. Significant management judgment is required to determine the amount of deferred tax assets that can be recognised, based upon the

likely timing and level of future taxable profits together with future tax planning strategies.

The Company which is in the tax exemption period of Board of Investment of Sri Lanka recognise deferred tax in their Financial Statements, for temporary differences which will reverse after the expiry of the tax holiday period. Significant management judgment is required to determine the future tax implications arising from particularly property, plant and equipment after the expiration of the tax holiday.

In determining the temporary difference pertaining to property, plant and equipment, management adopted a revised estimation technique to better reflect the related tax consequence (Refer Note 25).

Defined Benefit Plans

The cost of the retirement benefit plan of employees is determined using an actuarial valuation. The actuarial valuation is based on assumptions concerning the rate of interest, rate of salary increase, staff turnover, retirement age and going concern of the Group. Due to the long term nature of the plan, such estimates are subject to significant uncertainty. (Refer Note 26)

Leases

The Company cannot readily determine the interest rate implicit in the lease, therefore, it uses its Incremental Borrowing Rate (IBR) to measure lease liabilities. The Company estimates the IBR using observable inputs (such as market interest rates) when available and is required to make certain entity-specific estimates.

Provision for Expected Credit Losses of Financial Assets

The Company has established a provision matrix that is based on its historical credit loss experience, adjusted for forward-looking factors specific to the debtors and the economic environment. (Refer Note 2.4.10)

2.4 Summary of Significant Accounting Policies Applied

2.4.1 Business Combination and Goodwill

Business combinations are accounted for using the acquisition method. The cost of an acquisition is measured as the aggregate of the consideration transferred measured at acquisition date fair value and the amount of any non-controlling interests in the acquiree. For each business combination, the Group elects whether to measure the non-controlling interests in the acquiree at fair value or at the proportionate share of the acquiree's identifiable net assets.

Transaction costs, other than those associated with the issue of debt or equity securities that the Group incurs in connection with a business combination are expensed and included in administrative expenses.

When the Group acquires a business, it assesses the financial assets and liabilities assumed for appropriate classification and designation in accordance with the contractual terms, economic circumstances and pertinent conditions as at the acquisition date. This includes the separation of embedded derivatives in host contracts by the acquiree.

If the business combination is achieved in stages, any previously held equity interest is re-measured at its acquisition date fair value and any resulting gain or loss recognised in Statement of Profit or Loss.

Any contingent consideration to be transferred by the acquirer will be recognised at fair value at the acquisition date. Contingent consideration classified as equity is not re-measured and its subsequent settlement is accounted for within equity. Contingent consideration classified as an asset or liability that is a financial instrument and within the scope of SLFRS 9 Financial Instruments, is measured at fair value with the changes in fair value recognised in the Statement of Profit or Loss in accordance with SLFRS 9. Other

contingent consideration that is not within the scope of SLFRS 9 is measured at fair value at each reporting date with changes in fair value recognised in the Statement of Profit or Loss.

Goodwill is initially measured at cost, being the excess of the aggregate of the consideration transferred and the amount recognised for non-controlling interests, and any previous interest held, over the net identifiable assets acquired and liabilities assumed. If the fair value of the net assets acquired is in excess of the aggregate consideration transferred, the Group re-assesses whether it has correctly identified all of the assets acquired and all of the liabilities assumed and reviews the procedures used to measure the amounts to be recognised at the acquisition date. If the reassessment still results in an excess of the fair value of net assets acquired over the aggregate consideration transferred, then the gain is recognised in Statement of Profit or Loss.

After initial recognition, goodwill is measured at cost less any accumulated impairment losses. For the purpose of impairment testing, goodwill acquired in a business combination is, from the acquisition date, allocated to each of the Group's cash-generating units that are expected to benefit from the combination, irrespective of whether other assets or liabilities of the acquiree are assigned to those units.

Where goodwill has been allocated to a cash-generating unit (CGU) and part of the operation within that unit is disposed of, the goodwill associated with the disposed operation is included in the carrying amount of the operation when determining the gain or loss on disposal. Goodwill disposed of in this circumstance is measured based on the relative values of the disposed operation and the portion the cash-generating unit retained.

2.4.1.1 Impairment of Goodwill

Impairment exists when the carrying value of an asset or cash generating unit exceeds its recoverable amount, which

is the higher of its fair value less costs to sell and its value in use (VIU). The fair value less costs to sell calculation is based on available data from an active market in an arm's length transaction of similar assets, or observable market prices less incremental costs for disposing of the asset. The value in use calculation is based on a discounted cash flow model. The cash flows are derived from the budget for the next five years and do not include restructuring activities that the Group is not yet committed to or significant future investments that will enhance the performance of the cash generating unit being tested. The recoverable amount is most sensitive to the discount rate used for the discounted cash flow model as well as the expected future cash inflows and the growth rate used for extrapolation purposes.

The recoverable amount of all CGUs have been determined based on the higher of fair value less costs to sell and its Value in Use (VIU) calculation. VIU is determined by discounting the future cash flows generated from continuing use of the unit. The recoverability of quoted entities determined based on share price existed as at reporting date. The key assumptions used are given below:

Business growth - volume growth has been budgeted on a reasonable and realistic basis by taking into account the growth rates of one to five years immediately subsequent to the budgeted year, based on industry growth rates.

Inflation - budgeted cost inflation is the inflation rate, based on projected economic conditions.

Discount rate - the discounting rate used is the risk free rate increased by an appropriate risk premium.

Margin - budgeted gross margins are the gross margins achieved in the year preceding, adjusted for projected market conditions and business plans.

Notes to the Financial Statements

2.4.2 Foreign Currency Translation

The Financial Statements are presented in Sri Lankan Rupees, which is the Group's functional and presentation currency.

Transactions in foreign currencies are initially recorded by the Group/ Company at the functional currency spot rate ruling at the date the transaction first qualifies for recognition. Monetary assets and liabilities denominated in foreign currencies are retranslated at the functional currency rate of exchange ruling at the reporting date.

Differences arising on settlement or translation of monetary items are recognised in Statement of Profit or Loss.

Non monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates as at the dates of the initial transactions. The gain or loss arising on translation of non-monetary items measured at fair value is treated in line with the recognition of gain or loss on change in fair value in the item (i.e., the translation differences on items whose fair value gain or loss is recognised in Other Comprehensive Income (OCI) or Profit or Loss are also recognised in OCI or profit or loss, respectively).

2.4.3 Current Versus Non-Current Classification

The Group presents assets and liabilities in the Statement of Financial Position based on current/non-current classification. An asset is current when it is:

- Expected to be realised or intended to sold or consumed in a normal operating cycle,
- Held primarily for the purpose of trading,
- Expected to be realised within twelve months after the reporting period or

- Cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

All other assets are classified as non-current.

A liability is current when:

- It is expected to be settled in a normal operating cycle,
- It is held primarily for the purpose of trading,
- It is due to be settled within twelve months after the reporting period or
- It does not have a right at the reporting date to defer settlement of the liability by the transfer of cash or other assets for at least twelve months after the reporting period.

The Company classifies all other liabilities as non-current.

2.4.4 Fair Value Measurement

Fair value related disclosures for assets measured at fair value or financial instruments that are not measured at fair value, for which fair values are disclosed, are summarized in the Note 17 to the Financial Statements.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either in the principal market for the asset or liability or in the absence of a principal market, in the most advantageous market for the asset or liability.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

The Group uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximising the use of relevant observable inputs and minimising the use of unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the Financial Statements are categorised within the fair value hierarchy, described as follows,

Level 1 - Quoted (unadjusted) market prices in active markets for identical assets or liabilities

Level 2 - Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable

Level 3 - Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable

For assets and liabilities that are recognised in the Financial Statements on a recurring basis, the Group determines whether transfers have occurred between levels in the hierarchy by re-assessing categorisation (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.

The management determines the policies and procedures for both recurring fair value measurement and For non-recurring measurement.

For the purpose of fair value disclosures, the Group has determined classes of assets and liabilities on the basis of the nature, characteristics and risks of the

asset or liability and the level of the fair value hierarchy as explained above.

2.4.5 Taxation

Current Taxes

Current income tax assets and liabilities for the current and prior years are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date.

Asiri Central Hospitals Ltd

Income tax wholly represents tax on income derived from interest income.

Central Hospital Ltd

Pursuant to the agreement dated 9 November 2007 and supplementary agreement dated 14th February 2009 entered into with the Board of Investment under section 17 of the Board of Investment Law No.4 of 1978, the Inland Revenue Act relating to the imposition, payment and recovery of income tax shall not apply to the business operating a hospital and providing healthcare services, for a period of 8 years commencing from the year the Company makes profits or any year of assessment not later than two years from the date on which the company commences commercial operations, whichever is earlier. Accordingly, the exemption is for a period of eight years commencing from financial year 2012/ 2013. This exemption has expired on 31st March 2020. Immediately following the afore mentioned tax exemption period, the Company's income tax on operating profit shall be charged at a concessionary tax rate of 15%. However, other income is liable for income tax at 24%.

The Company is liable to pay tax on other income earned at the prevailing tax rate.

Asiri Hospital Galle (Pvt) Ltd

Pursuant to the agreement entered into with the Board of Investments (BOI) on

13th September 2007, profits of Asiri Hospital Galle (Pvt) Ltd are exempted from income tax for a period of four (4) years. After the expiration of aforesaid tax exemption period, the profits of the Company shall be charged at the rate of 10% for a period of two (2) years immediately succeeding the last date of the exemption period. After the expiration of the aforesaid two years concessionary tax period at the rate of 10%, the profits of the Company shall, for any year of assessment, be charged at the rate of 20%. Accordingly, the profits of Asiri Hospital Galle (Pvt) Ltd for the year 2020/21 were charged at 20%. However, other income is liable for income tax at 24%.

Following Companies are liable to pay tax on business and other income earned at the prevailing tax rates.

- Asiri Hospital Holdings PLC
- Asiri Surgical Hospital PLC
- Asiri Diagnostics Services (Pvt) Ltd
- Asiri Hospital Matara (Pvt) Ltd
- Asiri AOI Cancer Centre (Pvt) Ltd

Deferred Taxation

Deferred tax is provided on temporary differences at the reporting date between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date. Deferred tax liabilities are recognised for all taxable temporary differences. Deferred tax assets are recognised for all deductible temporary differences, the carry forward of unused tax credits and any unused tax losses. Deferred tax assets are recognised to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, the carry forward of unused tax credits and unused tax losses can be utilised.

The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilised.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date. Unrecognised deferred tax assets are reassessed at each reporting date and are recognised to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.

Deferred tax relating to items recognised outside Statement of Profit or Loss is recognised outside Statement of Profit and Loss. Deferred tax items are recognised in correlation to the underlying transaction either in Other Comprehensive Income or directly in equity.

Deferred tax assets and deferred tax liabilities are offset if a legally enforceable right exists to set off current tax assets against current income tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority.

2.4.6 Property, Plant and Equipment

Property, plant and equipment are initially stated at cost and such cost includes the cost of replacing parts of the property, plant and equipment if the recognition criteria are met. When significant parts of property, plant and equipment are required to be replaced at intervals, the Group recognises such parts as individual assets with specific useful lives and depreciates them accordingly. Likewise, when a major inspection is performed, its cost is recognised in the carrying amount of the plant and equipment as a replacement if the recognition criteria are satisfied. All other repair and maintenance costs are recognised in the Statement of Profit or Loss as incurred.

An item of Property, Plant and Equipment is derecognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on

Notes to the Financial Statements

derecognising of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the Statement of Profit or Loss in the year the asset is derecognised.

The asset's residual values, useful lives and methods of depreciation are reviewed, and adjusted if appropriate, at each financial year end.

Capital expenditure incurred in relation to fixed assets which are not completed as at the reporting date are shown as capital work-in-progress and is stated at cost. On completion, the related assets are transferred to property, plant and equipment. Depreciation on capital work-in-progress commences when the assets are ready for their intended use.

Depreciation is calculated on a straight-line basis over the useful life of assets or components. The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed at each financial year end and adjusted prospectively, if appropriate.

Subsequent Measurement

Property, plant and equipment is stated at cost or valuation, excluding the costs of day to day servicing, less accumulated depreciation and accumulated impairment in value. Changes in the expected useful life are accounted for by changing the amortisation period or method, as appropriate, and treated as changes in accounting estimates.

Free hold land and buildings are subsequently measured at fair value at the date of revaluation while other classes of property, plant and equipment are measured using the cost model.

Valuations are performed with sufficient frequency to ensure that the fair value of a revalued asset does not differ materially from its carrying amount.

A revaluation surplus is recognised in Other Comprehensive Income and credited to the revaluation reserve in

equity. However, to the extent that it reverses a revaluation deficit of the same asset previously recognised in the Statement of Profit or Loss, such the increase is recognised in the Statement of Profit or Loss. A revaluation deficit is recognised in profit or loss, except to the extent that it offsets an existing surplus on the same asset recognised in the revaluation reserve.

2.4.7 Leases

Estimating the Incremental Borrowing Rate

The Company cannot readily determine the interest rate implicit in the lease, therefore, it uses its incremental borrowing rate (IBR) to measure lease liabilities. The IBR is the rate of interest that the Company would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the right-of-use asset in a similar economic environment. The IBR therefore reflects what the Company 'would have to pay', which requires estimation when no observable rates are available or when they need to be adjusted to reflect the terms and conditions of the lease. The Company estimates the IBR using observable inputs (such as market interest rates) when available and is required to make certain entity-specific estimates.

Right of Use Assets

The Group recognises right of use assets when the underlying asset is available for use. Right of use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right of use assets includes the amount of lease liabilities recognised, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received. Unless the Group is reasonably certain to obtain ownership of the leased asset at the end of the lease term, the recognised right of use assets are depreciated on a straight-line basis over the shorter of its estimated useful life or the lease term. Right of use assets are subject to impairment.

Lease Liabilities

At the commencement date of the lease, the Group recognises lease liabilities measured at the present value of lease payments to be made over the lease term. In calculating the present value of lease payments, the Group uses the incremental borrowing rate at the lease commencement date if the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the in-substance fixed lease payments or a change in the assessment to purchase the underlying asset.

Short-term Leases and Leases of Low-Value Assets

The Group applies the short-term lease recognition exemption to leases that have a lease term of 12 months or less from the commencement date. It also applies the lease of low-value assets recognition exemption to leases of office equipment that are considered of low value. Lease payments on short-term leases and leases of low-value assets are recognised as expense on a straight-line basis over the lease term.

Company as a Lessor

Leases in which the Company does not transfer substantially all the risks and rewards incidental to ownership of an asset are classified as operating leases. Rental income arising is accounted for on a straight-line basis over the lease terms and is included in the statement of profit or loss due to its operating nature. Initial direct costs incurred in negotiating and arranging an operating lease are added to the carrying amount of the leased asset and recognised over the lease term on the same basis as rental income. Contingent rents are recognised as in the period in which they are earned.

2.4.8 Borrowing Costs

Borrowing Costs are recognised as an expense in the period in which they are incurred except borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalised as part of the cost of the respective assets.

2.4.9 Financial Instruments - Initial Recognition and Subsequent Measurement

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

i) Financial Assets

Initial Recognition and Measurement

Financial assets are classified, at initial recognition, as subsequently measured at amortised cost, fair value through Other Comprehensive Income (OCI), and fair value through profit or loss.

The classification of financial assets at initial recognition depends on the financial asset's contractual cash flow characteristics and the Group's business model for managing them. With the exception of trade receivables that do not contain a significant financing component or for which the Group has applied the practical expedient, the Group initially measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss, transaction costs. Trade receivables that do not contain a significant financing component or for which the Group has applied the practical expedient are measured at the transaction price determined under SLFRS 15. Refer to the accounting policies in section 2.4.14 Revenue.

In order for a financial asset to be classified and measured at amortized cost or fair value through OCI, it needs to give rise to cash flows that are 'solely payments of principal and interest (SPPI)' on the principal amount outstanding.

This assessment is referred to as the SPPI test and is performed at an instrument level. The Group's business model for managing financial assets refers to how it manages its financial assets in order to generate cash flows. The business model determines whether cash flows will result from collecting contractual cash flows, selling the financial assets, or both.

Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place (regular way trades) are recognised on the trade date, i.e., the date that the Group commits to purchase or sell the asset.

Subsequent Measurement

For purposes of subsequent measurement, financial assets are classified in four categories:

1. Financial assets at amortized cost (debt instruments)
2. Financial assets at fair value through OCI with recycling of cumulative gains and losses (debt instruments)
3. Financial assets designated at fair value through OCI with no recycling of cumulative gains and losses upon de-recognition (equity instruments)
4. Financial assets at fair value through profit or loss.

However, the classification of the financial assets of the Group are limited to financial assets at amortised cost (debt instruments) and financial assets designated at FVOCI (equity instruments).

Financial Assets at Amortised Cost (Debt Instruments)

This category is the most relevant to the Group. The Group measures financial assets at amortised cost if both of the following conditions are met:

- The financial asset is held within a business model with the objective to hold financial assets in order to collect contractual cash flows and

- The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding

Financial assets at amortised cost are subsequently measured using the Effective Interest Rate (EIR) method and are subject to impairment. Gains and losses are recognised in profit or loss when the asset is de-recognised, modified or impaired.

The Group's financial assets at amortised cost includes trade and other receivables, cash and bank and loans granted to related parties.

Financial Assets Designated at Fair Value Through OCI (Equity Instruments)

Upon initial recognition, the Group can elect to classify irrevocably its equity investments as equity instruments designated at fair value through OCI when they meet the definition of equity under LKAS 32 Financial Instruments: Presentation and are not held for trading. The classification is determined on an instrument-by-instrument basis.

Gains and losses on these financial assets are never recycled to profit or loss. Dividends are recognised as other income in the Statement of Profit or Loss when the right of payment has been established, except when the Group benefits from such proceeds as a recovery of part of the cost of the financial asset, in which case, such gains are recorded in OCI. Equity instruments designated at fair value through OCI are not subject to impairment assessment.

The Group elected to classify irrevocably its equity investments under this category.

Derecognition

A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily de-recognised (i.e., removed from the Group's Statement of Financial Position) when:

Notes to the Financial Statements

- The rights to receive cash flows from the asset have expired,

Or

- The Group has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a 'pass-through' arrangement and either (a) the Group has transferred substantially all the risks and rewards of the asset, or (b) the Group has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset

Impairment of Financial Assets

The Group recognises an allowance for Expected Credit Losses (ECLs) for all debt instruments not held at fair value through profit or loss. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group expects to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.

ECLs are recognised in two stages. For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided for credit losses that result from default events that are possible within the next 12-months (a 12-month ECL). For those credit exposures for which there has been a significant increase in credit risk since initial recognition, a loss allowance is required for credit losses expected over the remaining life of the exposure, irrespective of the timing of the default (a lifetime ECL).

For trade receivables and contract assets, the Group applies a simplified approach in calculating ECLs. Therefore, the Group does not track changes in

credit risk, but instead recognises a loss allowance based on lifetime ECLs at each reporting date. The Group has established a provision matrix that is based on its historical credit loss experience, adjusted for forward-looking factors specific to the debtors and the economic environment

The Group considers a financial asset in default when contractual payments are 365 days past due. However, in certain cases, the Group may also consider a financial asset to be in default when internal or external information indicates that the Group is unlikely to receive the outstanding contractual amounts in full before taking into account any credit enhancements held by the Group. A financial asset is written off when there is no reasonable expectation of recovering the contractual cash flows.

Further disclosures relating to impairment of financial assets are also provided in the following notes:

- Trade Receivables Note 19

ii) Financial Liabilities

Initial Recognition and Measurement

Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss, loans and borrowings, payables, or as derivatives designated as hedging instruments in an effective hedge, as appropriate.

All financial liabilities are recognised initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.

The Group's financial liabilities include trade and other payables, bank overdrafts, loans and borrowings, financial guarantees contracts, and other financial liabilities.

Subsequent Measurement

The measurement of financial liabilities depends on their classification, as described below:

Loans and Borrowings

This is the category most relevant to the Group. After initial recognition, interest-bearing loans and borrowings are subsequently measured at amortized cost using the EIR method. Gains and losses are recognised in profit or loss when the liabilities are derecognised as well as through the EIR amortization process.

Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortization is included as finance costs in the Statement of Profit or Loss.

Financial Guarantee Contracts

Financial guarantee contracts issued by the Company are those contracts that require a payment to be made to reimburse the holder for a loss it incurs because the specified debtor fails to make a payment in accordance with the terms of a debt instrument. Financial guarantee contracts are recognised initially as a liability at fair value, adjusted for transaction costs that are directly attributable to the issuance of the guarantee.

Subsequently, the liability is measured at the higher of the best estimate of the expenditure required to settle the present obligation at the reporting date and the amount recognised less cumulative amortisation.

Derecognition

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the de-recognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognised in the Statement of Profit or Loss.

2.4.10 Impairment of Non Financial Assets

The Group assesses, at each reporting date, whether there is an indication that an asset may be impaired. If any indication exists, or when annual impairment testing for an asset is required, the Group estimates the asset's recoverable amount. An asset's recoverable amount is the higher of an asset's or CGU's fair value less costs of disposal and its value in use. The recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets. When the carrying amount of an asset or CGU exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount.

In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. In determining fair value less costs of disposal, recent market transactions are taken into account. If no such transactions can be identified, an appropriate valuation model is used. These calculations are corroborated by valuation multiples, quoted share prices for publicly traded companies or other available fair value indicators.

The Group bases its impairment calculation on detailed budgets and forecast calculations, which are prepared separately for each of the Group's CGUs to which the individual assets are allocated. These budgets and forecast calculations generally cover a period of five years. A long-term growth rate is calculated and applied to project future cash flows after the fifth year.

Impairment losses of continuing operations are recognised in the statement of profit or loss in expense categories consistent with the function of the impaired asset, except for properties previously revalued with the revaluation taken to Other

Comprehensive Income. For such properties, the impairment is recognised in Other Comprehensive Income up to the amount of any previous revaluation.

For assets excluding goodwill, an assessment is made at each reporting date to determine whether there is an indication that previously recognised impairment losses no longer exist or have decreased. If such indication exists, the Group estimates the asset's or CGU's recoverable amount. A previously recognised impairment loss is reversed only if there has been a change in the assumptions used to determine the asset's recoverable amount since the last impairment loss was recognised. The reversal is limited so that the carrying amount of the asset does not exceed its recoverable amount, nor exceed the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognised for the asset in prior years. Such reversal is recognised in the Statement of Profit or Loss unless the asset is carried at a revalued amount, in which case, the reversal is treated as a revaluation increase.

Goodwill is tested for impairment annually as at 31 March and when circumstances indicate that the carrying value may be impaired. Impairment is determined for goodwill by assessing the recoverable amount of each CGU (or group of CGUs) to which the goodwill relates. When the recoverable amount of the CGU is less than its carrying amount, an impairment loss is recognised.

Impairment losses relating to goodwill cannot be reversed in future periods. Intangible assets with indefinite useful lives are tested for impairment annually as at 31 March at the CGU level, as appropriate, and when circumstances indicate that the carrying value may be impaired

2.4.11 Inventories

Inventories are valued at the lower of cost and net realisable value, after making due allowances for obsolete and

slow moving items. Net realisable value is the price at which inventories can be sold in the ordinary course of business.

The cost incurred in bringing inventories to its present location and conditions are accounted on First-in First-out basis.

2.4.12 Cash and Cash Equivalents

Cash and Cash Equivalents are defined as cash in hand, demand deposits and short-term highly liquid investments, readily convertible to known amounts of cash and subject to insignificant risk of changes in value.

For the purpose of Cash Flow Statement, Cash and Cash Equivalents consist of the above net of outstanding bank overdrafts. Investments with short maturities (i.e. three months or less from the date of acquisition) are also treated as Cash and Cash Equivalents.

2.4.13 Provisions

Provisions are recognised when the Group has a present obligation (legal or constructive) as a result of a past event, where it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Group expects some or all of a provision to be reimbursed, the reimbursement is recognised as a separate asset but only when the reimbursement is virtually certain. The expense relating to any provision is presented in the Statement of Profit or Loss net of any reimbursement.

2.4.14 Post Employment Benefits

a) Defined Benefit Plan – Gratuity

The Group measures the present value of the promised retirement benefits of gratuity which is a defined benefit plan with the advice of an independent professional actuary at the end of every financial year using the Projected Unit Credit Method (PUC) as recommended by LKAS 19 – Employee benefits. Accordingly, the employee benefit liability is based on the actuarial

Notes to the Financial Statements

valuation carried out by Messrs Actuarial and Management Consultants (Pvt) Ltd, Actuaries. The actuarial valuation involves making assumptions about discount rate, future salary increase rate and mortality rates etc. All assumptions are reviewed at each reporting date.

Provision has been made for retirement gratuities from the beginning of service for all employees, in conformity with LKAS 19 on employee benefit. However, under the Payment of Gratuity Act No. 12 of 1983, the liability to an employee arises only on completion of 5 years of continued service.

The Group's accounting policy for defined benefit plans is to recognise actuarial gains and losses in the period in which they occur in full in the Statement of Other Comprehensive Income. The gratuity liability is not externally funded.

b) Defined Contribution Plans: Employees' Provident Fund and Employee' Trust Fund

Employees are eligible for Employees' Provident Fund and Employee' Trust Fund contributions, in line with respective statute and regulations. The Group contributes 12% and 3% of gross remuneration of employees to Employees' Provident Fund and Employee' Trust Fund.

2.4.15 Revenue

The Group/Company is in the business of providing healthcare services and sale of pharmaceuticals. Revenue from contracts with customers is recognised when control of the goods or services are transferred to the customer at an amount that reflects the consideration to which the Group/Company expects to be entitled in exchange for those services or goods.

The Group/Company recognised the revenue based on SLFRS 15 with effect from 1st April 2018. It applies to all contracts with customers to provide goods and services in the ordinary

course of business. The Group/Company adopts principle based five steps model for revenue recognition.

Accordingly, revenue is recognised only when all of the following criteria are met:

- The parties to the contract have approved the contract/s;
- The entity can identify each party's rights regarding goods or services to be transferred;
- The entity can identify the payment term for the goods or services to be transferred;
- The contract has commercial substance;
- It is probable that the entity will collect the consideration to which it will be entitled in exchange for goods or services that will be transferred to the customer.

Under SLFRS 15, the Group/Company determines at contract inception whether it satisfies the performance obligation over time or at a point in time. For each performance obligation satisfied overtime, the Group/Company recognises the revenue over time by measuring the progress towards complete satisfaction of that performance obligation.

Revenue from sale of pharmaceutical items are recognised at a point in time when control of that items is transferred to the customer.

Revenue from outpatients are recognised at the point in time when services are rendered.

Revenue from inpatients are recognised over time by measuring the progress towards complete satisfaction of that performance obligation.

The Group/Company assesses its revenue arrangements against specific criteria in order to determine if it is acting as principle or agent. The Group/Company has concluded that the

service revenues are presented net of doctor fees in cases where the Group/Company is not the primary obligor and does not have the pricing latitude.

2.4.16 Contract Assets

Contract assets are Group's/Company's right to consideration in exchange for goods or services that the Group/Company has transferred to a customer, with rights that are conditioned on some criteria other than the passage of time. Upon satisfaction of the conditions, the amounts recognised as contract assets are reclassified to Trade Receivables.

2.4.16.1 Contract Liabilities

Contract liabilities are Group's/Company's obligation to transfer goods or services to a customer for which the Group/Company has received consideration (or the amount is due) from the customer. Contract liabilities include long-term advances received to deliver goods and services, short-term advances received to render certain services. Contract liabilities of the Group / Company have been disclosed in Trade and Other Payable Note 27.

2.4.17 Dividend Income

Dividend income is recognised when the Group's right to receive the payment is established.

2.4.18 Other Income

Other income is recognised in the Statement of Profit or Loss as it accrues.

2.4.19 Finance Income

Interest income is recorded as it accrues using the Effective Interest Rate (EIR), which is the rate that exactly discounts the estimated future cash payments or receipts through the expected life of the financial instrument or a shorter period, where appropriate, to the net carrying amount of the financial asset or liability. Interest income is included under finance income in the Statement of Profit or Loss.

2.4.20 Finance Expense

Finance costs comprise interest expense on borrowings and guarantee cost.

Interest expense is recorded as it accrues using the effective interest rate (EIR), which is the rate that exactly discounts the estimated future cash payments through the expected life of the financial instrument or a shorter period, where appropriate, to the net carrying amount of the financial liability.

2.4.21 Expenditure

Expenses are recognised in the Statement of Profit or Loss on the basis of a direct association between the cost incurred and the earning of specific items of income. All expenditure incurred in the running of the business and in maintaining the property, plant and equipment in a state of efficiency has been charged to the Statement of Profit or Loss.

For the purpose of presentation of the Statement of Profit or Loss, the “function of expenses” method has been adopted, on the basis that it presents fairly the elements of the Group’s performance.

2.4.22 Dividend

The Group recognises a liability to pay a dividend when the distribution is authorised and the distribution is no longer at the discretion of the Group. A corresponding amount is recognised directly in equity.

2.4.23 Earnings Per Share

Basic EPS is calculated by dividing the profit for the year attributable to ordinary equity holders of the parent by the weighted average number of ordinary shares outstanding during the year.

2.4.24 Segment Reporting

An operating segment is a component of the Group that engages in business activities from which it may earn revenues and incur expenses, including revenues and expenses that relate to transactions with any of the Company’s other components.

All operating segments’ operating results are reviewed regularly by the Senior Management Committee to make decisions about resources to be allocated to the segment and assess its performance, and for which discrete financial information is available.

2.4.25 Statement of Cash Flow

The Statement of Cash Flows has been prepared using the “indirect method”.

2.5 Standards Issued But Not Yet Effective

The new and amended standards and interpretations that are issued, but not yet effective, up to the date of issuance of the Company’s Financial Statements are disclosed below. The Company intends to adopt these new and amended standards and interpretations, if applicable, when they become effective.

2.5.1 Amendments to SLFRS 16 – COVID – 19 Related Rent Concessions

The amendments provide relief to lessees from applying SLFRS 16 guidance on lease modification accounting for rent concessions arising as a direct consequence of the COVID-19 Pandemic. As a practical expedient, a lessee may elect not to assess whether a COVID-19 related rent concession from a lessor is a lease modification. A lessee that makes this election accounts for any change in lease payments resulting from COVID-19 related rent concession the same way it would account for the change under SLFRS16, if the change were not a lease modification. The amendment applies to annual reporting periods beginning on or after 01st June 2020.

2.5.2 Property, Plant and Equipment: Proceeds before Intended Use – Amendments to LKAS 16

In March 2021, the ICASL adopted amendments to LKAS16-Property, Plant and Equipment - Proceeds before Intended Use, which prohibits entities deducting from the cost of an item of property, plant and equipment, any proceeds from selling items produced

while bringing that asset to the location and condition necessary for it to be capable of operating in the manner intended by management. Instead, an entity recognises the proceeds from selling such items, and the costs of producing those items, in profit or loss. The amendment is effective for annual reporting periods beginning on or after 1st January 2022 and must be applied retrospectively to items of property, plant and equipment made available for use on or after the beginning of the earliest period presented when the entity first applies the amendment.

2.5.3 Amendments to SLFRS 3

The amendments update SLFRS 3 so that it refers to the 2018 Conceptual Framework instead of the 1989 Framework. They also add to SLFRS 3 a requirement that, for obligations within the scope of LKAS 37, an acquirer applies LKAS 37 to determine whether at the acquisition date a present obligation exists as a result of past events. For a levy that would be within the scope of IFRIC 21 Levies, the acquirer applies IFRIC 21 to determine whether the obligating event that gives rise to a liability to pay the levy has occurred by the acquisition date. Finally, the amendments add an explicit statement that an acquirer does not recognise contingent assets acquired in a business combination. The amendments are effective for business combinations for which the date of acquisition is on or after the beginning of the first annual period beginning on or after 1st January 2022. Early application is permitted if an entity also applies all other updated references (published together with the updated Conceptual Framework) at the same time or earlier.

Notes to the Financial Statements

3. REVENUE AND OTHER INCOME

3.1 Revenue

	Group		Company	
	2021	2020	2021	2020
	Rs.	Rs.	Rs.	Rs.
Healthcare Services	14,326,057,612	13,897,537,271	5,457,241,415	4,898,623,815
Sale of Goods	1,458,465,180	1,612,884,771	681,097,881	808,082,509
	15,784,522,792	15,510,422,042	6,138,339,296	5,706,706,324

3.1.a Segment Information

The Senior Management Committee is the Chief Operating Decision Maker (CODM) and monitors the operating results of its business units separately for the purpose of making decisions about resource allocation and performance assessment. Segment performance is evaluated based on revenue and other income generated and is measured consistently with revenue and other income in the Consolidated Financial Statements.

The Group has identified the following segments based on the information provided to CODM for the purpose of making decisions about resource allocation and performance assessment.

- Pre Care which include Out Patient Department (OPD) revenue, channeling revenue and OPD lab investigation services
- Post Care which include all In Patient Department (IPD) revenue including inpatient drugs and lab investigation
- Pharmaceutical which includes OPD pharmacy revenue

The following table presents the revenue and other income generated by the Group's segments for the year ended 31st March 2021 and comparative figures for the year ended 31st March 2020:

	Group		Company	
	2021	2020	2021	2020
	Rs.	Rs.	Rs.	Rs.
Pre Care	7,004,149,780	4,370,672,190	1,863,477,693	1,824,241,621
Post Care	7,321,907,832	9,526,865,081	3,593,763,722	3,074,382,194
Pharmaceutical	1,458,465,180	1,612,884,771	681,097,881	808,082,509
	15,784,522,792	15,510,422,042	6,138,339,296	5,706,706,324

3.1.b Timing of Revenue Recognition

	Group		Company	
	2021	2020	2021	2020
	Rs.	Rs.	Rs.	Rs.
Services and Goods Transferred at a Point In Time	8,462,614,960	5,983,556,961	2,544,575,574	2,632,324,130
Services Transferred Over Time	7,321,907,832	9,526,865,081	3,593,763,722	3,074,382,194
	15,784,522,792	15,510,422,042	6,138,339,296	5,706,706,324

3.2 Other Income

	Group		Company	
	2021	2020	2021	2020
	Rs.	Rs.	Rs.	Rs.
Rental Income	77,625,054	103,483,305	27,802,506	13,281,669
Other Laboratory Income	59,799,037	75,263,725	59,799,037	75,263,725
Net Loss on Disposal of Property, Plant and Equipment	(3,881,409)	(12,809,295)	(2,255,694)	(2,298,902)
Sundry Income	26,873,897	41,144,640	14,448,458	19,557,032
Exchange Gain /(Loss) on Foreign Currency	4,628,818	3,109,909	(131,557)	-
Gain on Disposal of Investment in Associates	30,000,000	-	-	-
	195,045,397	210,192,284	99,662,750	105,803,524

4. FINANCE COST/ INCOME AND DIVIDEND INCOME

4.1 Finance Cost

	Group		Company	
	2021	2020	2021	2020
	Rs.	Rs.	Rs.	Rs.
Interest Expense on Bank Borrowings	1,098,312,799	1,253,695,411	525,530,435	671,555,478
Interest Expense on Inter Company Borrowings	-	-	591,945,022	727,616,276
Bank Charges on Interest Bearing Loans	26,179,213	25,790,838	13,104,762	5,734,905
Interest on Bank Overdrafts	247,064,711	444,618,783	188,938,170	284,096,106
Lease Interest	61,825,633	65,868,707	33,843,468	30,319,608
Guarantee Expense	-	-	20,559,828	12,312,721
	1,433,382,356	1,789,973,739	1,373,921,685	1,731,635,094

4.2 Finance Income

Interest Income	236,921,004	166,628,050	49,115,049	78,939,506
Guarantee Income	-	-	25,213,045	13,422,379
Dividend Income	5,410,428	25,071,500	-	-
	242,331,432	191,699,550	74,328,094	92,361,885

4.3 Dividend Income

Dividend from Subsidiaries	-	-	1,617,051,213	-
	-	-	1,617,051,213	-

Notes to the Financial Statements

5. PROFIT BEFORE TAX

Profit Before Tax is stated after charging all expenses including the following:

	Group		Company	
	2021	2020	2021	2020
	Rs.	Rs.	Rs.	Rs.
Included in Cost of Sales				
Depreciation	650,268,040	583,186,128	217,621,308	147,567,049
Staff related Expenses including the following :-	2,678,184,312	2,945,733,916	1,006,886,979	996,846,502
- Defined Contribution Plan Costs - EPF and ETF	250,818,773	264,458,282	93,053,856	91,911,437
Included in Administrative Expenses				
Depreciation	691,831,489	649,683,041	378,999,973	268,038,114
Staff related Expenses including the following :-	1,038,271,915	896,638,067	369,587,726	324,750,272
- Defined Benefit Plan Costs - Gratuity	126,361,485	110,560,881	49,096,281	39,306,463
- Defined Contribution Plan Costs - EPF and ETF	62,117,007	63,616,724	23,206,753	21,648,844
Directors' Fees and Remuneration	32,587,471	46,544,214	24,342,271	36,640,094
Amortisation of Right of Use Assets	178,900,256	146,078,908	91,293,496	89,895,443
Donations	2,205,590	2,004,019	120,590	504,019
Legal Fees	7,463,613	11,317,733	572,958	1,142,230
Audit Fees and Reimbursable Expenses	4,279,903	3,929,619	940,791	846,936
Included in Selling and Distribution Costs				
Advertising Expenses	150,872,290	142,378,157	32,262,386	57,778,003
Impairment of Trade Debtors	29,850,197	16,697,426	208,898	(8,041)

6. INCOME TAX

The Major Components of Income Tax Expense are as follows :

	Group		Company	
	2021	2020	2021	2020
	Rs.	Rs.	Rs.	Rs.
Current Income Tax				
Current Income Tax charge	206,831,088	403,948,282	-	-
ESC write-off	-	3,802,954	-	-
(Over)/Under Provision in Respect of Previous Years	(189,792,740)	78,315,761	11,610,162	87,548,064
Deferred Income Tax				
Deferred Taxation recognised in Profit or Loss (Note 25)	(150,678,006)	6,423,277	(66,824,132)	22,908,837
Income Tax Expense reported in the Statement of Profit or Loss	(133,639,658)	492,490,274	(55,213,970)	110,456,901
Deferred Income Tax				
Deferred Taxation recognised in Other Comprehensive Income (Note 25)	(579,084,544)	180,284,122	(344,566,308)	129,327,897
Income Tax Expense reported in the Statement of Other Comprehensive Income	(579,084,544)	180,284,122	(344,566,308)	129,327,897

Notes to the Financial Statements

6.1 Reconciliation between Tax Expense and Accounting Profit

	Group		Company	
	2021	2020	2021	2020
	Rs.	Rs.	Rs.	Rs.
Accounting Profit/(Loss) before Tax	1,610,978,185	1,410,697,392	1,823,481,085	(191,003,498)
Dividend Income from Group Companies	1,617,051,214	-	-	-
Other Consolidation Adjustments	(17,145,811)	15,709,521	-	-
Profit/ (Loss) after adjustment	3,210,883,588	1,426,406,913	1,823,481,085	(191,003,498)
Exempt Profits	(5,410,429)	(369,311,849)	-	-
Profits not Liable for Income Tax	(860,688)	(105,643,554)	-	(105,643,554)
Investment Income	(943,989,907)	(653,264,636)	(50,998,106)	(92,221,175)
Resident Dividend	(1,617,051,214)	-	(1,617,051,214)	-
Adjusted Accounting Profit/ (Loss) chargeable to Income Taxes	643,571,350	298,186,873	155,431,765	(388,868,227)
Deductible Expenses	(2,379,876,634)	(1,455,096,699)	(1,348,191,662)	(1,069,064,104)
Non Deductible Expenses	2,159,611,882	1,360,521,109	1,020,450,247	941,827,088
Other Source of Income	2,561,041,121	653,264,636	1,668,049,320	92,221,175
Set off against Tax Losses	(1,651,289,648)	-	(1,495,739,670)	-
Taxable Income	1,333,058,071	856,875,919	-	(423,884,068)

Tax has been computed at 14% for all standard rate companies (including listed companies), at 15% for Central Hospital Ltd and 20% for Asiri Galle Hospital (Pvt) Ltd.

Income Tax at 14%- 2021	73,919,711	-	-	-
Income Tax at 24% - 2021	132,911,377	-	-	-
Income Tax at 28% - 2020	-	403,948,282	-	-
Current Income Tax charge	206,831,088	403,948,282	-	-

The enacted Act at end of the reporting period was Inland Revenue Act No 24 of 2017. As per the enacted act, the tax rate applicable to the Company on the Healthcare Services is 28%.

Subsequently, the Gazette Bill for the Inland Revenue Act No 24 of 2017 issued on 18th March 2021 the tax rate applicable to the Company on healthcare industry is 14%. The new tax rate is applicable from 1st January 2020.

CA Sri Lanka issued a guideline dated 23rd April 2021, clarifying the fact that entities can apply the proposed tax rate in the Approved Bill for both Income Tax and Deferred Tax. Accordingly, the Group/ Company has used the proposed income tax rates in computing the Income Tax and Deferred Tax.

7. EARNINGS PER SHARE

Basic Earnings Per Share is calculated by dividing the net profit for the year attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during the year. The weighted average number of ordinary shares outstanding during the year and the previous year are adjusted for events that have changed the number of ordinary shares outstanding, without a corresponding change in the resources such as a bonus issue.

The following reflects the income and share data used in the Basic Earnings Per Share computations:

	Group		Company	
	2021	2020	2021	2020
	Rs.	Rs.	Rs.	Rs.
Profit/(Loss) Attributable to Equity Holders of the Parent Company	1,531,236,445	807,995,772	1,878,695,055	(301,460,399)
Basic Earnings/(Loss) Per Share	1.35	0.71	1.65	(0.27)
	Group		Company	
	2021	2020	2021	2020
Number of Ordinary Shares used as the Denominator				
Weighted Average Number of Ordinary Shares	1,137,533,596	1,137,533,596	1,137,533,596	1,137,533,596

8. DIVIDENDS

Declared During the Year

	Group		Company	
	2021	2020	2021	2020
	Rs.	Rs.	Rs.	Rs.
Equity Dividends on Ordinary Shares :				
- Dividend Per Share	1.60	-	1.60	-
- Interim Dividends	1,820,053,753	-	1,820,053,753	-

Notes to the Financial Statements

9. PROPERTY, PLANT AND EQUIPMENT

9.1 Group

9.1.1 Gross Carrying Amounts

	Balance As at 01.04.2020 Rs.	Acquisition of Subsidiary Rs.	Additions Rs.	Transfers Rs.	Revaluation Rs.	Disposals Rs.	Balance As at 31.03.2021 Rs.
At Cost or Valuation							
Land	6,073,115,000	-	425,000	-	15,750,000	-	6,089,290,000
Buildings	12,328,697,772	215,000,000	464,686,902	(206,832,375)	266,864,064	-	13,068,416,363
Furniture, Fittings and Fixtures	1,634,624,402	1,046,023	82,787,945	67,579,159	-	(75,989,184)	1,710,048,346
Medical Equipment	7,413,111,762	404,603,919	510,206,617	-	-	6,985,484	8,334,907,781
Plant & Machinery	199,400,255	-	41,246,900	(67,579,159)	-	-	173,067,995
Motor Vehicles	249,853,411	-	2,590,000	-	-	(12,765,000)	239,678,411
Sundry Equipment	2,394,952,857	28,049,439	332,778,681	-	-	(32,134,439)	2,723,646,538
	30,293,755,459	648,699,381	1,434,722,046	(206,832,375)	282,614,064	(113,903,139)	32,339,055,434
Capital Work in Progress	28,652,163	-	91,184,647	(59,394,709)	-	-	60,442,101
Total Value of Assets	30,322,407,622	648,699,381	1,525,906,693	(266,227,084)	282,614,064	(113,903,139)	32,399,497,535

9.1.2 Accumulated Depreciation

	Balance As at 01.04.2020 Rs.	Acquisition of Subsidiary Rs.	Charge for the Year Rs.	Transfers Rs.	Disposals Rs.	Balance As at 31.03.2021 Rs.
Buildings	33,512,772	-	263,970,503	(266,227,084)	-	31,256,191
Furniture, Fittings and Fixtures	1,020,681,709	101,964	115,320,743	20,046,820	(24,835,122)	1,131,316,113
Medical Equipment	3,606,353,726	81,774,611	650,268,040	-	(16,505,457)	4,321,890,921
Plant & Machinery	11,087,947	-	25,323,146	(20,046,820)	-	16,364,274
Motor Vehicles	114,238,412	-	28,278,026	-	(7,715,215)	134,801,224
Sundry Equipment	1,265,697,834	9,086,139	258,939,071	-	(23,345,162)	1,510,377,882
Total Depreciation	6,051,572,400	90,962,714	1,342,099,529	(266,227,084)	(72,400,956)	7,146,006,604

Transfers include the accumulated depreciation amounting to Rs.266 Mn (2020 - Rs. 218Mn) as at revaluation date that was eliminated against the gross carrying amount of the revalued assets.

9.2 Company

9.2.1 Gross Carrying Amounts

	Balance As at 01.04.2020 Rs.	Additions Rs.	Transfers Rs.	Revaluation Rs.	Disposals Rs.	Balance As at 31.03.2021 Rs.
At Cost or Valuation						
Land	2,945,000,000	-	-	-	-	2,945,000,000
Buildings	5,708,700,000	401,823,058	(123,745,510)	129,422,452	-	6,116,200,000
Medical Equipment	2,370,822,433	191,302,320	67,579,159	-	(36,650,511)	2,593,053,401
Plant & Machinery	199,400,255	41,246,900	-	-	-	240,647,154
Furniture and Fittings	535,588,448	40,005,642	(67,579,159)	-	(2,484,932)	505,529,999
Motor Vehicles	119,614,244	2,590,000	-	-	(4,965,000)	117,239,244
Sundry Equipment	1,142,777,575	190,507,034	-	-	(18,624,519)	1,314,660,091
	13,021,902,954	867,474,954	(123,745,510)	129,422,452	(62,724,962)	13,832,329,889
Capital Work-in-Progress	3,128,922	23,225,234	-	-	-	26,354,156
Total Value of Assets	13,025,031,876	890,700,187	(123,745,510)	129,422,452	(62,724,962)	13,858,684,045

9.2.2 Accumulated Depreciation

	Balance As at 01.04.2020 Rs.	Charge for the Year Rs.	Transfers Rs.	Disposals Rs.	Balance As at 31.03.2021 Rs.
Buildings	-	123,745,510	(123,745,510)	-	-
Medical Equipment	684,905,301	202,898,845	20,046,820	(24,054,957)	883,796,008
Plant & Machinery	11,087,947	25,323,146	-	-	36,411,093
Furniture and Fittings	129,749,379	74,978,920	(20,046,820)	(834,936)	183,846,544
Motor Vehicles	37,363,082	12,245,430	-	(2,219,551)	47,388,962
Sundry Equipment	356,884,078	157,429,430	-	(11,021,201)	503,292,305
Total Depreciation	1,219,989,787	596,621,281	(123,745,510)	(38,130,645)	1,654,734,912

Notes to the Financial Statements

9.3 Net Book Values

	Group		Company	
	2021	2020	2021	2020
	Rs.	Rs.	Rs.	Rs.
Land	6,089,290,000	6,073,115,000	2,945,000,000	2,945,000,000
Buildings	13,037,160,172	12,295,185,000	6,116,200,000	5,708,700,000
Furniture, Fittings and Fixtures	578,732,233	613,942,694	321,683,455	1,685,917,131
Medical Equipment	4,013,016,861	3,806,758,036	1,709,257,393	188,312,307
Plant & Machinery	156,703,721	188,312,307	204,236,061	405,839,069
Motor Vehicles	104,877,187	135,614,999	69,850,283	82,251,162
Sundry Equipment	1,213,268,656	1,129,255,015	811,367,786	785,893,498
	25,193,048,830	24,242,183,051	12,177,594,977	11,801,913,168
Capital Work in Progress	60,442,101	28,652,163	26,354,156	3,128,922
Total Carrying Amount of Property, Plant and Equipment	25,253,490,931	24,270,835,214	12,203,949,133	11,805,042,090

9.4 During the year, the Group acquired Property, Plant and Equipment to the aggregate value of Rs. 1,525,906,692/- (2020 - Rs. 4,232,996,610/-). Cash payments amounting to Rs. 1,525,906,692/- (2020 - Rs. 4,232,996,610/-) were made during the year for purchase of Property, Plant and Equipment. During the year, the Company acquired Property, Plant and Equipment to the aggregate value of Rs. 890,700,187/- (2020 - Rs. 7,484,990,254/-). Cash payments amounting to Rs. 890,700,187/- (2020 - Rs. 1,425,470,434/-).

9.5 Group Property, Plant and Equipment with a carrying value of Rs. 10,647,677,000/- (2020 - Rs. 10,467,078,867/-) have been pledged as security for term loans obtained, details of which are disclosed in Note 24.3.

9.6 Group's Property, Plant & Equipment include fully depreciated assets which are still in use, the cost of which at the reporting date amounted to Rs. 3,967 Mn (2020 - Rs. 2,267 Mn). Company's fixed assets include fully depreciated assets, which are still in use the cost of which at the reporting date amounted to Rs. 664 Mn (2020 - Rs. 540 Mn).

9.7 The provision for depreciation is calculated by using a straight line method on the cost/revaluation of all Property, Plant and Equipment in order to write off such amounts over the following estimated useful lives by equal instalments.

	Group/Company
	2020/2021
Buildings	Over 50-60 Years
Furniture and Fittings	Over 10 Years
Medical Equipment	Over 10 Years
Plant and Machinery	Over 10 Years
Motor Vehicles	Over 5-8 Years
Sundry Equipment	
Computer and Office Equipment	Over 4-5 Years
Short Life Assets	Over 2-3 Years
Other	Over 10 Years

- 9.8** The carrying amount of revalued assets that would have been included in the Financial Statements had the assets been carried at cost less depreciation is as follows:

Class of Asset	Group			
	Cost Rs.	Cumulative Depreciation If Assets were Carried at Cost Rs.	Net Carrying Amount 2021 Rs.	Net Carrying Amount 2020 Rs.
Freehold Land	1,653,467,153	-	1,653,467,153	1,653,467,153
Buildings	11,228,916,692	1,399,622,602	9,829,294,090	9,552,667,728
	12,882,383,845	1,399,622,602	11,482,761,243	11,206,134,881

Class of Asset	Company			
	Cost Rs.	Cumulative Depreciation If Assets were Carried at Cost Rs.	Net Carrying Amount 2021 Rs.	Net Carrying Amount 2020 Rs.
Freehold Land	799,140,898	-	799,140,898	799,140,898
Buildings	5,726,918,437	332,879,724	5,394,038,713	5,098,984,562
	6,526,059,335	332,879,724	6,193,179,611	5,898,125,460

Notes to the Financial Statements

9.9 The following properties are fair valued and recorded under freehold land and buildings. Fair Value measurement disclosure for revalued land and buildings based on un-observable inputs are as follows:

Company	Location	Extent	Effective Date of Valuation	Method of Valuation	Range of Estimates for Significant Unobservable Inputs	Per square feet Value - Rs.		Fair Value Measurement Rs.
						2021	2020	
Property Valuations by G. W. G. Abeygunawardene (Chartered Valuation Surveyor)								
Asiri Hospital Holdings PLC	No 181, Kirula Road, Colombo 05	1 A 2 R 13.98 P 2 Buildings 105,157 square feet	31st March 2021	Land - OMV*	12.00	-	-	2,945,000,000
				Buildings - DCC*	-	3,350 - 9,600	3,250 - 9,500	953,400,000
	No 907, Peradeniya Road, Kandy	1 Building 346,641 square feet	2021	Buildings - DCC	-	7,000 - 19,650	7,000 - 18,750	5,162,800,000
Asiri Surgical Hospital PLC	No 21, Kirimandala Mawatha, Narahenpita	3 Buildings 368,123 square feet	31st March 2021	Buildings - DCC	-	3,250 - 9,930	3,250 - 10,000	2,420,600,000
	No 21, Kirimandala Mawatha, Narahenpita	2 Floors - Ground Floor 3355 square feet and 1st Floor 3355 square feet	31st March 2021	Buildings - DCC	-	32,000	32,042	214,700,000
Property Valuations by P. B. Kalugalagedara & Associates (Chartered Valuation Surveyor)								
Asiri Hospital Matara (Pvt) Ltd	No 15, Dharmapala Mawatha, Uyanwatta	1 A 2 R 1.65 P 2 Buildings 76,581 square feet	31st March 2021	Land - OMV	0.95-1.325	0.9-1.25	-	301,530,000
				Buildings - DCC	-	600 - 8,500	600 - 8,500	424,620,000
Central Hospital Ltd	No 114, Norris Canal Road, Colombo 10	1 A 0 R 21.03 P 1 Building 453,840 square feet	31st March 2021	Land - OMV	11.00 to 12.00	11.00 to 12.00	-	2,172,360,000
				Buildings - DCC	-	2,000 - 10,000	2,000 - 10,000	3,455,817,000
Asiri Hospital Galle (Pvt) Ltd	No.59, Wackwella, Galle	2R 24.83P & OR 48.37P 4 Buildings 44,255 square feet	31st March 2021	Land - OMV	4.00 to 5.00	4.00 to 5.00	-	670,400,000
				Buildings - DCC	-	2500-9,750	8500	450,700,000

* OMV - Open Market Value Method, DCC - Direct Capital Comparison Method
Unobservable inputs are positively correlated with fair values.

10. RIGHT OF USE ASSETS

10.1 Amounts Recognised in the Statement of Financial Position and Statement of Profit or Loss.

Set out below are the, carrying amounts of the right of use assets and the movements for the period ended 31 March 2021.

10.2 Right of Use Assets

	Group				Company		
	2021				2021		
	Leasehold Properties	BOI Lands	Motor Vehicles	Total	Leasehold Properties	Motor Vehicles	Total
	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.
At the Beginning of the Year	1,322,163,094	23,177,155	22,129,180	1,367,469,429	905,107,736	37,695,038	942,802,774
Additions and Improvements	121,860,343	-	299,387	122,159,730	95,102,907	-	95,102,907
Amortisation for the Year	(166,713,632)	(356,255)	(11,830,369)	(178,900,256)	(84,650,627)	(6,642,869)	(91,293,496)
Derecognition of Lease Assets	(869,106)	-	-	(869,106)	-	-	-
At the End of the Year	1,276,440,699	22,820,900	10,598,198	1,309,859,796	915,560,016	31,052,168	946,612,185

	Group				Company		
	2020				2020		
	Leasehold Properties	BOI Lands	Motor Vehicles	Total	Leasehold Properties	Motor Vehicles	Total
	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.
At the Beginning of the Year	-	-	-	-	-	-	-
SLFRS-16 Initial Recognition	804,696,917	23,413,657	52,052,090	880,162,664	-	44,338,163	44,338,163
Addition-SLFRS16 Initial Recognition	255,081,415	-	-	255,081,415	908,730,041	-	908,730,041
Additions and Improvements	378,304,258	-	-	378,304,258	79,630,012	-	79,630,012
Amortisation for the Year	(115,919,496)	(236,502)	(29,922,910)	(146,078,908)	(83,252,318)	(6,643,125)	(89,895,443)
At the End of the Year	1,322,163,094	23,177,155	22,129,180	1,367,469,429	905,107,736	37,695,038	942,802,774

10.3 Leasehold Property as at 31 March 2021 consists of the below;

- Asiri Surgical Hospital PLC obtained leasehold right to the land (extent of land is 2 Acres, 1 Rood and 11.6 perches) situated at No.21, Kirimandala Mawatha, Colombo 05 for 99 years from the Board of Investment of Sri Lanka by agreement dated 29th March 2000.
- Asiri Hospital Matara (Pvt) Ltd obtained lease hold right to land (extent of land is perches 38.34) and building situated at No 37, Anagarika Dharmapala Mawatha, Matara for 20 years commencing from 04th October 2006.
- Asiri Hospital Holdings PLC has entered into a lease agreement with Urban Development Authority for a lease of the land (extent of land is 2 Acres 15.5 perches) situated at No 907, Peradeniya Road, Kandy for period of 50 years commencing from 18th January 2015.

Notes to the Financial Statements

11. INVESTMENT PROPERTY

	Note	Group	
		2021	2020
		Rs.	Rs.
Balance as at the Beginning of the Year		215,000,000	193,724,248
Changes in Fair Value		-	19,211,705
Additions		-	2,064,047
Transferred to Property Plant & Equipment	9.1.1	(215,000,000)	-
Balance as at the End of the Year		-	215,000,000

12. GOODWILL

	Group	
	2021	2020
	Rs.	Rs.
Balance as at the Beginning of the Year	609,654,071	609,654,071
Acquisition of a Subsidiary	-	-
Balance as at the End of the Year	609,654,071	609,654,071

The aggregate carrying amount of goodwill allocated to each unit is as follows:

	Group	
	2021	2020
	Rs.	Rs.
Asiri Surgical Hospital PLC	548,706,564	548,706,564
Asiri Hospital Galle (Pvt) Ltd	60,947,507	60,947,507
	609,654,071	609,654,071

12.1 Impairment of Goodwill

Accounting Judgements, Estimates and Assumptions

The recoverable amount of all CGUs have been determined based on the higher of fair value less costs to sell and its Value in Use (VIU) calculation. VIU is determined by discounting the future cash flows generated from continuing use of the unit. The recoverability of quoted entities determined based on share price existed as at reporting date. The key assumptions used to determined VIU of the CGUs are given below:

- Business growth - Volume growth has been budgeted on a reasonable and realistic basis by taking into account the growth rates of one to five years immediately subsequent to the budgeted year, based on industry growth rates.
- Inflation - Budgeted cost inflation is the inflation rate, based on projected economic conditions.
- Discount rate - The discounting rate used is the risk free rate increased by an appropriate risk premium.
- Margin - Budgeted gross margins are the gross margins achieved in the year preceding, adjusted for projected market conditions and business plans.

13. INVESTMENT IN SUBSIDIARY COMPANIES/ASSOCIATES/JOINT VENTURES**Investment In Subsidiary Companies****13.1 Quoted**

Company	2021	2020	2021		2020	
	Direct Holding		Carrying Value	Market Value	Carrying Value	Market Value
	%	%	Rs.	Rs.	Rs.	Rs.
Asiri Surgical Hospital PLC	79.96	78.54	2,796,871,687	5,831,264,699	2,675,628,945	3,728,192,688
			2,796,871,687	5,831,264,699	2,675,628,945	3,728,192,688

13.2 Un-quoted

Company	2021	2020	2021	2020
	Direct Holding		Carrying Value	Carrying Value
	%	%	Rs.	Rs.
Asiri Diagnostics Services (Pvt) Ltd	66.54	66.54	2,691,400	2,691,400
Asiri Hospital Matara (Pvt) Ltd	100	100	261,780,971	261,780,971
Central Hospital Ltd	99.73	99.73	7,119,787,789	7,119,787,789
Asiri Central Hospitals Ltd	94.48	94.42	1,709,044,759	1,708,467,514
Asiri Laboratories (Pvt) Ltd	100	100	1,000,000	1,000,000
Asiri Hospital Galle (Pvt) Ltd	100	100	450,000,000	450,000,000
Asiri Diagnostic Services (Asia) Pte. Ltd	100	100	133	133
Asiri Myanmar Limited	100	100	1	1
			9,544,305,053	9,543,727,808
Carrying Value of Investment in Subsidiaries			12,341,176,740	12,219,356,753

- 13.3** The Shares of Subsidiary Companies owned by Asiri Hospital Holdings PLC were pledged on behalf of the loans and overdraft facilities obtained by the Company. (Refer Note 24.5)

Notes to the Financial Statements

13.4 Material Partly-owned Subsidiaries

Financial information of subsidiaries that have material non-controlling interests is provided below:

Proportion of Equity Interest held by Non-Controlling Interests:

	2021	2020
	%	%
Company Name		
Asiri Surgical Hospital PLC	20.04%	21.46%
Asiri Diagnostics Services (Pvt) Ltd	33.46%	33.46%

Summarised Statement of Total Comprehensive Income for year ended 31 March:

	Asiri Surgical Hospital PLC		Asiri Diagnostics Services (Pvt) Ltd	
	2021	2020	2021	2020
	Rs.	Rs.	Rs.	Rs.
Revenue	3,898,338,863	3,654,663,091	58,619,344	70,413,641
Cost of Services	(2,507,690,676)	(2,265,592,297)	(37,265,673)	(42,201,361)
Profit for the Year	784,647,219	433,110,772	7,582,961	11,409,989
Total Comprehensive Income for the Year	947,981,812	517,815,017	7,389,771	10,780,673
Attributable to Non-controlling Interests	189,974,192	111,123,103	2,472,617	3,607,213

Summarised Statement of Financial Position as at 31 March:

	Asiri Surgical Hospital PLC		Asiri Diagnostics Services (Pvt) Ltd	
	2021	2020	2021	2020
	Rs.	Rs.	Rs.	Rs.
Current Assets	2,552,669,085	2,296,361,548	53,004,954	69,954,761
Non- Current Assets	5,698,415,960	5,571,614,206	333,479,283	335,054,513
Current Liabilities	1,280,531,468	1,737,038,201	39,979,720	54,261,817
Non- Current Liabilities	2,415,156,018	2,074,332,891	19,923,388	15,894,982
Total Equity	4,555,397,561	4,056,604,662	326,581,129	334,852,474
Attributable to:				
Equity Holders of Parent	3,642,502,442	3,186,057,302	217,307,083	222,810,836
Non-controlling Interests	912,895,120	870,547,360	109,274,046	112,041,638
Dividend to Non-controlling Interests	91,891,816	-	5,496,360	-

Summarised Statement of Cash Flow for the year ended 31 March:

	Asiri Surgical Hospital PLC		Asiri Diagnostics Services (Pvt) Ltd	
	2021	2020	2021	2020
	Rs.	Rs.	Rs.	Rs.
Cashflow from / (used) in Operating Activities	474,858,694	294,297,913	2,259,120	(12,907,547)
Cashflow from / (used) in Investing Activities	(180,029,223)	(1,702,058,941)	22,479,217	14,519,119
Cashflow from / (used) in Financing Activities	(163,512,816)	1,666,801,991	(22,996,924)	(6,483,487)
Net increase / (decrease) in Cash and Cash Equivalents	131,316,655	259,040,963	1,741,413	(4,871,915)

13.5 Investment in Associates/Joint Ventures

	Group		Company	
	2021	2020	2021	2020
	Investments in Equity Accounted Investees	-	32,245,027	-
	-	32,245,027	-	30,000,000

Group Investments in Equity Accounted Investees

	Group		Company	
	2021	2020	2021	2020

Investments in Joint Ventures

Unquoted

Asiri AOI Cancer Centre (Pvt) Ltd	13.5.2	-	31,624,671	-	-
		-	31,624,671	-	-

Investments in Associates

Unquoted

Digital Health (Pvt) Ltd	13.5.1	-	-	-	30,000,000
		-	-	-	30,000,000
Cumulative Profit Accruing to the Group net of Dividend		-	620,356	-	-
		-	32,245,027	-	30,000,000

13.5.1 Digital Health (Pvt) Ltd

The Group's investments in Digital Health (Pvt) Ltd derecognised the Associate investment and recognised the Investment as an equity investment, designated at Fair Value through OCI. (Refer 15.3)

Notes to the Financial Statements

13.5.2 Asiri A O I Cancer Centre (Pvt) Ltd

The Group's investments in its associates and joint venture are accounted for using the equity method till 31st March 2020. The Group has reassess the circumstances and the documents were reviewed in detailed by the management. As a result of these review & discussions, the Management has decided the Asiri Surgical Hospital PLC as the parent company of Asiri AOI Cancer Centre (Pvt) Ltd with effect from 1st April 2020. On 31st March 2021, AOI is accounted as a subsidiary company of Asiri Hospital Holdings PLC with 39.98%.

Assets and Liabilities of Asiri AOI Cancer Centre (Pvt) Ltd at the Acquisition.

	Rs.
Assets	
Property, Plant and Equipment	342,736,666
Inventories	2,009,685
Trade and Other Receivables	11,479,127
Other Current Assets	251,045
Cash in Hand and at Bank	27,555,476
	384,031,999
Liabilities	
Retirement Benefit Liability	850,584
Trade and Other Payable	44,356,204
Interest Bearing Loans and Borrowings	268,055,052
Deferred Tax Liability	3,161,926
	316,423,766
Net Identifiable Assets	67,608,233
Cash Consideration	-
Cash at Bank and in Hand Acquired	(27,555,476)
	(27,555,476)

14. OTHER NON CURRENT ASSETS

	Group		Company	
	2021	2020	2021	2020
	Rs.	Rs.	Rs.	Rs.
Security Deposits	54,472,751	54,292,771	28,490,753	28,310,771
	54,472,751	54,292,771	28,490,753	28,310,771

15. NON CURRENT FINANCIAL ASSETS**15.1 Quoted/Non Quoted Equity Investments**

		Group			
		2021	2020	2021	2020
		Number of	Number of	Market	Market
		Shares	Shares	Value	Value
				Rs.	Rs.
Investment in Equity Securities					
National Development Bank PLC	15.2	3,606,952	3,606,952	293,258,010	360,695,200
Digital Health (Pvt) Ltd	15.3	3,000,000	-	30,000,000	-
Total Investment in Equity Securities		6,606,952	3,606,952	323,258,010	360,695,200

15.2 Investment in Quoted Equity Securities

	Group	
	2021	2020
	Rs.	Rs.
Balance at the Beginning of the Year	360,695,200	323,946,456
Fair Value (Loss)/Gain	(67,437,190)	19,554,134
Share Allotment as Scrip Dividends	-	17,194,610
Balance at the End of the Year	293,258,010	360,695,200

15.3 Non-Quoted Equity Investments

	Group/Company			
	2021	2020	2021	2020
	Number of	Number of	Market	Market
	Shares	Shares	Value	Value
			Rs.	Rs.
Investment in Non Quoted Equity Securities				
Digital Health (Pvt) Ltd	3,000,000	-	30,000,000	-
	3,000,000	-	30,000,000	-

Notes to the Financial Statements

16. FINANCIAL ASSETS AND FINANCIAL LIABILITIES

16.1 Financial Assets

	Group		Company	
	2021	2020	2021	2020
	Rs.	Rs.	Rs.	Rs.
Financial Assets at Fair value through OCI (Equity Instruments)				
Non Current Financial Assets	323,258,010	360,695,200	30,000,000	-
Financial Assets at Amortised Cost				
Trade and Other Receivables	789,098,929	902,177,693	551,037,804	368,877,292
Loans Granted to Related Parties	1,679,771,446	1,733,487,186	133,717	50,990,120
Cash and Cash Equivalents	985,680,944	1,448,291,268	530,712,583	817,434,641
Carrying Value of Financial Assets	3,777,809,329	4,444,651,347	1,111,884,104	1,237,302,053
Fair Value of Financial Assets	3,777,809,329	4,444,651,347	1,111,884,104	1,237,302,053

16.2 Financial Liabilities

	Group		Company	
	2021	2020	2021	2020
	Rs.	Rs.	Rs.	Rs.
Financial Liabilities at Amortised Cost				
Interest Bearing Loans and Borrowings	14,211,252,684	12,912,016,140	14,064,001,735	13,715,068,204
Trade and Other Payables	1,878,268,180	1,969,935,399	1,125,787,044	1,095,821,628
Bank Overdraft	2,716,949,746	3,616,289,805	2,563,497,602	2,674,895,151
Dividend Payable	91,176,933	38,711,372	73,144,253	30,429,896
Carrying Value of Financial Liabilities	18,897,647,543	18,536,952,716	17,826,430,634	17,516,214,879
Fair Value of Financial Liabilities	18,897,647,543	18,536,952,716	17,826,430,634	17,516,214,879

The management assessed that, cash in hand and at bank, short term investments, loans granted to related parties, trade and other receivables, trade and other payables, current portion of interest bearing borrowings and bank overdrafts approximate to their fair value largely due to the short-term maturities of these instruments. The fair value of financial assets at amortised cost and financial liabilities does not significantly vary from the value based on the amortised cost methodology for the Group/Company.

16.3 Fair Value of Financial Liabilities Not Carried at Fair Value

Except for the below indicated loans and borrowing non-current balance, carrying value of financial liabilities based on other methods of valuation approximates the fair value.

16.4 Group

	Carrying Amount		Fair Value (Level 2)	
	2021	2020	2021	2020
	Rs.	Rs.	Rs.	Rs.
Financial Liabilities				
Loans and Borrowings- Non Current	8,199,548,738	7,116,012,063	8,199,548,738	7,116,012,063

16.5 Company

	Carrying Amount		Fair Value (Level 2)	
	2021	2020	2021	2020
	Rs.	Rs.	Rs.	Rs.
Financial Liabilities				
Loans and Borrowings- Non Current	10,603,858,481	11,240,572,603	10,603,858,481	11,240,572,603

The following describes the methodologies and assumptions used to determine the fair values for those financial instruments which are not recorded using fair value measurement basis in the Financial Statements.

For financial liabilities that have a short term maturity (original maturities less than a year), it is assumed that the carrying amounts approximate their fair values.

Financial liabilities with variable interest rates are also considered to be carried at fair value.

17. FAIR VALUE HIERARCHY

The Group uses the following hierarchy for determining and disclosing the fair value of assets by valuation technique:

Level 1 : Quoted (unadjusted) prices in active markets for identical assets or liabilities.

Level 2 : Other techniques for which all inputs that have a significant effect on the recorded fair value are observable, either directly or indirectly.

Level 3 : Techniques that use inputs that have a significant effect on the recorded fair value that are not based on observable market data.

Notes to the Financial Statements

17.1 GROUP

Assets Measured at Fair Value:

	31 March 2021 Rs.	Level 1 Rs.	Level 2 Rs.	Level 3 Rs.
Financial Assets at Fair value through OCI	323,258,010	-	293,258,010	30,000,000
Land and Buildings	19,126,450,172	-	-	19,126,450,172

	31 March 2020 Rs.	Level 1 Rs.	Level 2 Rs.	Level 3 Rs.
Financial Assets at Fair value through OCI	360,695,200	-	360,695,200	-
Investment Property	215,000,000	-	-	215,000,000
Land and Buildings	18,368,300,000	-	-	18,368,300,000

Company

Assets Measured at Fair Value:

	31 March 2021 Rs.	Level 1 Rs.	Level 2 Rs.	Level 3 Rs.
Financial Assets at Fair value through OCI	30,000,000	-	-	30,000,000
Land and Buildings	9,061,200,000	-	-	9,061,200,000

	31 March 2020 Rs.	Level 1 Rs.	Level 2 Rs.	Level 3 Rs.
Land and Buildings	8,653,700,000	-	-	8,653,700,000

18. INVENTORIES

	Group		Company	
	2021 Rs.	2020 Rs.	2021 Rs.	2020 Rs.
Chemical and Test Materials	116,676,314	115,127,377	73,641,103	80,536,126
Pharmaceuticals and Surgical	498,451,152	490,085,597	116,932,673	113,402,259
Consumables	51,823,481	62,763,156	12,453,298	14,978,052
Provision for Slow Moving Stocks	(2,653,935)	(2,349,756)	-	-
	664,297,012	665,626,374	203,027,074	208,916,437

19. TRADE AND OTHER RECEIVABLES**19.1 Trade and Other Receivables**

	Group		Company	
	2021	2020	2021	2020
	Rs.	Rs.	Rs.	Rs.
Trade Debtors	759,720,395	686,673,484	224,876,544	216,453,284
Related Parties (Note 19.2)	39,017,548	51,267,820	186,041,214	48,157,177
Less - Impairment of Trade Debtors	(52,575,157)	(43,397,808)	(1,880,454)	(1,693,988)
	746,162,786	694,543,496	409,037,304	262,916,473
Other Debtors - Related Parties (Note 19.3)	1,379,532	52,174,042	125,183,296	77,991,497
Staff Loans	11,530,187	9,057,096	9,031,075	7,150,199
Other Receivables	30,026,424	146,403,059	7,786,129	20,819,123
	789,098,929	902,177,693	551,037,804	368,877,292

19.1.1 Movement in Provision for Trade and Other Receivables

	Group		Company	
	2021	2020	2021	2021
	Rs.	Rs.	Rs.	Rs.
At the Beginning of the Year	43,397,808	41,393,869	1,693,988	1,880,237
Provision for Impairment of Trade and Other Receivables	29,850,197	9,646,287	208,898	11,634
Written offs During the Year	(20,672,848)	(7,642,348)	(22,432)	(197,883)
At the End of the Year	52,575,157	43,397,808	1,880,454	1,693,988

Notes to the Financial Statements

19.2 Trade Debtors - Related Parties

	Group		Company	
	2021	2020	2021	2020
	Rs.	Rs.	Rs.	Rs.
Parent Company				
Softlogic Holdings PLC	906,793	13,623,017	3,001,157	-
Subsidiaries				
Central Hospital Ltd	-	-	98,080,742	38,101,515
Asiri Surgical Hospital PLC	-	-	7,842,172	1,978,742
Asiri Diagnostics Services (Pvt) Ltd	-	-	13,336,878	4,534,746
Asiri Hospital Matara (Pvt) Ltd	-	-	20,245,724	332,766
Asiri Hospital Galle (Pvt) Ltd	-	-	31,518,835	2,521,492
Asiri AOI Cancer Centre (Pvt) Ltd	-	-	716,699	-
Asiri Myanmar Limited	-	-	8,036,347	-
Asiri Diagnostic Services (Asia) Pte. Ltd	-	-	3,262,661	-
Investment in Joint Venture/Associates				
Digital Health (Pvt) Ltd	-	3,484,960	-	-
Asiri AOI Cancer Centre (Pvt) Ltd	-	-	-	687,917
Companies under Common Control				
Softlogic Life Insurance PLC	26,542,308	33,167,013	-	-
Softlogic Retail (Pvt) Ltd	617,017	826,000	-	-
Jendo Innovations (Pvt) Ltd	3,034,760	166,830	-	-
Softlogic Communication Services (Pvt) Ltd	52,000	-	-	-
Softlogic Computers (Pvt) Ltd	19,500	-	-	-
Softlogic Corporate Services (Pvt) Ltd	13,000	-	-	-
Softlogic Finance Plc	13,000	-	-	-
Softlogic Information Technologies (Pvt) Ltd	234,000	-	-	-
Softlogic International (Pvt) Ltd	34,500	-	-	-
Softlogic Restaurants (Pvt) Limited	2,778,446	-	-	-
Softlogic City Hotels (Pvt) Ltd	194,400	-	-	-
Softlogic Supermarkets (Pvt) Ltd	4,209,686	-	-	-
Softlogic BPO Services (Pvt) Ltd	147,587	-	-	-
Odel PLC	220,550	-	-	-
	39,017,548	51,267,820	186,041,214	48,157,177

19.3 Other Debtors - Related Parties

	Group		Company	
	2021	2020	2021	2020
	Rs.	Rs.	Rs.	Rs.
Parent Company				
Softlogic Holdings PLC	-	627,313	-	-
Subsidiaries				
Asiri Hospital Matara (Pvt) Ltd	-	-	-	7,812,170
Central Hospital Ltd	-	-	14,125,508	59,971,598
Asiri Surgical Hospital PLC	-	-	105,471,239	-
Asiri Diagnostics Services (Pvt) Ltd	-	-	4,207,017	10,198,139
Asiri Hospital Galle (Pvt) Ltd	-	-	-	9,589
Investment in Joint Venture/Associates				
Digital Health (Pvt) Ltd	-	11,260,168	-	-
Companies under Common Control				
Softlogic Life Insurance PLC	-	32,773,586	-	-
Softlogic Restaurants (Pvt) Ltd	-	2,637,493	-	-
Softlogic Finance PLC	-	382,753	-	-
Softlogic Retail (Pvt) Ltd	1,379,532	1,228,617	1,379,532	-
Softlogic Supermarkets (Pvt) Ltd	-	3,578,315	-	-
Softlogic City Hotels (Pvt) Ltd	-	21,600	-	-
Odel PLC	-	291,510	-	-
	1,379,532	52,174,042	125,183,296	77,991,497

20. OTHER CURRENT ASSETS**Advances, Deposits and Prepayments**

	Group		Company	
	2021	2020	2021	2020
	Rs.	Rs.	Rs.	Rs.
Advances, Deposits and Prepayments	313,238,394	401,065,497	137,706,227	116,699,192
Other Tax Receivables	88,457,145	137,135,075	42,810,277	44,810,718
	401,695,539	538,200,572	180,516,504	161,509,910

Notes to the Financial Statements

21. LOANS GRANTED TO RELATED PARTIES

Relationship	Group		Company		
	2021	2020	2021	2020	
	Rs.	Rs.	Rs.	Rs.	
Softlogic Holdings PLC	Parent Company	1,679,771,446	1,733,487,185	133,717	50,990,120
		1,679,771,446	1,733,487,185	133,717	50,990,120

The interest for the Loans Granted to Related Parties were charged based on AWPLR

22. STATED CAPITAL

	Company/Group			
	2021		2020	
	Number	Rs.	Number	Rs.
Balance at the Beginning of the Year	1,137,533,596	4,748,108,334	1,137,533,596	4,748,108,334
Balance at the End of the Year	1,137,533,596	4,748,108,334	1,137,533,596	4,748,108,334

23. OTHER COMPONENTS OF EQUITY

	Group		Company	
	2021	2020	2021	2020
	Rs.	Rs.	Rs.	Rs.
Revaluation Reserve	4,185,577,785	3,384,550,012	2,293,120,542	1,827,032,313
Fair Value Reserve of Financial Assets at FVOCI	(46,240,071)	7,799,793	-	-
Other Reserve	(920,570,832)	(863,976,833)	-	-
Foreign Currency Translation Reserve	(670,556)	-	-	-
Balance at End of the Year	3,218,096,325	2,528,372,972	2,293,120,542	1,827,032,313

Revaluation Reserve

Revaluation reserve consists of the net surplus on the revaluation of Land and Buildings.

Fair Value Reserve of Financial Assets at FVOCI

Fair value reserve of financial assets at FVOCI includes changes in fair value of financial instruments designated as financial assets at FVOCI.

Other Reserve

Other reserve is used to recognise goodwill or gains from purchases on subsequent acquisitions of further equity interests in subsidiaries and gains or losses arising from partial and deemed acquisitions/disposals in its subsidiaries.

- 23.1** Asiri Hospital Holdings PLC obtained certificate of amalgamation from the registrar of companies to amalgamate its wholly owned subsidiary, Asiri Hospital Kandy (Pvt) Ltd with effect from 26th July 2019. The effect of this amalgamation is given below.

Assets and Liabilities of Asiri Hospital Kandy (Pvt) Ltd as at 26th July 2019.

	Rs.
Assets	
Property Plant and Equipment	6,059,519,820
Right-of-use Assets	697,164,600
Inventory	74,814,736
Trade & Other Receivables	487,858,678
Amounts Due from Related Parties	20,893,745
	7,340,251,578
Liabilities	
Interest Bearing Loans & Borrowings	2,634,256,000
Trade, Other Payables & Accrued Expenses	269,828,328
Amounts Due to Related Parties	4,271,932,615
Cash and Cash Equivalents Amalgamated	395,594,813
	7,571,611,757
Net Assets Amalgamated	(231,360,179)
Investment in Subsidiary	171,110,348
Amalgamation Reserve	(402,470,527)

24. INTEREST BEARING LOANS AND BORROWINGS

Group	2021			2020		
	Amount	Amount	Total	Amount	Amount	Total
	Repayable	Repayable		Repayable	Repayable	
	Within 1 Year	After 1 Year	Within 1 Year	After 1 Year		
Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	
Bank Loans (Note 24.1)	2,936,099,632	7,963,805,697	10,899,905,329	3,144,065,042	6,762,654,093	9,906,719,135
Short Term Loans	2,905,961,746	-	2,905,961,746	2,528,483,710	-	2,528,483,710
Lease Liability (Note 24.2)	169,642,568	235,743,041	405,385,620	123,455,324	353,357,971	476,813,295
	6,011,703,946	8,199,548,738	14,211,252,684	5,796,004,076	7,116,012,064	12,912,016,140

Notes to the Financial Statements

24.1 Bank Loans - Group

	2021	2020
	Rs.	Rs.
At the Beginning of the Year	9,906,719,135	7,507,499,638
Acquisition of Subsidiary	268,055,051	-
Loan Obtained	2,642,268,628	4,128,382,276
Interest Charge	818,564,339	1,056,698,277
Repayments	(2,735,701,824)	(2,785,861,056)
At the End of the Year	10,899,905,329	9,906,719,135

24.2 Lease Liability

	2021			2020		
	Motor Vehicles	Leasehold Properties	Total	Motor Vehicles	Leasehold Properties	Total
	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.
At the Beginning of the Year	73,118,885	403,694,410	476,813,295	26,895,443	22,056,666	48,952,109
SLFRS-16 Initial Recognition	-	-	-	32,069,661	216,206,983	248,276,644
Opening Adjustments	(40,618,551)	40,618,551	-	-	-	-
Facility Obtained	-	112,368,839	112,368,839	-	331,581,706	331,581,706
Interest Charge	3,105,111	58,720,522	61,825,633	31,158,149	34,710,558	65,868,707
Repayments	(19,574,486)	(226,047,660)	(245,622,146)	(17,004,368)	(200,861,503)	(217,865,871)
At the End of the Year	16,030,959	389,354,662	405,385,620	73,118,885	403,694,410	476,813,295

24.2.1 Leasehold Land- Board of Investment of Sri Lanka (BOI) - Under Leasehold Properties

Asiri Surgical Hospital PLC obtained leasehold right to the land (extent of land is 2 Acres, 1 Rood and 11.6 perches) situated at No.21, Kirimandala Mawatha, Colombo 05 for 99 years from the Board of Investment of Sri Lanka by agreement dated 29th March 2000.

An annual sum equivalent to 4% of the total market value of leasehold land (Rs.101,800,000/-) as at the date of the lease agreement, over a period of 25 years commencing from the financial year 2000/2001.

BOI reserves the right to revise the annual lease rent every five years on the basis of an annual increase not greater than the Average Weighted Deposit Rate prevailing at the end of each year as determined by the Central Bank of Sri Lanka or 10%, per annum which ever is lower.

24.3 Long-Term Loan Details

Details of the Long Term Loans	Loan Balance		Repayment	Security	Carrying value of Tangible Collateral
	2021	2020			
24.3.1 Asiri Surgical Hospital PLC					
Commercial Bank of Ceylon PLC	149Mn	191Mn	95 equal monthly instalments of Rs 5,328,000/- each and a final instalment of Rs 5,266,000/-.	Concurrent Mortgage Bond No 3329/4687 with Hatton National Bank PLC over hospital property at No.181, Kirula Road, Colombo 5, owned by Asiri Hospital Holdings PLC.	125 Mn
Hatton National Bank PLC	150Mn	800Mn	12 equal monthly instalments.	Corporate Guarantee of Asiri Hospital Holdings PLC	148Mn
DFCC Bank PLC	1183Mn	1200Mn	72 equal monthly instalments after a grace period of 12 months from the date of first disbursement.	Corporate Guarantee of Asiri Hospital Holdings PLC	1200Mn
Sampath Bank PLC	800Mn	-	59 equal monthly instalments of Rs 13,300,000/- each and a final instalment of Rs 15,300,000/- after a grace period of 6 months from the date of first disbursement.	-	-
	200Mn	-	59 equal monthly instalments of Rs 3,300,000/- each and a final instalment of Rs 5,300,000/- after a grace period of 6 months from the date of first disbursement.	-	-
24.3.2 Asiri Hospital Matara (Pvt) Ltd					
Nations Trust Bank PLC	9Mn	28Mn	60 equal monthly instalments of Rs. 1,608,383/-	Assignment over Amex Receivables, Loan Agreement for 96.5Mn	Rs.96.5 Mn
Nations Trust Bank PLC	16Mn	37Mn	24 equal monthly instalments.	Assignment over Amex Receivables	Rs.100 Mn

Notes to the Financial Statements

Details of the Long Term Loans	Loan Balance		Repayment	Security	Carrying value of Tangible Collateral
	2021	2020			
24.3.3 Central Hospital Ltd					
Sampath Bank PLC	88Mn	125Mn	95 equal monthly instalment each worth is Rs.3,396,000/- and final instalment is Rs.3,380,000/-	Corporate Guarantee from Asiri Hospital Holdings PLC for Rs. 326 Mn.	326 Mn
Sampath Bank PLC	564Mn	670Mn	120 Equal monthly instalments of Rs: 9,600,000 and a final instalment of Rs: 7,600,000 commencing from the month following the disbursement of the loan to be served monthly	Securitisation of all future credit/debit card receivables of the Company and assignment over credit/debit card receivables of the Company and future credit/debit card receivables.	1,150Mn
Sampath Bank PLC	1,000Mn	-	59 Equal monthly instalments Rs. 16,750,000/- Final Instalment Rs. 11,750,000/-	Loan agreement for Rs. 1,000,000,000/-, Mortgage over all future Credit/Debit and cash receivables of the Company for Rs. 1,000,000,000/-, Letter of Set off, Notice of Assignment	1,000Mn
Commercial Bank of Ceylon PLC	936Mn	1024Mn	53 Equal monthly instalments Rs. 23,150,000/- Final Instalment Rs. 23,050,000/- (Five years including Four months grace period)	-	-
Bank of Ceylon PLC	178Mn	280Mn	94 Equal monthly instalments Rs. 10,146,667/- Final Instalment Rs. 6,268,816/- (Ten years including two years grace period)	Primary Concurrent Mortgage over freehold land and buildings at No114, Norris Canal Rd, Colombo 10.	960 Mn

Details of the Long Term Loans	Loan Balance		Repayment	Security	Carrying value of Tangible Collateral
	2021	2020			
24.3.4 Asiri Hospital Galle (Pvt) Ltd					
Sampath Bank PLC	193Mn	200Mn	The capital repayment of the loan commences after a grace period of 12 months from the date of first disbursement and is payable in 108 equal monthly instalments (1st 24 months Rs.1,000,000/, 2nd 24 months Rs.1,800,000/-, 3rd 36 months Rs.2,000,000/-, 4th 23 months Rs.2,500,000/- and a final instalment of Rs.3,300,000).	Third party Primary Mortgage Bond for Rs. 200Mn over premises at No.59, Wackwella Road, Galle owned by the Asiri Hospital Galle (Pvt) Ltd	200 Mn
Sampath Bank PLC	244Mn	244Mn	The capital repayment of the loan commences after a grace period of 124 months from the date of first disbursement and is payable in 108 equal monthly instalments in following manner, together with interest on 26th of each month.	Loan Agreement for - 244,350,000.00, Primary Mortgage Bond - For 74,000,000 over Property (Lot No. 56) & for 84,000,000.00 Over Property (Lot No. 57), Additional Mortgage Bond For 86,350,000 Over Property (Plan No. 19007 Owned By AHG)	-
Seylan Bank PLC	145Mn	65Mn	60 months inclusive of a grace period of 12 months commencing from the date of grant. To be payable in 48 equal instalments of Rs. 3,125,000 together with interest	Corporate Guarantee of Asiri Hospital Holdings PLC for Rs. 450Mn for short term loan of Rs. 300Mn+ Rs.150Mn long term loan	-
24.3.5 Asiri AOI Cancer Centre (Pvt) Ltd					
Hatton National Bank PLC	197.5Mn	268Mn	48 equal monthly installments of Rs. 5 Mn commencing after an initial grace period of one year.	Corporate Guarantee of Asiri Surgical Hospital PLC	300Mn

Notes to the Financial Statements

24.4 Company

	2021			2020		
	Amount	Amount	Total	Amount	Amount	Total
	Repayable	Repayable		Repayable	Repayable	
	Within 1 Year	After 1 Year	Within 1 Year	After 1 Year		
Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	
Bank Loans (Note 24.4.1)	755,870,000	3,235,281,137	3,991,151,137	841,777,720	3,821,178,364	4,662,956,084
Short Term Loans	2,455,139,287	-	2,455,139,287	1,425,001,743	-	1,425,001,743
Loans due to Related Parties (Note 24.4.2)	192,542,850	7,179,557,803	7,372,100,653	192,542,850	7,213,953,572	7,406,496,422
	3,403,552,137	10,414,838,940	13,818,391,077	2,459,322,313	11,035,131,936	13,494,454,249
Lease Liability (Note 24.4.3)	56,591,118	189,019,541	245,610,659	15,173,287	205,440,667	220,613,953
	3,460,143,255	10,603,858,481	14,064,001,736	2,474,495,601	11,240,572,603	13,715,068,203

24.4.1 Bank Loans

	2021	2020
	Rs.	Rs.
At the Beginning of the Year	4,662,956,084	2,886,053,592
Loans Obtained	124,300,000	2,634,256,000
Interest Charge	372,842,766	639,272,255
Repayments	(1,168,947,712)	(1,496,625,763)
At the End of the Year	3,991,151,137	4,662,956,084

24.4.2 Loans Due to Related Parties

	As at 01.04.2020 Rs.	Temporary Finance Obtained Rs.	Interest Charge Rs.	Repayments Rs.	As at 31.03.2021 Rs.
Asiri Surgical Hospital PLC	1,611,061,320	212,000,000	124,904,091	(91,058,721)	1,856,906,689
Asiri Diagnostics Services (Pvt) Ltd	314,406,545	-	25,769,902	(23,314,456)	316,861,991
Asiri Central Hospitals Ltd	2,517,798,311	-	195,024,440	(337,173,859)	2,375,648,892
Central Hospital Limited	2,763,161,110	317,950,000	231,641,609	(627,883,192)	2,684,869,526
Asiri Hospital Matara (Pvt) Ltd	200,069,136	-	14,604,980	(76,860,561)	137,813,555
	7,406,496,422	529,950,000	591,945,022	(1,156,290,789)	7,372,100,653

24.4.3 Lease Liability

	2021			2020		
	Motor Vehicles	Property	Total	Motor Vehicles	Property	Total
	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.
At the Beginning of the Year	11,499,636	209,114,317	220,613,953	20,928,023	-	20,928,023
SLFRS 16 Initial Recognition	-	-	-	-	182,944,009	182,944,009
Facility Obtained	-	92,212,953	92,212,953	-	79,630,012	79,630,012
Interest Charge	679,411	33,164,057	33,843,468	1,818,225	28,501,383	30,319,607
Repayments	(11,705,927)	(89,353,776)	(101,059,703)	(11,246,612)	(81,961,087)	(93,207,699)
At the End of the Year	473,119	245,137,551	245,610,659	11,499,636	209,114,317	220,613,953

Notes to the Financial Statements

24.5 Long Term Loan Details

Details of the Long Term Loans	Balance as at		Repayment Terms	Security	Security Amount
	2021	2020			
Commercial Bank of Ceylon PLC	82Mn	-	23 equal monthly instalments of Rs.5,180,000/- each and a final instalment of Rs.5,160,000/- together with interest	Leeway available in the existing securities of the Commercial Bank of Ceylon PLC Loans	Rs.
Commercial Bank of Ceylon PLC	167Mn	206Mn	95 equal monthly instalments of Rs.5,584,000/- each and a final instalment of Rs.5,520,000/- together with interest	Corporate Guarantee of Asiri Surgical Hospital PLC for Rs.550 Mn	550 Mn
Commercial Bank of Ceylon PLC	750Mn	925Mn	95 equal monthly instalments of Rs.25,025,000/- and a final instalment of Rs.24,591,000/- together with interest	Primary Mortgage Bond No 3919 over 74,454,026 shares of Central Hospital Limited for Rs. 2,225 Mn	2,225 Mn
Sampath Bank PLC	328Mn	390Mn	119 equal monthly instalments of Rs: 5,600,000 and a final instalment of Rs: 3,600,000 commencing from the month following the disbursement of the loan to be served monthly with interest.	Securitization of all future credit/debit card receivable of the Company. Loan agreement for Rs: 670Mn. Assigning over credit /debit card receivable of the Company and future debit /credit card receivable.	670 Mn
Sampath Bank PLC	403Mn	450Mn	107 equal monthly instalments of Rs. 4,200,000/- and a final instalment of Rs: 600,000/- together with interest, after a capital grace period of 12 months commencing from the date of disbursement & served monthly with interest.	Third party Primary Mortgage Bond for Rs. 450Mn over premises at No.59, Wackwella Road, Galle owned by the Asiri Hospital Galle (Pvt) Ltd.	450Mn
Hatton National Bank PLC	31Mn	187Mn	48 equal monthly instalments of Rs.15,625,000/- together with interest	Deposit over share certificate of Asiri Hospital Galle (Pvt) Ltd together with Irrevocable Power of Attorney	

25. DEFERRED TAX ASSETS AND LIABILITIES

25.1 Net Deferred Tax Liability

	Group		Company	
	2021	2020	2021	2020
	Rs.	Rs.	Rs.	Rs.
At the Beginning of the Year	1,833,614,913	1,644,385,751	900,909,924	748,673,190
Acquisition of a Subsidiary	3,161,926	-	-	-
Charge Recognised in Statement of Profit or Loss (Note 25.2)	(150,678,006)	6,423,277	(66,824,132)	22,908,837
Charge Recognised in Statement of Other Comprehensive Income (Note 25.2)	(579,084,544)	180,284,122	(344,566,308)	129,327,897
At the End of the Year	1,107,083,521	1,833,614,913	489,519,484	900,909,924

The closing deferred tax asset and liability balances relates to the following.

	Group		Company	
	2021	2020	2021	2020
	Rs.	Rs.	Rs.	Rs.
Revaluation of Land and Buildings	1,046,085,562	1,628,818,942	372,807,961	709,473,737
Accelerated Depreciation for Tax Purpose	400,014,607	628,145,400	235,249,092	362,942,411
Employee Benefit Liabilities	(96,561,505)	(126,677,069)	(36,271,867)	(57,666,163)
Losses Available for off set against Future Taxable Income	(242,183,033)	(297,011,419)	(82,103,571)	(116,377,540)
Impairment of Trade Receivables	(317,116)	(2,198,420)	-	-
Net of ROU Assets & Liability	45,006	2,537,479	(162,136)	2,537,479
	1,107,083,521	1,833,614,913	489,519,484	900,909,924

Notes to the Financial Statements

25.2 Deferred Tax Charge/ (Release)

	Group		Company	
	2021	2020	2021	2020
Income Statement				
Deferred Tax Expense Arising From;				
Accelerated Depreciation for Tax Purposes	(5,635,284)	118,631,091	25,779,474	139,128,345
Deferred Tax Reversal due to Rate Change	(170,838,730)	-	(62,544,172)	-
Revaluation of Investment Property to Fair Value	-	1,921,171	-	-
Employee Benefit Liabilities	(6,736,548)	(317,560)	(4,206,494)	(2,379,448)
Benefit Arising from Tax Losses	30,347,128	(116,348,905)	(23,914,801)	(116,377,540)
Others	2,185,427	2,537,479	(1,938,139)	2,537,479
	(150,678,006)	6,423,277	(66,824,132)	22,908,837
Other Comprehensive Income				
Deferred Tax Expense Arising From;				
Deferred Tax Reversal due to Rate Change	(607,301,754)	-	(354,736,868)	-
Revaluation of Land and Building to Fair Value	39,108,739	189,070,882	18,071,092	134,538,019
Actuarial Loss on Employee Benefit Liabilities	(10,891,529)	(8,786,760)	(7,900,532)	(5,210,121)
	(579,084,544)	180,284,122	(344,566,308)	129,327,898

25.3 Tax Losses Carried Forward

	Group		Company	
	2021	2020	2021	2020
Tax Losses Brought Forward	1,588,864,971	1,164,980,903	423,884,068	-
Adjustments on Finalisation of Liability	1,720,862,135	-	1,676,956,737	-
Acquisition of Subsidiary	449,326,160	-	-	-
Tax Losses Arising During the Year	54,857,777	423,884,068	-	423,884,068
Utilisation of Tax Losses	(1,892,328,779)	-	(1,495,739,671)	-
	1,921,582,264	1,588,864,971	605,101,134	423,884,068

The Group has tax losses amounting to Rs. 1,921,582,264 Mn (2020 - Rs.1,588,864,971) available to offset against future taxable profits but not utilised for recognition of these losses as deferred tax assets.

With the introduction of the Inland Revenue Act no. 24 of 2017, which is effective from 01st April 2018, significant changes have been introduced to the income tax law of Sri Lanka. Further the Department of Inland Revenue has issued a Gazette notification no. 2064/53 on the transitional provisions that would be applicable in implementing the above Act.

As per the gazette notification issued in relation to the transitional provisions, any unclaimed loss as at 31st March 2018 is deemed to be a loss incurred for the year of assessment commencing on or after 01st April 2018 and shall be carried forward up to 6 years.

26. EMPLOYEE BENEFIT LIABILITY**26.1 Retirement Benefit Obligations- Gratuity**

	Group		Company	
	2021	2020	2021	2020
	Rs.	Rs.	Rs.	Rs.
At the Beginning of the Year	555,610,806	484,450,831	205,950,583	178,844,982
Acquisition of a Subsidiary	855,287	-	-	-
Employees Transferred in	-	-	229,790	-
Interest on Retirement Benefit Liability	51,380,903	53,225,635	18,742,246	19,671,638
Current Service Cost/Amalgamation	74,980,582	57,335,246	30,354,035	19,634,825
Actuarial Loss for the Year	79,859,407	38,232,002	56,432,374	18,607,573
Benefit Paid During the Year	(96,397,140)	(77,632,908)	(52,624,267)	(30,808,433)
Defined Benefits Obligation at the End of the Year	666,289,845	555,610,806	259,084,763	205,950,583
Charge for the Period				
Interest Charge for the Year	51,380,903	53,225,635	18,742,246	19,671,638
Current Service Cost	74,980,582	57,335,246	30,354,035	19,634,825
Actuarial Loss for the Year	79,859,407	38,232,002	56,432,374	18,607,573
	206,220,892	148,792,883	105,528,655	57,914,036

26.2 Messrs. Actuarial and Management Consultants (Pvt) Ltd, Actuaries, carried out an actuarial valuation of the defined benefit plan gratuity as at 31st March 2021. Appropriate and compatible assumptions were used in determining the cost of retirement benefits. The principal assumptions used are as follows:

	Group	
	2021	2020
Discount Rate	6.5% p.a	9.00% p.a
Salary Increase Rate	7.0% p.a	7.0% p.a
Staff Turnover Rate-Up to 49 Years	20%	29%-46%

The demographic assumptions underlying the valuation are retirement age of 55 years.

Notes to the Financial Statements

26.3 Sensitivity to Assumptions Used

If there is a one percentage point changes in the assumptions, it would have the following effect:

	Group		Company	
	2021	2020	2021	2020
Effect on the Defined Benefit Obligation Liability:				
Increase by one percentage point in discount rate	(24,637,310)	(13,705,621)	(9,588,458)	(5,290,549)
Decrease by one percentage point in discount rate	26,712,180	14,251,002	10,396,143	5,627,735
Effect on the Defined Benefit Obligation Liability:				
Increase by one percentage point in salary increment rate	29,379,382	17,295,603	11,461,025	6,680,732
Decrease by one percentage point in salary increment rate	(27,589,418)	(16,596,781)	(10,761,866)	(6,388,079)

26.4 The Following Payments are Expected Contributions to the Defined Benefit Plan in Future Years:

	Group		Company	
	2021	2020	2021	2020
	Rs.	Rs.	Rs.	Rs.
Within the next 12 months	158,804,844	181,458,082	63,635,984	70,697,065
Between 1 to 2 years	173,311,197	182,937,559	64,323,267	62,097,600
Between 3 to 5 years	174,707,043	125,921,272	65,295,683	45,920,086
Between 6 to 10 years	119,969,375	57,226,264	50,050,543	22,959,551
Beyond 10 years	39,497,386	8,067,629	15,779,285	4,276,281
Total Expected Payments	666,289,845	555,610,806	259,084,763	205,950,583

26.5 Weighted Average Durations of Service

The Group's and the company's weighted average durations of service in is 4.2 years (2020 -3 years) and 4.4 years (2020-3.4 years) respectively.

27. TRADE AND OTHER PAYABLES

27.1 Trade and Other Creditors

	Group		Company	
	2021	2020	2021	2020
	Rs.	Rs.	Rs.	Rs.
Trade Payables	843,819,930	1,198,552,732	382,885,380	560,940,342
Trade Payable - Related Parties (Note 27.3)	123,358,870	125,620,779	73,162,867	74,403,648
Other Payables (Note 27.2)	942,159,280	672,657,088	676,313,472	484,854,843
	1,909,338,080	1,996,830,599	1,132,361,719	1,120,198,833

27.2 Other Payables

	Group		Company	
	2021	2020	2021	2020
	Rs.	Rs.	Rs.	Rs.
Sundry Creditors Including Accrued Expenses	911,089,381	645,761,888	242,406,340	136,272,942
Other Payable Related Parties (Note 27.4)	-	-	427,332,458	324,204,696
Other Tax Payables	7,819,538	24,377,206	6,574,674	24,377,206
Contract Liabilities	23,250,361	2,517,994	-	-
	942,159,280	672,657,088	676,313,472	484,854,843

27.3 Trade Payable - Related Parties

	Group		Company	
	2021	2020	2021	2020
	Rs.	Rs.	Rs.	Rs.
Parent Company				
Softlogic Holdings PLC	71,952,572	38,987,813	47,136,690	8,404,369
Investment in Joint Ventures/Associates				
Digital Health (Pvt) Ltd	-	1,703,818	-	-
Companies under Common Control				
Softlogic Life Insurance PLC	2,343	2,343	-	-
Softlogic BPO Services (Pvt) Ltd	20,094,492	24,534,532	11,140,986	16,481,194
Softlogic Communications (Pvt) Ltd	4,389	-	4,389	-
Softlogic Corporate Services (Pvt) Ltd	2,103,439	4,632,457	496,027	2,925,669
Softlogic Finance PLC	1,124,780	149,574	416,062	-
Softlogic Mobile Distribution (Pvt) Ltd	-	352,710	-	-
Softlogic Supermarkets (Pvt) Ltd	5,749,606	1,648,060	5,188,442	747,935
Softlogic Computers (Pvt) Ltd	2,285,746	1,723,442	548,041	1,026,501
Softlogic Information Technologies (Pvt) Ltd	5,377,463	32,960,545	2,286,207	29,833,151
Softlogic Retail (Pvt) Ltd	13,923,156	16,152,383	5,790,474	12,960,395
Future Automobiles (Pvt) Ltd	704,534	2,341,006	155,549	1,831,199
Softlogic Automobiles (Pvt) Ltd	690	424,237	-	193,235
Nextage (Pvt) Ltd	35,658	7,859	-	-
	123,358,870	125,620,779	73,162,867	74,403,648

Notes to the Financial Statements

27.4 Other Payable - Related Parties

	Company	
	2021	2020
	Rs.	Rs.
Subsidiaries		
Asiri Surgical Hospital PLC	315,193,452	149,795,699
Asiri Diagnostics Services (Pvt) Ltd	13,216,218	31,888,304
Central Hospital Ltd	75,282,699	3,703,221
Asiri Hospital Matara (Pvt) Ltd	6,231,787	11,628,384
Asiri Central Hospitals Ltd	-	121,980,408
Asiri Hospital Galle (Pvt) Ltd	10,173,302	5,208,679
Asiri AOI Cancer Centre (Pvt) Ltd	7,235,000	-
	427,332,458	324,204,696

Outstanding balances with related parties as at the year end are unsecured, non-interest bearing and settlement occurs in cash.

28. INCOME TAX PAYABLE

	Group		Company	
	2021	2020	2021	2020
	Rs.	Rs.	Rs.	Rs.
Balance at Beginning of the Year	380,597,336	384,329,638	50,916,945	103,340,181
Provision for Income Tax During the Year (Note 6)	206,831,088	400,874,841	-	2,530,157
Utilisation of Tax Refunds	(71,976,472)	3,802,954	-	-
(Over)/Under Provision and Adjustments (Note 6)	(189,792,739)	78,315,762	11,610,162	85,017,907
Payments made During the Year	(253,728,683)	(486,725,859)	(39,549,111)	(139,971,301)
Balance at the End of the Year	71,930,530	380,597,337	22,977,995	50,916,945

29. CASH AND CASH EQUIVALENTS IN THE CASH FLOW STATEMENT

29.1 Favourable Cash and Cash Equivalents Balance

	Group		Company	
	2021	2020	2021	2020
	Rs.	Rs.	Rs.	Rs.
Cash in Hand and at Banks	702,829,005	1,188,090,938	247,860,644	557,234,309
Short Term Investments less than 3 months	282,851,939	260,200,330	282,851,939	260,200,332
	985,680,944	1,448,291,268	530,712,583	817,434,641

29.2 Unfavourable Cash and Cash Equivalents Balance

Bank Overdraft	(2,716,949,746)	(3,619,289,805)	(2,563,497,602)	(2,674,895,151)
Total Cash and Cash Equivalents for the Purpose of the Cash Flow Statement	(1,731,268,802)	(2,170,998,536)	(2,032,785,019)	(1,857,460,510)

30. COMMITMENTS AND CONTINGENCIES

30.1 Capital Expenditure Commitments

There were no material commitments outstanding as at 31 March 2021 for future capital expenditure except for the below,

	Group	
	2021	2020
	Rs.	Rs.
Capital Expenditure Commitments	225,081,725	536,673,394
	225,081,725	536,673,394

30.2 Contingent Liabilities

(a) Legal Claims

Pending litigations against Asiri Hospital Holdings PLC, Asiri Surgical Hospital PLC and Central Hospital Ltd with a maximum liability of Rs. 41 Mn, Rs.13.2 Mn and 100Mn respectively exist as at the reporting date. (2020 - Asiri Hospital Holdings PLC - Rs. 41 Mn, Asiri Surgical Hospital PLC -Rs. 13.2 Mn, Central Hospital Ltd - Rs. 100Mn)

H.C. (Civil) 417/2015/MR- Krishnan Thangaraj Vs. Asiri Central Hospitals Limited, Oraz International Property Developers and Construction (Private) Limited and H.G. Shalika Perera relating to a permanent injunction restraining the payment of any commission on the sale of the land and premises bearing Assessment No.37, Horton Place, Colombo 07 to P.P.M. Edwards. An Enjoining Order was issued restraining above at the First instance.

Based on the information currently available the Management is in the view that the ultimate resolution of such legal procedures would not likely to have a material adverse effect on the result of the operations, financial position or liquidity of the Company. Accordingly, no provision for any liability has been made in these Financial Statements.

(b) Guarantees

The respective Group companies have signed Corporate Guarantee Bonds with Sampath Bank PLC, Hatton National Bank PLC, Commercial Bank of Ceylon PLC, Bank of Ceylon, Seylan Bank PLC and DFCC Bank PLC securing the following banking facilities obtained by the Group:

	Company	
	2021	2020
	Rs.	Rs.
Guarantees Value	3,184,400,000	3,184,400,000
	3,184,400,000	3,184,400,000

Outstanding Banking Facilities as at 31st March 2021 is Rs.1,927,710,573 (2020- Rs. 2,571,460,819)

Notes to the Financial Statements

30.3 Contingent Income Taxes

A dispute has arisen with the Department of Inland Revenue with regard to the applicability of the income tax exemption in terms of the agreement entered between Asiri Surgical Hospital PLC and the Board of Investment of Sri Lanka (BOI) in 2000. Since there is litigation in the Court of Appeal in CA (Writ) 386/ 2016 with regard to this matter, in accordance with Paragraph 92 of LKAS 37, we are unable to provide further information on this and associated risks, in order not to impair the outcome and/or prejudice the Company's position in this matter. The aforesaid matter is coming up for argument on September 2021 at the Court of Appeal.

31. EVENTS OCCURRING AFTER THE REPORTING DATE

There were no material events that occurred after the reporting date that require adjustments or disclosure to the Financial Statements.

32. RELATED PARTY DISCLOSURES

Details of significant related party disclosures are as follows:

32.1 Transactions with Related Entities

	Group		Company	
	2021	2020	2021	2020
	Rs.	Rs.	Rs.	Rs.
Subsidiaries				
Opening Balance 01 April	-	-	(7,637,759,993)	(1,034,009,909)
Repayment of Temporary Finance Obtained and Fund Transfers	-	-	626,340,789	(1,966,417,487)
Interest Charged	-	-	(591,945,022)	(727,616,276)
Sale of Goods/Services	-	-	164,601,160	295,825,212
Channelling Fee Collected by Related Party/ (Company on Behalf of the Related Party)	-	-	(77,228,087)	(119,860,145)
Impact from amalgamation	-	-	-	(4,108,955,130)
Settlements	-	-	728,225	-
Expenses incurred by the Company on Behalf of Related Party	-	-	22,673,637	23,273,742
Closing Balance 31 March	-	-	(7,492,589,290)	(7,637,759,993)
Associates/Joint Ventures				
Opening Balance 01 April	248,166,069	62,054,738	99,526,045	8,653,452
De-recognition of Investment in Associate	(372,269,769)	-	(223,629,745)	-
Sale/(Purchase) of Goods/Services	-	380,895,821	-	(3,984,059)
Channelling Fee Collected by Related Party	124,103,700	94,856,652	124,103,700	94,856,652
Expenses incurred by the Company on Behalf of Related Party	-	96,750,450	-	-
Settlements	-	(386,391,592)	-	-
Closing Balance 31 March	-	248,166,069	-	99,526,045

	Group		Company	
	2021	2020	2021	2020
	Rs.	Rs.	Rs.	Rs.
Parent Entity				
Opening Balance 01 April	1,849,272,521	1,318,605,647	78,203,386	395,551,023
Repayment of Temporary Finance Obtained, Fund Transfers	-	-	-	(375,000,000)
Temporary Finance Granted	443,964,433	479,112,129	-	-
Interest Charged	180,051,718	106,560,152	48,000,483	57,652,363
Purchase of Goods/Services	(86,567,654)	(82,567,896)	-	-
Settlements	(688,536,179)	27,562,489	(80,746,513)	-
Expenses incurred by the Company on Behalf of Related Party	(89,459,172)	-	(89,459,172)	-
Closing Balance 31 March	1,608,725,668	1,849,272,521	(44,001,816)	78,203,386
Affiliate Companies				
Opening Balance 01 April	(134,888,765)	167,774,361	(167,935,409)	(1,271,562)
Temporary Finance Granted	-	-	-	-
Interest Charged	194,732,234	-	-	-
Purchase of Goods/ Services	(203,687,272)	(340,315,589)	(159,797,038)	(212,663,126)
Settlements	131,927,792	37,652,462	319,097,370	45,999,279
Expenses Incurred by the Company on behalf of Related Party/ (Related Party on behalf of the Company)	-	-	(16,011,567)	-
Closing Balance 31 March	(11,916,011)	(134,888,765)	(24,646,644)	(167,935,409)
Transactions with Key Management Personnel and Their Close Family Members				
Opening Balance 01 April	-	-	-	-
Sale/(Purchase) of Goods/ Services	-	-	-	-
Closing Balance 31 March	-	-	-	-
Balance as at 31 March	1,596,809,657	1,962,549,826	(7,561,237,751)	(7,627,965,971)
Included Under Trade Receivables (Note 19.1)	39,017,548	51,267,820	186,041,214	48,157,177
Included Under Other Receivables (Note 19.3)	1,379,532	52,174,042	125,183,296	77,991,497
Included Under Loans granted to Related Parties (Note 21)	1,679,771,446	1,733,487,185	133,717	50,990,120
Included Under Interest Bearing Loans and Borrowings (Note 24.4)	-	-	(7,372,100,653)	(7,406,496,422)
Included Under Trade Payables (Note 27.3)	(123,358,870)	(125,620,779)	(73,162,867)	(74,403,648)
Included Under Other Payables (Note 27.4)	-	-	(427,332,458)	(324,204,696)
	1,596,809,657	1,962,549,826	(7,561,237,751)	(7,627,965,971)

Notes to the Financial Statements

32.2 Management fees paid to Softlogic Holdings PLC amounted to Rs.39,812,642/- in the current financial year. (2020 - Rs.26,911,065/-)

32.3 The Company carried out transactions in the ordinary course of its business under relevant commercial terms and conditions with parties who are defined as related parties in Sri Lanka Accounting Standard LKAS 24 – Related party disclosure.

32.4 Non-Recurrent Related Party Transactions

There were no any non-recurrent related party transactions which aggregate value exceeds 10% of the equity or 5% of the total assets whichever is lower of the Company as per 31st March 2021 Audited Financial Statements, which required additional disclosures in the 2020/21 Annual Report under Colombo Stock Exchange listing Rule 9.3.2 and Code of Best Practices on Related Party Transactions under the Security Exchange Commission Directive issued under Section 13 (c) of the Security Exchange Commission Act.

32.5 Recurrent Related Party Transactions

There were no recurrent related party transactions which in aggregate value exceeds 10% of the revenue of the Company as per 31st March 2021 Audited Financial Statements, which required additional disclosures in the 2020/21 Annual Report under Colombo Stock Exchange listing Rule 9.3.2 and Code of Best Practices on Related Party Transactions under the Securities and Exchange Commission Directive issued under Section 13(c) of the Securities and Exchange Commission Act.

32.6 Compensation of Key Management personnel*

	Group		Company	
	2021	2020	2021	2020
	Rs.	Rs.	Rs.	Rs.
Short Term Employee Benefits	32,587,471	46,544,214	24,342,271	36,640,094
	32,587,471	46,544,214	24,342,271	36,640,094

*Key management personnel include Board of Directors of Asiri Hospital Holdings PLC, its parent Company.

32.7 Other Transactions

Company

The shareholders of the Company are eligible for discounts up to 50% on the hospital bills excluding the charges for drugs, medical consumables, professional fees and blood charges up to a limit of 12.5% per annum, of the nominal value of the shares held for a minimum period of three months. Discounts are also given on investigation on out patients channeling such as on Laboratory, MRI, X-Ray, ECG, Ultrasound Scanning and others provided by the Company.

This facility is extended to the shareholder and three nominees, subject to the above limit.

33. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES

Risk is associated with any business. The type of risk and the degree to which it affects a particular business varies. Uncertainties provide both risk and opportunity with a potential to erode or enhance the enterprise value. The Board of Directors is mindful of these uncertainties and through the Management at various levels have put in place adequate systems to identify the probable occurrence of such risks in advance and to exercise mitigating measures to minimize the impact.

The key Financial Risks include Credit Risk, Market Risk including Currency Risk, Interest Rate Risk, Price Risk, and Liquidity Risk. Managing these risks is part of the Group's/Company's risk management process.

Mechanisms adopted by the Group/Company in managing eventual impact of such risk are given below.

33.1 Credit Risk

The Group/Company admit patients on placement of a deposit or in an emergency, even without a deposit. Further, the hospital admit patients who are corporate clients. There is a risk of a patient not having adequate funds to settle his/her bill at the time of discharge. In order to mitigate such risk, the Group/Company issues interim bills to the patients requesting periodic bill settlement. Further there is a risk of corporate clients' payments being delayed or not being paid. The Group/Company evaluates credit worthiness of companies before granting credit facilities to corporate clients in order to minimize the non-collection of bills.

	Group		Company	
	2021	2020	2021	2020
	Rs.	Rs.	Rs.	Rs.
Financial Assets at Amortised Cost				
Loans Granted to Related Parties	1,679,771,446	1,733,487,185	133,717	50,990,120
Trade and Other Receivables	789,098,929	902,177,693	551,037,804	368,877,292
Cash and Cash Equivalents	985,680,944	1,448,291,268	530,712,583	817,434,641
Total Credit Risk Exposure	3,454,551,319	4,083,956,146	1,081,884,104	1,237,302,053
Financial Assets Designated at Fair value through OCI (equity instruments)				
Investment in Quoted/Unquoted Equity Securities	323,258,010	360,695,200	30,000,000	-
Total Equity Risk Exposure	323,258,010	360,695,200	30,000,000	-
Total	3,777,809,329	4,444,651,346	1,111,884,104	1,237,302,053

Loans Granted to Related Parties

Loans to related parties is made up of working capital loans which are given to Softlogic Holdings PLC as per the agreements made. Those agreements state the necessary provisions on the repayment and recovery of those loans.

Trade Receivables

Customer credit risk is managed by each business unit according to the Group's established policy, procedures and control relating to customer credit risk management. Credit quality of the customer is assessed based on a credit rating scorecard and individual credit limits are defined in accordance with this assessment. Outstanding customer receivables are regularly monitored and outstanding of major customers are, where feasible, covered by bank guarantees or other forms of credit insurance.

Group	Total	Neither Past Due nor Impaired	Past Due but not Impaired			Impaired > 365 days
			31 - 60 days	61 - 90 days	91 - 365 days	
2021						
Gross Trade Receivable Balance	798,737,943	424,813,843	131,014,413	71,546,490	102,150,674	69,212,523
Less - Impairment	(52,575,157)	-	-	-	-	(52,575,157)
	746,162,786	424,813,843	131,014,413	71,546,490	102,150,674	16,637,366
2020						
Gross Trade Receivable Balance	737,941,304	394,822,580	134,763,309	67,677,903	97,279,705	43,397,809
Less - Impairment	(43,397,808)	-	-	-	-	(43,397,809)
	694,543,496	394,822,580	134,763,309	67,677,903	97,279,705	-

Notes to the Financial Statements

Company	Total	Neither Past Due nor Impaired	Past Due but not Impaired			Impaired > 365 days
			31 - 60 days	61 - 90 days	91 - 365 days	
2021						
Gross Trade Receivable Balance	536,101,052	136,604,077	124,113,570	42,370,078	193,804,068	39,209,259
Less - Impairment	(1,880,454)	-	-	-	-	(1,880,454)
	534,220,598	136,604,077	124,113,570	42,370,078	193,804,068	37,328,805
2020						
Gross Trade Receivable Balance	342,601,959	48,790,514	97,612,307	14,420,122	175,549,525	6,229,490
Less - Impairment	(1,693,988)	-	-	-	-	(1,693,988)
	340,907,971	48,790,514	97,612,307	14,420,122	175,549,525	4,535,502

The requirement for impairment is analysed at each reporting date on an individual basis for major clients. The calculation is based on actual historical data.

Cash and Short-term Deposits

Deposits with banks consist mainly of fixed and call deposits. Credit risk from balances with banks and financial institutions is managed by the Group's treasury department in accordance with the Group's policy. Investments of surplus funds are made only with approved counterparties and within credit limits assigned to each counterparty. Counterparty credit limits are reviewed annually, and may be updated during the year subject to appropriate approval. The limits are set to minimise the concentration of risks and therefore mitigate financial loss through the counterparty's failure to make payments. The Group's maximum exposure to credit risk for the components of the statement of financial position are the carrying amounts as shown.

Foreign Exchange Risk

Foreign Exchange Risk is the Group's/Company's exposure to adverse movement in foreign currency against the Sri Lankan Rupee. The group do not have any significant direct impact from the foreign exchange risk.

33.2 Interest Rate Risk

Interest rate risk is the Group's/Company's exposure to adverse movement in interest rates. The Group/Company has obtained multiple facilities from various banks for working capital, capital expenditure and investment at varying terms and conditions. The finance function negotiate with banks and finance institutions to get the best interest rates and favourable terms for both long and short term borrowing facilities.

Exposure to Interest Rate Risk

The interest rate profile of the Group's/Company's interest bearing financial instruments is as follows:

As at 31 March	Group		Company	
	2021	2020	2021	2020
	Rs.	Rs.	Rs.	Rs.
Financial Assets at Variable Rates				
Financial Liabilities	14,211,252,684	12,912,016,140	13,818,391,077	13,494,454,249
	14,211,252,684	12,912,016,140	13,818,391,077	13,494,454,249

Interest Rate Sensitivity

The following table demonstrates sensitivity to a reasonably possible change in interest rates on loans and borrowings that may be affected. Provided all other variables are held constant, the Group's/Company's profit before tax can be affected by changes on floating rate borrowings, as follows:

	Increase in Basis Points	Effect on Profit Before Tax	
		Group	Company
		Rs.	Rs.
2021	+ 400	(602,190,680)	(345,274,121)
	- 400	602,190,680	345,274,121
2020	+ 200	(289,649,203)	(166,839,282)
	-200	289,649,203	166,839,282

The spread of interest rates used in the sensitivity analysis is based on the currently observable market environment.

Notes to the Financial Statements

33.3 Equity Price Risk

A common uncertainty associated with investments is that they may not provide the desired returns. The Group invests substantial sums in capital expenditure for expansion and new services in addition to investments in other companies. Returns on such investments are closely monitored and benefits are periodically evaluated.

The Group holds equity securities which are susceptible to market-price risk arising from uncertainties about future values of these securities. Periodic reports on equity investment portfolios are submitted to the Senior Management of individual business segments. These respective Boards of Directors review and approve all equity investment decisions.

	Note	Group	
		2021 Rs.	2020 Rs.
Other Non Current Financial Assets			
Financial Assets at Fair Value through OCI	15	323,258,010	360,695,200
		323,258,010	360,695,200

Sensitivity Analysis

The following table demonstrates the sensitivity of aggregate fair value to reasonably possible changes in equity prices provided all other variables are held constant:

	Change in Equity Price %	Group	
		Effect on Fair Value Reserve of Financial Assets at FVOCI Rs.	Effect on Equity Rs.
2021			
Quoted/Unquoted Equity Investments	+10	32,325,801	32,325,801
	-10	(32,325,801)	(32,325,801)
2020			
Quoted Equity Investments Listed on the Colombo Stock Exchange	+10	36,069,520	36,069,520
	-10	(36,069,520)	(36,069,520)

33.4 Liquidity Risk

Liquidity risk is the risk that the difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Group's approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when they are due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Group's reputation.

The Group's objective is to maintain a balance between continuity of funding and flexibility through the use of bank overdrafts, bank loans, finance leases and that will always have sufficient liquidity to meet its liabilities when due under normal and stressed conditions. The Group assessed the concentration of risk with respect to refinancing its debt and concluded it to be low. Access to sources of funding is sufficient and debt maturing within 12 months can be rolled over with existing lenders. This risk has been managed by maintaining a balance between bank overdrafts, bank loans, and inter company borrowings. The Company is in position to maintained the short term financial obligation through the roll over the short term maturity date by using funds provided by the Group Companies, roll over the Bank Overdrafts facilities and Deferment of Intercompany Payables.

As at 31 March	Group		Company	
	2021	2020	2021	2020
Cash in Hand and at Banks	985,680,944	1,448,291,268	530,712,583	817,434,641
Total Liquid Assets	985,680,944	1,448,291,268	530,712,583	817,434,641
Current portion of Interest Bearing Borrowings	5,708,924,267	5,426,926,607	4,067,427,449	2,240,592,690
Bank Overdrafts	2,716,949,746	3,619,289,805	2,563,497,602	2,674,895,151
Total Liabilities	8,425,874,013	9,046,216,412	6,630,925,051	4,915,487,841
Net Debt	(7,440,193,069)	(7,597,925,144)	(6,100,212,468)	(4,199,112,902)

The maturity profile of the Group's and Company's financial liabilities are as follows :

	Group				Company			
	2021				2021			
	Interest Bearing Loans and Borrowings	Lease Liability	Trade and Other Payables	Total	Interest Bearing Loans and Borrowings	Lease Liability	Trade and Other Payables	Total
	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.
0-12 Months	5,708,924,267	191,841,011	1,901,518,541	7,802,283,819	4,067,427,449	77,012,976	1,125,787,044	5,270,227,469
1-5 years	7,705,757,848	289,102,150	-	7,994,859,998	2,880,118,239	236,750,093	-	3,116,868,332
>5 years	1,268,733,080	38,673,910	-	1,307,406,990	674,846,413	38,673,910	-	713,520,323
Total	14,683,415,195	519,617,071	1,901,518,541	17,104,550,807	7,622,392,101	352,436,979	1,125,787,044	9,100,616,124

Notes to the Financial Statements

	Group 2020				Company 2020			
	Interest Bearing Loans and Borrowings	Lease Liability	Trade and Other Payables	Total	Interest Bearing Loans and Borrowings	Lease Liability	Trade and Other Payables	Total
	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.
0-12 Months	5,426,926,607	245,622,145	1,972,453,393	7,645,002,145	2,240,592,690	101,059,703	1,095,821,628	3,437,474,021
1-5 years	6,261,441,451	387,334,177	-	6,648,775,628	3,055,192,109	224,989,891	-	3,280,182,000
>5 years	1,196,303,839	61,105,213	-	1,257,409,052	393,647,281	56,355,213	-	450,002,494
Total	12,884,671,897	694,061,535	1,972,453,393	15,551,186,825	5,689,432,080	382,404,807	1,095,821,628	7,167,658,515

Capital Management

The primary objective of the Group's capital management is to ensure that it maintains a strong credit rating and healthy capital ratios in order. No changes were made in the objectives, policies or processes for managing capital during the year ended 31st March 2021. The Group monitors capital using a gearing ratio for the company to support its business and maximise shareholder value.

The Group manages its capital structure and makes adjustments to it in light of changes in economic conditions. To maintain or adjust the capital structure, the Group may adjust the dividend payment to shareholders, return capital to shareholders or issue of new shares and subsidiaries, net debt divided by total capital plus net debt, which is monitored closely by senior management. Net debt of the Group includes, interest bearing loans and borrowings, trade and other payables less cash and cash equivalents (excluding discontinued operations).

	Group		Company	
	2021	2020	2021	2020
Net Debt	15,942,521,487	15,083,014,676	16,096,786,754	15,832,729,044
Equity	11,297,258,091	10,861,303,833	8,411,068,940	7,934,871,252
Capital and Total Net Debt	27,239,779,578	25,944,318,509	24,507,855,694	23,767,600,296
Gearing Ratio	59%	58%	66%	67%

Supplementary Information

Shareholder Information	116
Five Year Summary	119
Economic Value Added Statement	121
Notice of Meeting	122
Form of Proxy	123
Corporate Information	IBC

Shareholder Information

Ordinary shares of the Company are listed in the Colombo Stock Exchange of Sri Lanka.

The Audited Financial Statements of the Company for the year ended 31st March 2021 and copies of this Annual Report have been submitted to the Colombo Stock Exchange.

DISTRIBUTION OF SHAREHOLDING

There were 5613 registered shareholders as at 31st March 2021

Number of shares held	31 March 2021			31 March 2020		
	Number of shareholders	Holding	Holding %	Number of shareholders	Holding	Holding %
1 – 1,000	2,777	824,555	0.07	2,656	792,199	0.07
1,001 – 10,000	1,773	7,214,816	0.64	1,745	7,102,300	0.62
10,001 – 100,000	840	28,792,043	2.53	838	28,505,141	2.51
100,001 – 1,000,000	197	51,175,829	4.50	202	50,269,885	4.42
Over 1,000,000	26	1,049,526,353	92.26	30	1,050,864,071	92.38
Total	5,613	1,137,533,596	100.00	5,471	1,137,533,596	100.00

COMPOSITION OF SHAREHOLDERS

Category	31 March 2021			31 March 2020		
	Number of shareholders	Holding	Holding %	Number of shareholders	Holding	Holding %
Individual	5426	118,258,607	10.40	5,301	120,562,328	10.60
Institutional	187	1,019,274,989	89.60	170	1,016,971,268	89.40
Total	5613	1,137,533,596	100	5,471	1,137,533,596	100.00
Resident	5573	731,389,459	64.30	5,430	730,726,165	64.24
Non-resident	40	406,144,137	35.70	46	406,807,431	35.76
Total	5613	1,137,533,596	100	5,471	1,137,533,596	100.00

TWENTY MAJOR SHAREHOLDERS

The 20 major shareholders as at the end of the financial year and their percentage holding are as follows:

Asiri Hospital Holdings PLC Top 20 as at 31st March 2021

Total Shares: 1,137,533,596

	Name	Shares	%
1	SOFTLOGIC HOLDINGS PLC	580,468,443	51.03
2	MERRILL LYNCH PIERCE FENNER & SMITH-TPG GROWTH III SF PTE LTD	328,258,328	28.86
3	BNYMSANV RE-LF RUFFER INVESTMENT FUNDS : LF RUFFER PACIFIC AND EMERGING MARKETS FUND	40,148,930	3.53
4	SEB AB-TUNDRA SUSTAINABLE FRONTIER FUND	30,000,000	2.64
5	SOFTLOGIC LIFE INSURANCE PLC-A/C NO. 04 (PARTICIPATING FUND) 5 (NON PARTICIPATING FUND)	14,956,877	1.31
6	MR. CHAMINDA DILANTHA WEERASINGHE (DECEASED)	9,375,000	0.82
7	SRI LANKA INSURANCE CORPORATION LTD-LIFE FUND	7,851,792	0.69
8	MR. PUJITHA PUNSIRI SUBASINGHE	7,281,566	0.64
9	UNION BANK OF COLOMBO PLC/SOFTLOGIC HOLDINGS PLC	5,655,789	0.50
10	DR. WELAGEDARA MUDIYANSELAGE SWARNAMALI WELAGEDARA	3,375,000	0.30
11	MR. AHAMED UMAR MANIKU	3,219,350	0.28
12	DR. LUHUBANDUWADUGE DON ABO CLAUDIUS LUVIS	2,841,720	0.25
13	SRI LANKA INSURANCE CORPORATION LTD-GENERAL FUND	2,807,417	0.25
14	MR. HEWA KOMANAGE JAYANTHA DHARMADASA	2,788,920	0.25
15	MR. AJITH HARINDRA WEERASURIYA	2,600,000	0.23
16	CBHK S/A PLATINUM BROKING COMPANY LIMITED	2,218,881	0.20
17	MR. MOHAMED FAIZER HASHIM	2,081,160	0.18
18	MISS THEJA THUSHARI WEERASINGHE	1,746,630	0.15
19	PEOPLES BANK	1,514,157	0.13
20	SOFTLOGIC FINANCE PLC	1,467,834	0.13
	SUB TOTAL	1,050,657,794	92.36
	OTHERS	86,875,802	7.64
	GRAND TOTAL	1,137,533,596	100

Shareholder Information

SHARE TRADING

Market price (LKR)	2020/2021	2019/2020
Highest (31/12/2020)	34.60	23.50
Lowest (12/05/2020)	14.40	16.60
As at year-end (31/03/2021)	25.50	17.00
Number of trades	10,728	2553
Number of shares traded	51,544,899	15,418,892
Value of the shares traded (LKR)	1,454,703,894	320,897,171
Market capitalisation (LKR)	29,007,106,698	19,338,071,132
Earnings per share (LKR)	1.35	0.71
Dividend per share (LKR)	1.60	-
Net assets per share (LKR)	9.05	8.76
P/E Ratio	18.89	23.94

The Float- adjusted market capitalization as at 31st March, 2021 is Rs. 5,404,023,978 and the Company is in compliance with option 4 of the Listing Rules 7.13.1 (a) which requires 10% minimum public holding percentage and 500 minimum public shareholders.

Five Year Summary

Year ended 31 March	2021	2020	2019	2018	2017
	Rs. '000	Rs. '000	Rs. '000	Rs. '000	Rs. '000
Income Statement					
Revenue	15,784,523	15,510,422	13,476,097	12,025,178	10,396,219
Cost of Sales	(8,994,513)	(8,499,001)	(7,140,008)	(6,476,262)	(5,683,140)
Gross Operating Profit	6,790,010	7,011,421	6,336,089	5,548,916	4,713,079
Other Laboratory Income	59,799	75,264	79,003	89,716	97,661
Administration & Distribution Expenses	(4,183,026)	(4,232,558)	(3,403,040)	(3,052,839)	(2,446,357)
Profit from Operations	2,666,783	2,854,127	3,012,052	2,585,793	2,041,712
Other Income	135,246.36	154,140	158,064	821,163	80,820
Share of Profit /(Loss) of Associate/ Joint Venture	-	704	73	(3,609)	(21,833)
Profit Before Interest & Tax	2,802,029	3,008,972	3,170,189	3,403,347	2,100,699
Finance Income	242,331	191,700	73,911	65,791	31,376
Finance Expenses	(1,433,382)	(1,789,974)	(877,065)	(869,506)	(834,867)
Profit Before Tax	1,610,978	1,410,697	2,367,035	2,599,632	1,297,208
Income Tax	133,640	(492,490)	(575,311)	(699,567)	177,206
Profit After Tax	1,744,618	918,207	1,791,723	1,900,064	1,120,002
Non-Controlling Interest	(213,381)	(110,211)	(109,171)	(161,545)	(91,984)
Profit after Non-Controlling Interest & tax	1,531,236	807,996	1,682,552	1,738,519	1,028,019
Balance Sheet					
Property, Plant & Equipment	25,253,491	24,270,835	21,552,376	18,035,916	15,341,387
Right of Use Assets	1,309,860	1,367,469	-	-	-
Investment Property	-	215,000	193,724	-	-
Investment in Associate/Joint Venture	-	32,245	31,625	31,558	8,167
Intangible Assests	609,654	609,654	609,654	548,707	548,707
Non Current Assets	54,473	54,293	-	-	-
Other Non Current Financial Assets	323,258	360,695	323,946	345,762	349,972
Deferred Tax Assets	-	-	-	-	107,562
Inventories	664,297	665,626	452,519	523,341	515,311
Trade and Other Receivables	789,099	902,178	724,620	534,427	475,412
Other Current Assets	401,696	538,201	1,192,134	413,748	422,236
Loans Granted to Related Parties	1,679,771	1,733,487	1,458,627	-	-
Cash and Cash Equivalents	985,681	1,448,291	242,986	1,297,340	1,072,828
Total Assets	32,071,279	32,197,975	26,782,211	21,730,795	18,841,583

Five Year Summary

Year ended 31 March	2021	2020	2019	2018	2017
	Rs. '000	Rs. '000	Rs. '000	Rs. '000	Rs. '000
Issued Share Capital	4,748,108	4,748,108	4,748,108	4,748,108	4,748,108
Revaluation Reserve	4,185,578	3,384,550	2,846,611	2,376,640	2,311,857
Fair Value Reserve of Financial Assets at FVOCI	(46,240)	7,800	(7,676)	79,448	92,513
Reserve on Consolidation	(920,571)	(863,977)	(862,299)	(862,299)	(840,432)
Retained Earnings	2,327,574	2,683,467	1,951,119	1,149,357	100,010
Foreign Currency Translation Reserve	(671)	-	-	-	-
Non-Controlling Interest	1,003,479	901,355	792,320	700,717	946,375
Total Equity	11,297,258	10,861,304	9,468,184	8,191,971	7,358,431
Amount Due on Leasehold Property	405,386	476,813	22,057	26,129	30,201
Interest Bearing Borrowings & Bank Overdraft	16,522,817	16,054,493	12,247,449	10,486,102	9,325,202
Deferred Tax	1,107,084	1,833,615	1,644,386	1,312,292	271,906
Deferred Liabilities	666,290	555,611	484,451	465,672	400,973
Trade Creditors	1,909,338	1,996,831	809,275	569,383	439,886
Other Payables	163,107	419,309	2,106,411	679,246	1,014,984
Total Equity & Liabilities	32,071,279	32,197,975	26,782,211	21,730,795	18,841,583
Net Cash From Operating Activities	2,706,998	2,764,395	904,246	2,580,345	1,528,120
Net Cash Flows Used in Investing Activities	(1,182,351)	(4,330,673)	(3,651,124)	(1,879,670)	(2,099,832)
PBIT/Turnover (%)	18	19	24	22	21
GP Margin (%)	43	45	47	46	45
Return on Equity (%)	15	8	20	23	15
Return on Assets (%)	5	3	7	9	6
Dividend Pay Out (%)	118.86	-	54.05	39.26	105.12
Debts to Equity	1.50	1.52	1.29	1.28	1.27
Interest Cover	2.12	1.79	3.70	3.99	2.55
Quick Asset Ratio	0.36	0.39	0.40	0.44	0.51
Dividend Per Share	1.60	0.00	0.80	0.60	0.95
Net Assets Value per Share	9.05	8.76	7.63	6.59	5.64
Earnings per Share	1.35	0.71	1.48	1.53	0.90


Economic Value Added Statement

The creation of wealth is the main purpose of existence of any commercial organisation.

The value added statement highlights the wealth created by the activities of the company over the last two years and the distribution of this wealth created among its stakeholders

	31-Mar-2021	%	31-Mar-2020	%
	Rs. '000		Rs. '000	
Direct Economic Value Generated				
Turnover	6,138,339	78%	5,706,706	97%
Finance Income	74,328	1%	92,362	1%
Dividend Income	1,617,051	20%	-	0%
Other Income	99,663	1%	105,804	2%
	7,929,381	100%	5,904,872	100%
Economic Value Distributed				
To Employees				
Employee Wages & Benefits	1,376,475	17.37%	1,321,597	22.38%
Operating Cost				
Other Operating Expenses	2,758,883	34.79%	2,627,038	44.49%
Payments to Government				
Taxes Paid	39,549	0.50%	139,971	2.37%
Payments to Providers of Capital				
To Lenders as Interest	1,340,257	16.90%	1,713,587	29.02%
To Shareholders as Dividends	1,820,054	22.95%	-	-
Expansion & Growth				
Depreciation	596,621	7.52%	415,605	7.04%
Retained Earnings	(2,457)	-0.03%	(312,926)	-5.30%
	7,929,381	100%	5,904,872	100%

DISTRIBUTION OF ECONOMIC VALUE ADDED (%)



Notice of Meeting

NOTICE IS HEREBY GIVEN that the 41st Annual General Meeting of the Company will be held by electronic means on 23rd August, 2021 at 10.30 a.m. centered at No 114, Norris Canal Road, Colombo 10 for the following purposes:

- (1) To receive and consider the Annual Report of the Board of Directors and Financial Statements of the Company and of the Group for the year ended 31st March 2021 together with the Report of the Auditors thereon.
- (2) To ratify the First Interim Dividend of LKR. 0.80 per share paid on 12th October, 2020 and Second Interim Dividend of LKR 0.80 per share paid on 16th April, 2021 as the Final Dividend for the year ended 31st March, 2021.
- (3) To re-elect Mr. S A B Rajapaksa who retires by rotation in terms of Article 24 (6) of the Articles of Association, as a Director of the Company.
- (4) To re-elect Mr. A N Thadani who retires by rotation in terms of Article 24 (6) of the Articles of Association, as a Director of the Company.
- (5) To elect Mr. S Ahangama who retires in terms of Article 24 (2) of the Articles of Association, as a Director of the Company.
- (6) To pass the ordinary resolution set out below to re-appoint Mr G L H Premaratne who is 73 years of age, as a Director of the Company.

"IT IS HEREBY RESOLVED THAT the age limit stipulated in Section 210 of the Companies Act No. 07 of 2007 shall not apply to Mr G L H Premaratne who is 73 years of age and that he be and is hereby reappointed a Director of the Company in terms of Section 211 of the Companies Act No. 07 of 2007".

- (7) To re-appoint Messrs Ernst & Young as Auditors of the Company for the ensuing year and to authorise the Directors to fix their remuneration.
- (8) To authorise the Directors to determine and make donations for the year ending 31st March 2022 and up to the date of the next Annual General Meeting.

By Order of the Board,
ASIRI HOSPITAL HOLDINGS PLC

Sgd.
SOFTLOGIC CORPORATE SERVICES (PVT) LTD.
Company Secretaries

Colombo
30 June 2021

Notes

1. A Shareholder who is entitled to participate, speak and vote at the meeting is entitled to appoint a proxy to attend and vote on behalf of him/her by electronic means as per the attached guidelines.
2. A proxy need not be a Shareholder of the Company.
3. The Form of Proxy is enclosed for this purpose.
4. Shareholders are advised to follow the Guidelines and Attendance Registration Process for the Annual General Meeting attached hereto.

Form of Proxy

I/We.....
 of being a* member/members of ASIRI HOSPITAL
 HOLDINGS PLC, do hereby appointof
 or failing *him/her

Mr A K Pathirage	of Colombo or failing him
Dr S Selliah	of Colombo or failing him
Dr K M P Karunaratne	of Colombo or failing him
Mr G L H Premaratne	of Colombo or failing him
Mr S A B Rajapaksa	of Colombo or failing him
Mr. S Ahangama	of Colombo or failing him
Mr. V Bali	of India or failing him
Mr. A N Thadani	of India

as *my/our Proxy to represent *me/us and to speak and vote for *me/us on *my/our behalf at the 41st Annual General Meeting of the Company to be held by electronic means on 23rd August, 2021 at 10.30 a.m. and at any adjournment thereof, and at every poll which may be taken in consequence thereof.

	For	Against
(1) To receive and consider the Annual Report of the Board of Directors and Financial Statements of the Company and of the Group for the year ended 31st March 2021 together with the Report of the Auditors thereon.	<input type="checkbox"/>	<input type="checkbox"/>
(2) To ratify the First Interim Dividend of LKR. 0.80 per share paid on 12th October, 2020 and Second Interim Dividend of LKR 0.80 per share paid on 16th April, 2021 as the Final Dividend for the year ended 31st March, 2021.	<input type="checkbox"/>	<input type="checkbox"/>
(3) To re-elect Mr. S A B Rajapaksa who retires by rotation in terms of Article 24 (6) of the Articles of Association, as a Director of the Company.	<input type="checkbox"/>	<input type="checkbox"/>
(4) To re-elect Mr. A N Thadani who retires by rotation in terms of Article 24 (6) of the Articles of Association, as a Director of the Company.	<input type="checkbox"/>	<input type="checkbox"/>
(5) To elect Mr. S Ahangama who retires in terms of Article 24 (2) of the Articles of Association, as a Director of the Company.	<input type="checkbox"/>	<input type="checkbox"/>
(6) To pass the ordinary resolution set out below to re-appoint Mr G L H Premaratne who is 73 years of age, as a Director of the Company. "IT IS HEREBY RESOLVED THAT the age limit stipulated in Section 210 of the Companies Act No. 07 of 2007 shall not apply to Mr G L H Premaratne who is 73 years of age and that he be and is hereby re-appointed a Director of the Company in terms of Section 211 of the Companies Act No. 07 of 2007".	<input type="checkbox"/>	<input type="checkbox"/>
(7) To re-appoint retiring Auditors Messrs Ernst & Young and to authorise the Directors to fix their remuneration.	<input type="checkbox"/>	<input type="checkbox"/>
(8) To authorise the Directors to determine and make donations for the year ending 31st March 2022 and up to the date of the next Annual General Meeting.	<input type="checkbox"/>	<input type="checkbox"/>

Signed this day of Two Thousand and Twenty One.

.....
 *Signature/s

- Note:**
- (1) *Please delete the inappropriate words.
 - (2) A proxy need not be a shareholder of the Company.
 - (3) Instructions as to completion are noted on the reverse hereof.

Form of Proxy

INSTRUCTIONS FOR COMPLETION

1. The full name, National Identity Card number and the registered address of the shareholder appointing the Proxy and the relevant details of the Proxy should be legibly entered in the Form of Proxy which should be duly signed and dated.
2. The completed Proxy should be forwarded to the Company for deposit at the Registered Office through the Company Secretaries, Softlogic Corporate Services (Pvt) Ltd, No.14, De Fonseka Place, Colombo 05, marked "Asiri Hospital Holdings PLC – 41st Annual General Meeting" or email corporateservices@softlogic.lk not later than 48 hours before the time appointed for the Meeting.

In forwarding the completed and duly signed Proxy to the Company, please follow the Guidelines and Attendance Registration Process for the Annual General Meeting attached to the Notice of Annual General Meeting.

3. The Proxy shall –
 - (a) In the case of an individual be signed by the shareholder or by his attorney, and if signed by an attorney, a notarially certified copy of the Power of Attorney should be attached to the completed Proxy if it has not already been registered with the Company.
 - (b) In the case of a Company or Corporate / statutory body either be under its Common Seal or signed by its Attorney or by an Officer on behalf of the Company or Corporate / statutory body in accordance with its Articles of Association or the Constitution or the Statute. (as applicable)
4. Please indicate with a 'X' how the Proxy should vote on each resolution. If no indication is given, the Proxy in his discretion will vote as he thinks fit.

Corporate Information

NAME OF THE COMPANY

Asiri Hospital Holdings PLC

REGISTERED OFFICE

No. 181, Kirula Road, Colombo 05, Sri Lanka.

OFFICE AND ADMINISTRATIVE COMPLEX

Asiri Surgical Hospital PLC
No. 21, Kirimandala Mawatha,
Colombo 05, Sri Lanka.
Telephone: 011 452 4400
Email: info@asiri.lk
Web: www.asirihealth.com

COMPANY REGISTRATION NUMBER

PQ 204

LEGAL FORM

A quoted public company incorporated in Sri Lanka on 29 September 1980, under the Companies Act No. 17 of 1982, with limited liability.

Re-registered on 30 September 2008 under the Companies Act No. 07 of 2007.

STOCK EXCHANGE LISTING

The ordinary shares of the Company have been listed with the Colombo Stock Exchange since June 1986.

BOARD OF DIRECTORS

Mr. A K Pathirage –
Chairman/Managing Director
Dr. K M P Karunaratne –
Group Chief Executive Officer
Dr. S Selliah – Deputy Chairman
Mr. S A B Rajapaksa
Mr. G L H Premaratne
Mr. V Bali
Mr. A N Thadani
Mr. S Ahangama (Appointed w.e.f 27th
August 2020)
Mr. R A Ebell (Resigned w.e.f. 30th June 2020)

AUDIT COMMITTEE

Mr. S Ahangama - Chairman
Independent Non-Executive Director (Appointed
w.e.f. 22nd September 2020)

COMMITTEE MEMBERS

Mr. G L H Premaratne
Independent Non-Executive Director
Mr. S A B Rajapaksa
Independent Non-Executive Director

FREQUENCY OF MEETINGS

Committee meets quarterly

REMUNERATION COMMITTEE

Mr. G L H Premaratne – Chairman
Independent Non-Executive Director

COMMITTEE MEMBERS

Dr. S Selliah
Independent Non-Executive Director

FREQUENCY OF MEETINGS

Committee meets once a year

RELATED PARTY TRANSACTIONS REVIEW COMMITTEE

Mr. S A B Rajapaksa – Chairman
Independent Non-Executive Director

COMMITTEE MEMBERS

Mr. G L H Premaratne
Independent Non-Executive Director
Mr. S Ahangama
Independent Non-Executive Director (Appointed
w.e.f. 22nd September 2020)

FREQUENCY OF MEETINGS

Committee meets at least once a quarter

SUBSIDIARY COMPANIES

Central Hospital Ltd.
No. 114, Norris Canal Road, Colombo 10.

Asiri Central Hospitals Ltd.
No. 114, Norris Canal Road, Colombo 10.

Asiri Surgical Hospital PLC
No. 21, Kirimandala Mawatha, Colombo 5.

Asiri Diagnostics Services (Pvt) Ltd.
No. 181, Kirula Road, Colombo 05.

Asiri Hospital Matara (Pvt) Ltd.
No. 26, Esplanade Road, Uyanwatte, Matara.

Asiri Laboratories (Pvt) Ltd.
No. 181, Kirula Road, Colombo 05.

Asiri Hospital Galle (Pvt) Ltd.
No. 10, Wackwella Road, Galle.

Asiri AOI Cancer Centre (Pvt) Ltd.
No 21, Kirimandala Mawatha, Colombo 05

Asiri Diagnostic Services (Asia) Pte. Ltd.
No. 08 Temasek Boulevard,
No. 35-03 Suntec Tower 3
Singapore.

Asiri Myanmar Limited
Pan Hlaing Street, Unit 01, Level 08, Uniteam
Marine Office Building.
No. 08, Honelan Butar Quarter, Yangon City
Sanchaung Township
Yangon Region, Myanmar.

AUDITORS

Messrs Ernst & Young (Chartered Accountants)
No. 201, De Saram Place, Colombo 10.

SECRETARIES

Messrs Softlogic Corporate Services (Pvt) Ltd.
No. 14, De Fonseka Place, Colombo 05.

BANKERS

Commercial Bank of Ceylon PLC
Sampath Bank PLC
Nations Trust Bank PLC
Hatton National Bank PLC
Cargills Bank Limited
Bank of Ceylon PLC
National Development Bank PLC
Seylan Bank PLC

Designed & produced by

emagewise

Printed by Gunaratne Offset (Pvt) Ltd

